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1. Hirschsprung Disease: Diagnosis and Treatment
1.1 Diagnosis
Hirschsprung (HSCR) disease, also known as congenital megacolon, is characterized by the 
absence of enteric ganglia (aganglionosis) in the submucosal and myenteric plexuses of the 
gastrointestinal (GI) tract leading to a life-threatening bowel distention which presents itself 
usually shortly after birth.1 HSCR disease was first recognized in 1887 by the Danish pediatri-
cian Harald Hirschsprung. He described two boys who died at age 8 and 11 years with severe 
constipation. HSCR is clinically characterized by a failure to pass meconium (the first stool) 
within 48 hours after birth, abdominal distention, vomiting or neonatal enterocoilitis.2 In par-
ticular, enterocolitis can prove life-threatening in HSCR. The mortality rate of HSCR disease 
due to enterocolitis ranges from 0-30%. The variation is most likely due to differences in di-
agnosing Hirschsprung-associated enterocolitis (HAEC).3,4 The gold standard for diagnosing 
HSCR disease is the histopathology of a full-thickness rectal biopsy in which the neurons and 
glial cells (ganglia) are absent in both the myenteric and submucosal plexus of the GI tract of 
HSCR patients.5 Measurement of the pressures in the rectum (rectal manometry) and X-rays 
made with a barium enema are methods that can provide extra information to the physi-
cian for an accurate diagnosis. The dilated (mega)colon is proximal to the aganglionic region, 
which narrows towards the distal part and an empty rectum is a common finding.1 In 75% 
of cases, the diagnoses is made within six weeks of birth and in 90% of cases, the disease is 
diagnosed before the age of five years.6 
The length of the aganglionic region varies and based on this HSCR disease is classified 
into short-segment HSCR (S-HSCR), long-segment HSCR (L-HSCR) and total colonic/intesti-
nal aganglionosis (TCA/TIA). S-HSCR is the most common type (80% of cases) and the length 
of the aganglionic region does not extend beyond the upper sigmoid. Fifteen percent of the 
patients have L-HSCR in which the aganglionic region extends beyond the upper sigmoid. 
In about 5% of cases, the TCA/TIA is diagnosed. In these patients the complete colon and the 
terminal part of the ileum show an absence of ganglia and in rare cases even the whole bowel 
can lack ganglia, which is a lethal condition.1, 7-9 
HSCR is the most common developmental disorder of the enteric nervous system (ENS) 
with a prevalence of 1 in 5000 newborns, although variation of the prevalence is observed be-
tween ethnic populations.10 Interestingly, a sex-dependent penetrance is observed in S-HSCR 
with a male:female ratio of 4:1. With respect to these findings, it is interesting to report that 
the transmission of disease-causing alleles in this group is also disturbed, as 78% of the com-
monly shared RET allele, the major risk factor for HSCR development, are maternally de-
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rived.11, 12 Whether the male:female ratio is caused by these differences in the transmission of 
associated alleles is not yet known. HSCR most commonly presents sporadically, although in 
approximately 20% of cases, several members in a family are affected (familial HSCR). In 70% 
of cases, HSCR occurs as an isolated trait and in the other 30% HSCR is associated with other 
congenital malformation or syndromes.
Figure 1 - A) Barium enema X-ray of HSCR patient’s bowel, the arrows shows the beginning of the agan-
glionic region. B) Treatment of HSCR patient with pull-through surgery to remove the aganglionic region 
and rejoin the healthy ganglionated colon to the anus. 
1.2 Treatment
Current treatment of HSCR is surgical resection of the aganglionic part of the gastro-
intestinal (GI) tract. These operations, so called pull-through operations, are mostly based 
on the procedures developed by Swenson, Duhamel or Soave. In this surgical procedure the 
affected region of the colon is removed and the healthy ganglionated region of the colon is 
rejoined with the anus.13-15 A one-stage procedure (one operation) is possible when the diag-
nosis of HSCR is made before the colon dilates. Otherwise a primary colostomy is temporarily 
required before the patient has the second pull-through surgery to remove the aganglionic 
region. Although the surgical procedure relieves the patient’s constipation and has proven 
life-saving, the long-term outcome remains rather poor, irrespective of the length of the agan-
glionic region. A retrospective study performed by Catto-Smith and colleagues showed that 
fecal incontinence is very common and episodic constipations have also been reported.16 
These clinical findings have led researchers to think about developing alternative treat-





Metzger and colleagues showed that enteric nervous system stem cells (ENSSCs) can be iso-
lated from postnatal human gut mucosal biopsy and used to generate neurosphere-like bod-
ies (NLBs). More importantly, they showed that these NLBs have the same stem cell plasticity 
as those generated from embryonic human gut tissue and, when grafted onto aganglionic 
chick hindgut, these NLBs have the ability to migrate and differentiate into glial cells and dif-
ferent types of ENS neurons. Whether these grafted cells function correctly and whether they 
repair the ENS system needs further investigation. These preliminary results show, however, 
that ENSSCs transplantation might have therapeutic potential and could, in the future, be 
considered as an additional therapy for HSCR disease.17
2. Pathogenesis of Hirschsprung Disease: Genetic Background 
2.1 Genes involved in the development of HSCR disease
The genetic dissection of HSCR has led to the identification of 12 genes and five susceptibil-
ity loci implicated in the development of HSCR disease. These 12 genes are expressed either 
in the enteric neural crest cells (ENCCs) or in other cells in the gut along the path of ENCCs 
migration during ENS development. The inheritance of HSCR is considered to be complex. 
The disease can be transmitted as a dominant trait or as a recessive trait, but in the majority 
of cases it is probably polygenic with differences in sex ratio, with a male predominance in S-
HSCR (4:1), incomplete penetrance and variable expression; associations with a large number 
of syndromes and congenital malformations have been observed.1 Linkage analyses of mul-
tiplex HSCR families revealed that the RET (REarrange during Transfection) gene, located 
at 10q11.2, is the major risk factor for Hirschsprung disease as almost all families showed 
linkage with RET.11, 18, 19 Coding sequence mutations in RET are responsible for a dominant 
form of HSCR (with incomplete penetrance) and coding and splice site mutations have been 
identified in up to 50% of familial cases and 15-35% of sporadic cases.20 The mutations are 
scattered throughout the RET coding sequence, including large and micro-deletions and a 
variety of point mutations. RET mutations associated with HSCR are believed to cause a loss 
of function (haploinsufficiency).21-23 However, RET mutations on their own might not result 
in aganglionosis of part of the GI tract, as the penetrance of the RET mutations (in general) is 
72% in males and 51% in females. Yet RET is believed to be the major gene underlying HSCR, 
as evidenced primarily in families enriched for L-HSCR.11 Mutations in the rest of the 11 
genes EDNRB 24, EDN3 25, 26, GDNF 27, 28, NTN 29, SOX10 30, PHOX2B 31, ECE1 32, KIAA1279/KBP 
33, ZFHX1B 34, 35, TTF-1 36 and NRG1 37 do not exceed 20% of the cases, supporting a genetic 
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heterogeneity for this disorder. Finally, rare heterozygous germline mutations of EDNRB in 
combination with RET germline mutations have also been detected in patients showing the 
HSCR phenotype.38 This supports the concept of synergistic heterozygosity for HSCR, i.e. that 
the disease phenotype could be the result of the cumulative effect of at least two mutations 
in different genes.
Figure 2 - Schematic representation of the encoded proteins known to be associated with HSCR develop-
ment and showing their possible interactions. 
Mutations in most of the 11 genes are found mostly in the syndromic cases where HSCR 
is associated with other congenital malformation (see Table 1). Mutations in EDNRB, EDN3 
and SOX10 were identified in a patient with Shah-Waardenburg syndrome (WS4), which is 
characterized by congenital hearing loss, pigmentary abnormalities of the hair, skin and eyes, 
and HSCR disease.30, 39 Mutations in PHOX2B have been identified in patients with congenital 
central hypoventilation (CCHS) and HSCR disease. This syndrome is also known as Hadd-
ad syndrome. CCHS is a rare disorder characterized by impairment of autonomic control of 
spontaneous respiration in the absence of other lung or cardiac disease.31 Mutations in ZF-
HX1B have been identified in patients with Mowat-Wilson syndrome, which is an autosomal 
dominant disorder characterized by mental retardation, epilepsy, delayed motor develop-








KBP) have been identified in patients with Goldberg-Shprintzen (GOSH) syndrome, a rare 
autosomal recessive disorder characterized by HSCR, microcephaly, mental retardation, and 
polymicrogria.33 A mutation in ECE1 was identified in a single patient with craniofacial and 
cardiac defects.32 
Besides mutations in these 11 genes, chromosomal abnormalities are frequently observed 
and found in 12% of all syndromic HSCR cases. Trisomy chromosome 21 (Down Syndrome 
(DS)) is the most frequent chromosomal abnormality (>90% cases) associated with HSCR dis-
ease. On the other hand, 77% of DS patients have associated gastrointestinal abnormalities, 
of which 2-15% can be explained by HSCR disease.41 This might implicate chromosome 21 in 
the etiology of HSCR, so it is not surprising that DS patients have a 40-fold higher chance of 
getting HSCR compared to the normal population.42 The other possible explanation could be 
that the genetic imbalance disturbs the homeostasis of genes expressed during development 
that eventually contribute to the disease phenotype.43 Interestingly, besides these possibilities, 
a variant in the RET gene also seems to be related to the HSCR phenotype in DS patients. It 
was shown that a common single nucleotide polymorphism (SNP), rs2435357 (C>T), located 
in the conserved region of intron 1 of the RET gene, when homozygous for the T-allele, gives 
DS patients a 5.3-fold increased risk of developing HSCR compared to DS patients who are 
homozygous for the wild-type C-allele.44 Furthermore, the frequencies of the T-allele differ 
significantly between individuals with DS alone (0.26±0.04), HSCR alone (0.61±0.04) and those 
with HSCR and DS (0.41±0.04), showing there is association and genetic interaction between 
RET and the chromosome 21 gene dosage.42 
Table 1 -  HSCR associated genes and their clinical features (Modified from Brooks A et al. 2005).
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2.2 Non-coding RET variants 
As mentioned above, RET coding mutations have been identified in 50% of the famil-
ial cases. However, regardless of the RET coding mutation status, almost all familial cases 
are linked to the RET locus.11, 45 This suggests that non-coding RET mutations must play a 
major role in the remaining familial cases. This idea was corroborated in association studies 
on sporadic (simplex) cases with and without RET coding mutations, performed on several 
Caucasian populations and an Asian population. These studies revealed a strong association 
between a certain haplotype (covering 27 kb in total) and the disease. This haplotype starts 4 
kb upstream of the RET transcription start site, going all the way to the beginning of exon 2. 
This haplotype is present in 56%-62% of patients, but in only 20% of the controls tested in the 
Caucasian population. In the Chinese patient population, the frequency of this same haplotype 
was 85% but 40% in the controls. This last finding might partially explain the higher incidence 
of HSCR in Asians compared to Caucasians. Several groups have focused their studies on fine-
mapping the associated region and tried to verify the location of the causative variant.12, 36, 46-48 
SNP -1(G>A) and -5 (A>C)
Two variants located in the RET promoter, SNP rs10900296 (G>A) and rs10900297 (A>C) 
located at -5 and -1 from the RET transcription start site respectively, were selected as proba-
bly causative. It was shown that the HSCR associated haplotype (AC) decreased the RET pro-
moter activity in luciferase assays.46 Extended functional studies performed by Garcia-Barcelo 
and colleagues showed that these two variants and their surrounding sequences were the 
binding site of TTF-1 (Thyroid Transcription Factor 1). The AC-haplotype reduces the binding 
affinity of TTF-1, hence reducing RET promoter activity.36 However, this effect proved to be 
cell-line-dependent and it is therefore difficult to conclude whether these two variants really 
are the causative ones. Another aspect that makes the interpretation difficult is the fact that 
these two variants are in a region with strong linkage disequilibrium (LD), which might mask 
the real functional variant(s).49 
SNP rs2435357 (C>T)
A similar study was performed by Emison and colleagues. They genotyped 28 SNPs 
spanning a region of 175 kb in 126 trios. The region covers RET and two other downstream 
genes, GALNACT-2 and RASGEF1A. They identified HSCR-associated SNPS in RET (13 out 
of 17), GALNACT-2 (3 out of 7) and RASGEF1A (2 out of 4). By multi-species alignment, they 
identified that one of the associated SNPs in RET, rs2435357 (C>T), is located in a highly con-
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served region called MSC+9.7 (Multi Species Conserved). This variant is not only conserved 
among nine different mammalian species, but also showed the largest transmission distortion 
(τ: 0.8) in transmission disequilibrium test (TDT) analysis. This data led the authors to pos-
tulate that SNP rs2435357 is most likely a disease-causing variant. They supported this idea 
with reporter (luciferase) assays and showed that, indeed, the MCS+9.7 region, containing 
the disease-associated variant (T-allele), reduced promoter activity when compared to the 
wild-type sequence (C-allele).12 Additional functional studies on SNP rs2435357 by the same 
group proved that SOX10, a transcription factor, binds to a sequence motif containing this 
specific variant.50 In addition in vivo functional studies on MCS+9.7 were performed by Grice 
and colleagues. They generated transgenic mice carrying this conserved region coupled to 
the LacZ reporter gene and studied the spatial temporal LacZ expression during embryonic 
development. They showed that LacZ expression, under the regulation of MSC+9.7, has a 
similar spatial temporal expression as the RET gene, indicating this region contributes to RET 
expression regulation.51 
SNP rs2506004 (C>A)
Burzynski and colleagues sequenced the shared common haplotype region from 10 kb 
upstream of the RET gene through intron 1 (a total of 33 kb) in a patient homozygous for the 
common risk haplotype and in a control individual homozygous for the most common non-risk 
haplotype. They identified eight variants, located in highly conserved regions, within putative 
transcription binding sites. Among these variants, SNP rs2506004 (C>A) proved to be conserved 
not only in vertebrates but also in an avian species (chicken). They hypothesized that the region 
containing the SNP might be an enhancer for RET expression and that this SNP would result in 
a reduction of RET expression.48 The variant is also located in the MSC+9.7 region, 217 bp down-
stream of SNP rs2435357 (C>T). These two SNPs are in strong linkage disequilibrium (r2=0.98). 
Recently we identified NXF/ARNT2 and SIM2/ARNT2 as the transcription factors and repres-
sors, respectively, for the wild-type C-allele of SNP rs2506004. Moreover, transfection of Nxf/
Arnt2 and Sim2/Arnt2 constructs into a mouse neuroblastoma cell line (Neuro2A) enhanced and 
reduced the RET endogenous expression, respectively, proving that NXF/ARNT2 and SIM2/
ARNT2 can indeed regulate RET expression endogenously (see Chapter 4).52 
Interestingly, the gene encoding one of the above transcription factors, SIM2, is located 
in the Down syndrome (DS) critical region on chromosome 21. It has been shown that overex-
pression of SIM2 reduces the expression of Drebrin (DBN1), encoding a protein that plays an im-
portant role in synaptic plasticity and hence suggested to play a role in the development of DS.53, 
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54 The overrepresented of SIM2 in DS patients, due to the trisomy of chromosome 21, might lead 
to SIM2 overexpression and, as a consequence, not only down-regulate DBN1 but also down-
regulate RET expression. This might then contribute to the development of HSCR and partly 
explain why DS patients have a 40-fold higher risk of HSCR disease compared to the normal 
population (Chapter 4).52 Together these data suggest that these four variants, all identified in 
the RET non-coding sequences, may play important roles in HSCR disease development. 
2.3 Susceptible HSCR loci
 As mentioned above, RET coding mutations are the major risk factor for HSCR develop-
ment. However, a RET mutation alone may not be sufficient to cause HSCR as the penetrance 
of mutant alleles, in general, is incomplete in HSCR patients (72% in males and 51% in fe-
males). Non-coding mutations, as described above, also contribution to the phenotype, espe-
cially in S-HSCR. Furthermore, mutations in other 11 HSCR genes can only explain a small 
proportion of the cases. In the majority of sporadic and simplex S-HSCR cases, it is therefore 
likely that mutations occur in the coding regions of as yet unknown genes. 
 Several studies have been searching for additional susceptibility loci, with or without 
them being in conjunction with a RET mutation. Bolk and colleagues (2000) performed a link-
age analysis in 12 multiplex HSCR families. They split them into two groups: the first consist-
ed of families that were linked to 10q1.2 and all had severe RET mutations (six families), while 
the second group consisted of five families that were also linked to the RET region but no 
clear RET-coding sequence mutation had been identified, and one family that was not linked 
to the RET region (and obviously had no RET mutation). Bolk and colleagues segregated a 
new locus at 9q31 in the second group (the six families without RET coding mutations). It was 
hypothesized that 9q31 is probably a modifier locus for development of HSCR disease.45 
 In another study, Gabriel and colleagues (2002) performed a genome-wide scan in 49 
nuclear families with S-HSCR. They carried out a sib-pair analysis and found significant allele 
sharing with markers on 10q11, where RET is located (p = 2.4 x 10-7), on 19q12 (p = 6.6 x 10-4) 
and on 3p21 (p=1.9 x 10-4), with non-parametric LOD scores of 5.02, 3.46 and 3.23, respectively. 
To validate these data, they checked the families mutation status for RET. Surprisingly, they 
only identified RET coding sequence mutations in only 40% of RET-linked families, suggest-
ing the importance of non-coding variants. The risk ratios, as determined by the associated 
risk haplotypes at 10q11, 3p21 and 19q21 were 8.3, 4.2 and 5.0-fold, respectively. Using a mul-
tiplicative model, the frequency of individuals being heterozygous for these three loci is close 
to the observed population incidence. Gabriel et al. therefore hypothesized that all three loci 
were necessary and possibly even sufficient for the observed occurrence of S-HSCR.11 
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 A fourth locus was identified by performing a genome-wide scan on 43 Mennonite trios, 
all belonging to the same large kindred. They identified three loci, two of which were known 
loci (13q22.3-q31.1 where the EDNRB gene is located and 10q11.21 containing the RET gene) 
and one new locus on 16q23.3. The LOD scores of the loci were 55.60, 5.6 and 3.01, respec-
tively, showing that EDNRB is the primary susceptibility factor for the disease phenotype in 
this kindred.55
 Studying a large multi-generational Dutch family with an isolated HSCR phenotype 
resulted in the identification of a new susceptibility locus on 4q31-32 (the fifth locus), with a 
parametric LOD score of 2.7.56 The low penetrance of the locus in this family suggests that this 
mutation is necessary but not sufficient for disease development. In this thesis we describe 
our search for the disease-causing gene on this locus and for modifiers elsewhere in the ge-
nome by exome sequencing performed in this family (see Chapter 3).
3. Pathogenesis of Hirschsprung Disease: Developmental background 
3.1 Enteric nervous system (ENS) development
(Adapted from Dyer, MA, et al., J Clin Pathol 57, 2004)
Figure 3 - Schematic representation of the neural tube. The enteric neural crest cells (ENCCs) are formed 
in the vagal region, in somites 1-7. From there they migrate rosto-caudally to colonize the whole gastro-
intestinal (GI) tract, later forming the enteric nervous system. Defects in ENCCs migration, proliferation 
or differentiation could lead to HSCR disease. The different lengths of the aganglionosis region in the GI 














The enteric nervous system (ENS) is a complex system that contains as many neurons as the 
spinal cord and it functions independently from the central nervous system (CNS). It coor-
dinates normal bowel motility and changes the blood flow and secretion of water and elec-
trolytes. The intrinsic innervation of the gut wall consists of two interconnected ganglionated 
nerve plexuses: the myenteric plexus, which is located between the longitudinal and circular 
muscle layers, and the submucous plexus, which is located between the mucosa and the cir-
cular muscle layers.57 Neurons and glial cells of the ENS all derive from neural crest stem cells 
(NCSCs), which are pluripotent stem cells. They are formed at the time the neural tube closes, 
at the border of the neural plate and the non-neural ectoderm. They directly migrate towards 
different structures in the embryo to form distinct (neural crest-derived) tissues. These tissues 
include the skin’s pigment cells, the craniofacial bones and cartilage, smooth muscle cells, 
peripheral and enteric neurons, and glial cells of the ENS .58, 59 It is the NCSCs which originate 
from the vagal region of the hind brain, specifically from somites 1 to 7, that give rise to the 
vast majority of the parasympathetic neurons and glial cells of the ENS.60 These precursor 
cells migrate from the vagal region towards the foregut rostocaudally in the 4th week of gesta-
tion in humans, colonize the whole GI tract and reach the end of the hindgut in the 7th week. 
57,61, 62 These precursor cells termed enteric neural crest-derived cells (ENCCs) when they enter 
the foregut.57 A small part of the ENS precursor cells derive from the sacral region. These cells 
migrate in the opposite direction from those from the vagal region and move from the end of 
the hindgut upwards. The sacral ENS precursor cells contribute to ENS development in the 
gut by colonizing the distal part of the GI tract, however, the real contribution of the sacral 
neural crest cells in ENS development is still under debate.63 For instance, a study in chick 
embryos suggested that sacral neural crest cells differentiate only into glial cells and not into 
the enteric neurons.64
All in all, the colonization of the whole GI tract by ENCCs and their later differentiation 
into neurons and glial cells is a very complex process. Timing and harmonization of the neces-
sary transcription factors, growth factors, their receptors and the signals they give is essential 
for each stage of ENS development.65, 66 Any defect in this process (ENCCs migration, prolifera-
tion, differentiation or survival of ENS progenitors) can lead to the development of HSCR.
3.2 Signaling pathways and genes involved in ENS development RET Signaling Pathway
RET is a transmembrane Tyrosine Kinase Receptor (RTK) that plays an important role in 
several intracellular signaling cascades that regulate differentiation, proliferation, migration 
and cell survival. Activation of RET signaling is unique among RTKs as it requires a multi-
protein complex instead of the customary direct receptor-ligand interaction. The RET activa-
12
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tion complex comprises a soluble ligand (GDNF, Neurturin, Persephin or Artemin), GFRα1-4 
(gylcosyl-phosphatidylinositol membrane-anchored co-receptor of GDNF) and RET itself. A 
complex containing the ligand and co-receptor heterodimers brings two RET molecules to-
gether and triggers auto-phosphorylation of tyrosine residues in the TK-domain of RET (see 
Figure 2).67, 68 
RET signaling has been proven critical in ENS development as mice deficient for GDNF, 
RET and GFRα1 show severe defects in enteric innervations (i.e. aganglionosis).21, 22, 27 But 
how RET signaling is involved in ENS development is only partly known. What is known 
is that GDNF, in particular, plays a crucial role, as it serves as a chemo-attractant for the 
RET-positive vagal ENCCs. GDNF is highly expressed in the stomach ahead of the migrating 
ENCCs wave-front and its expression is elevated in the caecum when ENCCs migrate to-
wards the distal part of the gut.66, 69 Besides GDNF, several other ligands can activate the RET 
signaling pathway, namely Neurturin (NTN), Artemin (ARTN) and Persephin (PSPN) that 
bind to GFRα2, GFRα3 and GFRα4, respectively. Mouse Ntn and Gfrα2 mutants show ENS 
defects, revealing their importance in ENS development.70, 71 Furthermore, HSCR patients 
carrying NTN mutations have also been reported.29 
Even though the RET signaling pathway is known to play a pivotal role in many pro-
cesses during ENS development, its downstream effectors, the proteins that transmit signals 
within the cells, are still largely unknown. In Chapter 5 we describe expression array studies 
performed on mouse ENCCs to gain more insight into the RET signaling pathways on GDNF 
stimulation. 
EDNRB-EDN3 Signaling Pathway 
A second pathway involved in HSCR is the Endothelin Receptor type B (EDNRB) path-
way. This belongs to the guanine nucleotide binding protein (G-protein-coupled) receptor fami-
ly, which is activated by its ligand Endothelin 3 (EDN3). END3-EDNRB signaling is required for 
the development of melanocytes and enteric neurons.72 Upstream of EDN3, ECE1 (Endothelin 
Converting Enzyme), the enzyme that converts the inactive precursor of END3 into the active 
EDN3 peptide, thus activates the EDNRB-EDN3 signaling pathway (see Figure 2).
In mouse embryonic gut, Ednrb is expressed in the migrating ENCCs and Edn3 is mainly 
expressed in the midgut and the hindgut mesoderm during the early phases of ENCCs migra-
tion, and at high levels in the caecum and the proximal colon when the ENCCs colonize the 
terminal gut region.73, 74 This pattern of expression suggests that, as for GDNF-RET signaling, 
EDN3-EDNRB signaling plays an important role in ENCCs migration. Furthermore, it also 
suggests that EDN3-EDNRB plays a role in cell proliferation as the Edn3 mutant mouse has 
13
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fewer neural crest stem cells compared to the wild-type mouse.73 Moreover, cell differen-
tiation is inhibited by EDN3-EDNRB signaling.75 Together these studies showed that EDN3-
EDNRB signaling is important for ENCCs migration and proliferation, and for maintaining 
ENCCs in their progenitor state during ENS development.
By using a system that allows the regulation of expression of Ednrb at different stages of 
development, Shin and colleagues showed that EDNRB is required during a limited period 
of ENS development in mouse, namely between embryonic days 10 to 12.5.72 Edn3, Ednrb 
and Ece1 knockout mice show aganglionosis and pigmentary abnormalities, similar to the 
phenotypic abnormalities seen in human patients carrying mutations in these genes (Shah-
Waardenburg syndrome). Mutations on these genes have been identified in approximately 
5% of HSCR cases.1 
RET and EDNRB Interaction
The RET and the EDNRB signaling pathways were considered independent signaling 
pathways, however there are several findings that indicate that the two pathways are indi-
rectly connected. A study by Puffenberger and colleagues identified a homozygous EDNRB 
mutation, which was found in association with a specific RET haplotype in a large Mennonite 
kindred with HSCR disease.76 The data was later corroborated in a genome-wide association 
study of 43 trios from the same Mennonite population. Joint transmission of a specific RET 
haplotype and the previously identified EDNRB mutation with HSCR was found more often 
than would have been expected by chance.55 In an Italian patient with HSCR, both a RET 
mutation, inherited from the unaffected mother, and an EDNRB mutation, from the unaf-
fected father, were identified.38 These studies suggest that there might be a genetic interaction 
between RET and EDNRB. 
Studies using animal models support this hypothesis. McCallion and colleagues (2003) in-
tercrossed mice carrying a Ret null mutation (Ret-/Ret+) and mice carrying an Ednrb loss-of-func-
tion mutation, Ednrbs/Ednrbs or Ednrbs-l/Ednrbs (s: piebald, s-l: piebald lethal). Of the offspring, 
100% of the males carrying the Ret-/Ret+; Ednrbs/Ednrbs genotype were affected, whereas only 
70% of the females were affected with variable lengths of aganglionic colon. In mice offspring 
carrying the Ret-/Ret+; Ednrbs-l/Ednrbs genotype, a genotype that expresses less EDNRB, both 
males and females were equally affected, showing that this sex difference is gene-dose depen-
dant. This suggests there is epistasis between EDNRB and RET.77 Similar studies showed that, 
whereas Ret51/51 and Edn3ls/ls (lethal spotting) mice display colonic aganglionosis, combinations of 
these mutant alleles lead to almost complete intestinal aganglionosis.73
Finally, SOX10, a transcription factor that regulates RET expression, also influences ED-
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NRB expression. Mice carrying Sox10-/- or Sox10-/+ either show reduced or loss of EDNRB ex-
pression, respectively.78  
Other Signaling Pathways
The signaling pathways described above are ones related to known HSCR genes. How-
ever, there are many more signaling pathways that play important roles in ENS development, 
such as the NOTCH, WNT and TGF-β /BMPs signaling pathways. NOTCH signaling is in-
volved in various aspects of neurogenesis. It could decrease cell proliferation (although not 
solely) and it is known to act as a negative regulator for neuron differentiation.79, 80 
WNT signaling induces cell proliferation and maintains the pluripotency of stem cells. 
However, a recent study showed that the result of Wnt signaling can differ between differ-
ent types of stem cells. In ENCCs, for example, WNT signaling is important for cell lineage 
decision-making rather than for maintaining the pluripotency of the stem cells, which is a 
function that WNT signaling has in hematopoietic and CNS stem cells. Deletion of Wnt1 and 
Wnt3a leads to a reduction of neural crest derivates.81 The WNT signaling pathway interacts 
with other signaling pathways, such as the NOTCH and the TGF-β/BMP pathways.
BMP are expressed in submucosal and myenteric plexus and BMP4 has been shown to 
direct or indirectly influence ENCCs migration. Even though BMP4 alone is not sufficient to 
promote cell migration, in the absence of BMP4 activity, the number of ENCCs that reach the 
hindgut is reduced. Furthermore, BMP4 and BMP2 are also required in vitro for cell aggrega-
tion of isolated enteric neurons, which might indicate an important role for BMPs in ganglion 
formation during ENS development.82 Chalazonist and colleagues proposed an interaction 
between GDNF and BMP4 in ENS. This was based on their data that the combination of 
these two proteins synergistically enhanced enteric neural development.83 This study indi-
cates there is possible cross-talk between the RET and BMP signaling pathways in ENS de-
velopment. Another possibility is that GDNF directly influences BMP signaling independent 
of RET, since it has been suggested that GDNF could also interact with neural cell adhesion 
molecule (NCAM), which has been known play a role in a number of developmental process 
including cell migration, neurite outgrowth, and synaptic plasticity.84
4. Aims and Outline of this Thesis
The aims of the studies described in this thesis were to: (1) identify new HSCR-causing genes 
in associated loci reported in previous studies, in particular in 9q31 and 4q31-32.45,56 (2) per-
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form functional assays on a non-coding RET variant (SNP rs2506004) identified by Burzynski 
et al.48 to reveal the pathogenic nature of the variant and to determine the molecular mecha-
nism of this SNP with respect to RET expression regulation; and (3) perform gene expression 
profiling of ENCCs in the presence and absence of GDNF to gain a better insight into the RET 
signaling pathway in this cell type.
Bolk and colleagues showed that the 9q31 region contains a gene or mutation that acts as 
a modifier in the development of HSCR disease.45 This locus was found in families that were 
linked to the RET region but in whom no clear RET-coding sequence mutation was identi-
fied and in one family that was not linked to the RET region. In Chapter 2, we focus on fine 
mapping the 9q31 region by genotyping 301 tagging-SNPs spanning a region of 7 Mb, in 137 
Dutch trios (121 patients without a RET-coding mutation and 16 patients with RET-coding 
mutations) and in Chinese case-controls (173 patients and 436 controls) study. 
In a previous linkage study performed by Brooks and colleagues on a Dutch multi-gen-
erational HSCR family, linkage was identified for a region on 4q31-32.56 In Chapter 3 we tried 
to discover the causative gene in this locus using exome sequencing. 
Previous studies showed strong association of HSCR with a haplotype containing part of 
the 5’ region of the RET gene. This haplotype was transmitted to 60-85% of the HSCR patients, 
but only to 20-40% of the controls. Some of the variants present on this haplotype have been 
reported and suggested as HSCR-causative variant(s) by functional studies. For some pos-
sible causative variants the pathogenic nature has not yet been examined, in particular, SNP 
rs2506004 (C>A) that was identified by Burzynski et al. In Chapter 4, we describe functional 
studies of this SNP. By in silico analysis we found that the C-allele (wild-type) is located in 
a Central Midline Element (CME) sequence, which is a binding site for NXF/ARNT2 tran-
scription activators and SIM2/ARNT2 repressors, respectively. Subsequently, we determined 
whether these transcription factors could indeed regulate RET expression and whether the 
mutant A-allele reduced the enhancer activity of this CME region on RET expression. 
It has been shown that the GDNF-RET signaling pathway plays a central role in ENS 
development. However, the actual downstream effectors of RET signaling, in particular in 
ENCCs, is still largely unknown. To gain a better insight into the downstream effects of GD-
NF-RET signaling, we performed expression microarray experiments on mouse embryonic 
gut and also on ENCCs isolated from mouse embryonic gut (Embryonic day 14.5), untreated 
and treated with GDNF, the ligand of RET. We analyzed the microarray data not only with 
single-gene analysis, but also performed pathway analysis using Gene Set Enrichment Analy-
sis (GSEA) software. The results are presented in Chapter 5.
The summary, general discussion and future perspective are presented in Chapter 6. 
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Hirschsprung disease (HSCR) is a congenital disorder characterized by the absence of ganglia 
along variable lengths of the intestine. The RET gene is the major HSCR gene.  Reduced pen-
etrance of RET mutations and phenotypic variability suggest the involvement of additional 
modifying genes in the disease.  A RET-dependent modifier locus was mapped to 9q31 in 
families bearing no coding sequence (CDS) RET mutations.  Yet, the 9q31 causative locus is 
to be identified. To fine-map the 9q31 region, we genotyped 301 tag-SNPs spanning 7 Mb on 
137 HSCR Dutch trios.  This revealed two HSCR-associated regions that were further investi-
gated in 173 Chinese HSCR patients and 436 controls using the genotype data obtained from 
a genome-wide association study (GWAS) recently conducted.  
Within one of the two identified regions SVEP1 SNPs were found associated with Dutch 
HSCR patients in the absence of RET mutations.  This ratifies the reported linkage to the 9q31 
region in HSCR families with no RET CDS mutations.  However, this finding could not be 
replicated.  In Chinese, HSCR was found associated with IKBKAP. In contrast, this association 
was stronger in patients carrying RET CDS mutations with p=5.10x10-6 [OR=3.32 (1.99, 5.59)] 
after replication. The HSCR-association found for IKBKAP in Chinese suggest population 
specificity and implies that RET mutation carriers may have an additional risk.  Our finding is 
supported by the role of IKBKAP in the development of the nervous system.
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INTRODUCTION
Hirschsprung disease (HSCR; aganglionic megacolon) is a congenital disorder characterized by 
the absence of enteric ganglia along a variable length of hindgut.  There is significant ethnic varia-
tion in the incidence of the disease, and it is most often found among Asians (2.8 per 10,000 live 
births.1 2  Non-familial HSCR has a complex pattern of inheritance and manifests with low, sex-de-
pendent penetrance and variability in the length of the aganglionic segment, according to which 
patients are classified into short segment (S-HSCR; 80%), long segment (L-HSCR; 15%), and total 
colonic aganglionosis (TCA 5%).  The male:female ratio (M:F) is ≈4:1 among S-HSCR patients 
and ≈1:1 among L-HSCR patients. HSCR presents mostly sporadically although it can be familial 
(5-20% of cases) where the recurrence risks to sibs vary from 1.5–33% depending on the gender 
and the length of the aganglionic segment in the proband, and the gender of the sibling.3
The RET gene, encoding a tyrosine-kinase receptor, is the major HSCR causing gene and its 
expression is crucial for the development of the enteric ganglia.4, 5  Mutations in the coding sequence 
(CDS) of RET account for up to 50% of the familial cases and between 15%-20% of the sporadic 
cases, indicating that additional HSCR-causing mutations exist.6  Other HSCR genes identified so 
far mainly code for protein members of interrelated signalling pathways involved in the develop-
ment of enteric ganglia: RET, endothelin receptor B (EDNRB), and the transcriptional regulator 
SOX10.  Yet, mutations in genes other than RET (GDNF, GFRA1, NRTN, PHOX2B, NKX2.1, SOX10, 
NRG1, EDNRB, EDN3, ECE-1, KIAA1279, ZFXH1B, NTRK3, L1CAM) account for only 7%.7-15  Fail-
ure to identify RET CDS mutations in some of the RET-linked families suggests that noncoding RET 
mutations, mutations in regulatory regions of RET could also contribute significantly to the disease. 
Indeed, common RET single nucleotide polymorphisms (SNPs) are strongly associated with HSCR, 
with the largest contribution to risk made by a functional SNP (rs2435357) lying in an enhancer-like 
sequence in intron 1.16-23  We have recently reported the genetic interaction of RET intron 1 rs2435357 
SNP with HSCR-associated NRG1 SNPs whereby the risk to HSCR is increased by 2.3-fold for the 
RET heterozygous genotype.24 Reduced penetrance of RET and other HSCR genes mutations and 
variable expression of the HSCR phenotype indicates that the disease may result from the combined 
effect of several genes whereby the outcome would be altered RET expression.25-28  
RET modifiers have been mapped to the following chromosomal regions: (i) 3p21; (ii) 
19q12 29; (iii) 4q31.3-q32.3 30 and (iv) 9q31.  Despite these important findings, the genes in these 
loci are yet to be identified.  The 9q31 locus segregated in families of European descent har-
bouring no or hypomorphic RET mutations, yet the families still showed linkage to 10q12 (RET 
locus). 31 To identify the HSCR locus in the 9q31 candidate region, we have conducted dense 




The overall study was approved by the institutional review board of The University of Hong 
Kong together with the Hospital Authority (IRB: UW 07-292).  
Dutch (Groningen) family-based association study
The Dutch patient cohort consisted of HSCR 140 trios that were genotyped using Illu-
mina GoldenGate platform for 370 SNPs spanning the 7 Mb (from 108.5–115.5 Mb) of the 9q31 
HSCR-associated region as described in Bolk et al.  Most of these 370 were tag SNPs.  Quality 
control based on identity-by-descent (IBD) revealed 3 duplicated trios.  SNPs with missing 
genotypes (>5%) and with minor allele frequency (MAF)<5% and/or violating Hardy-Wein-
berg equilibrium (p<0.001) were excluded, leaving a total of 301 SNPs for association study. 
PLINK 32 was then used to conduct the TDT analysis in the resulting 137 Dutch trios.  Sixteen 
HSCR probands carried RET CDS mutations.  
Chinese case-control analysis 
Subjects
For analysis of the 9q31 region in the Chinese sample, we revised the genotype data 
of the candidate 9q31.3 region obtained from a previously GWAS conducted on a total of 
181 HSCR Chinese patients and 386 healthy individuals (discovery group) using Affymetrix 
GeneChip®Human Mapping 500K Array as previously described. 24 To that data, we includ-
ed 92 additional controls recently genotyped (see below).  
For the replication of the association found when patients were stratified according to 
the RET mutation status, we included 21 independent HSCR cases bearing RET CDS muta-
tions and 71 control individuals from Mainland China (replication group).Characteristics of 
the patients are depicted in supplementary Tables 1 and 2.
Revision of the Affymetrix 500K data
Following the recent recommendations on quality control standards33 we imposed 
a more stringent filtering criterion based on heterozygosity to the GWAS described above. 
Heterozygosity screening aims at the identification of individuals who have more heterozy-
gous genotype calls than the average of the sample set, since the excess of heterozygosity is 
likely due to cross-contamination of samples.  Hence, outliers should be excluded from the 
analysis.  Prior to evaluating the heterozygosity of the samples, we pruned the SNP data set 
to avoid bias that could have been introduced by large quantities of SNPs in strong LD.  In 
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brief, we pruned the dataset (by removing 1 of a pair of SNPs with r2>0.25 within a window 
of 200 SNPs and shifts of 50 SNPs forward at each step) using PLINK.  In total, 56,000 SNPs 
in LD with each other remained. The heterozygosity screening excluded outliers with more 
heterozygous calls than the average (estimated inbreeding coefficient lower than 3 standard 
deviations from the average).  
After this filtering criteria, a total of 173 HSCR cases (31 patients bearing RET CDS muta-
tions) and 436 controls were included in the analysis.  Restricting by the region analyzed by 
the Dutch group, 988 SNPs falling within the 9q31 7 Mb candidate region (from 108.5–115.5 
Mb) were selected.  The mean call rate was 99.09%.  After filtering by MAF, genotyping rate 
and Hardy-Weinberg equilibrium, 981 SNPs were left for analysis.  
Correction for population structure and association analysis
We used the EIGENSOFT package on the whole genome data pruned for LD as de-
scribed above to detect population substructure.  The Tracy-Widom test (implemented in 
EIGENSOFT) nominated only the first two axes of variation as significant (p<0.05).  The first 
axis of variation corresponded to the ancestral differences between Northern and Southern 
Chinese as seen in supplementary Figure 1.  To correct for these ancestral differences, we ap-
plied EIGENSTRAT 34 (also implemented in EIGENSOFT) on the candidate regions based on 
the two axes of variation nominated by the Tracy-Widom test.  The Cochran-Armitage trend 
test was then used to assess the levels of association of the SNPs with HSCR.
Replication stage
EIGENSTRAT could not be applied to correct the replication sample for population strat-
ification as no genealogy information can be inferred when only two SNPs are genotyped. 
Logistic regression was carried out instead to assess the association in the combined sample 
(discovery + replication samples).  We included a covariate for the sample ancestral origin 
(northern and southern Chinese ancestry) and a covariate to distinguish GWAS and replica-
tion samples, thereby controlling for any possible allele frequency differences between known 
populations and between stages of association analysis.  We also tested the interaction terms 
between each covariate and the genotype, which were found to not be significant (p>0.5 for 
both, indicating that the effect is not significantly different between subpopulations or stages). 




Family-based association test on Dutch trios identifies two associated regions on 9q31
Through TDT analysis of 301 SNPs on 137 Dutch trios, we identified 17 SNPs (supplementary 
Table 3) (p<0.05) showing asymmetrical transmission from parents.  Of these, 10 SNPs could 
be grouped into 2 moderately associated peaks of 5 SNPs each, 9q31A (110.7–111.1Mb) and 
B (112.1-112.7Mb). 
The 9q31A region encompasses a gene-rich spot which contains 4 genes IKBKAP, C9orf6, 
CTNNAL1 and C9orf5 within a single LD block that spans about 100kb.  Among the 5 as-
sociated SNPs, the strongest evidence for association with HSCR was found for rs12351693 
(p=0.023) and rs10979637 (p=0.023) located within the intronic region of CTNNAL1 (Table 1 
and Figure 1A).  
CTNNAL1 encodes alpha-catulin, a protein that modulates the Rho signalling pathway 
by providing a scaffold for the ARHGEF1.35  The expression of its mouse homologue, Ctnnal1, 
was found to be severely reduced in intestines of Ret deficient mice (Retk-/k-) when compared 
to normal mice (Ret+/+) and consequently, the gene has been considered a putative RET modi-
fie.36  
However, the strongest associations lied in 9q31B and mapped upstream the TXNDC8 
gene (p=4.8x10-3 for rs7038415), and in the intronic region of SVEP1 (p=2.9x10-3 for rs10816998) 
(Table 1).  Other associated SNPs within the 9q31B region, mapped to the MUSK gene.  MUSK 
is required for neuromuscular junction formation in vivo and for the survival and devel-
opment of discrete neuronal subpopulations.37  The associations described above were con-
firmed by performing 1 million permutations (Table 1 and Figure 1). 
SVEP1 is associated with HSCR in Dutch patients without RET mutations
As it was reported that the 9q31 HSCR susceptibility locus segregated exclusively in 
RET-linked families depleted of RET CDS mutations31, we stratified the cases according to 
their RET CDS mutation status.  We defined RET CDS mutations as DNA changes in the cod-
ing region or exon/intron boundaries of RET that lead to frame-shift, non-sense or missense 
mutations in the RET protein and that have not been found in at least 400 control chromo-
somes.  PolyPhen 38 was used to predict the effect of the missense mutations on the RET pro-
tein.  Truncating mutations were considered highly deleterious.
The 301 SNPs in the 9q31 region were checked again for association.  The rs10816998 
and rs7038415 SNPs within SVEP1 were strongly associated with HSCR in families without 
RET mutations.  After stratification of the patients, the OR attained a significance level of 
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p=5.33x10-5 with OR=2.379 (95% CI:1.542, 3.671) for rs10816998 and p=7.50x10-5 with OR=2.345 
(95% CI:1.518, 3.622) for rs7038415.  These association values survived the conservative Bon-
ferroni correction for multiple testing (≈300 SNPs).  This finding in the Dutch population is in 
line with the reported linkage of 9q31 with HSCR in patients of European descent bearing no 
or hypomorphic RET mutations.31  
The SVEP1 SNPs rs10816998 and rs7038415, were then genotyped in 107 independent 
Dutch patients without RET CDS mutations and 183 controls. Unfortunately, the p value of 
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A: minor allele; B: major allele;  a: p-value for the transmission disequilibrium test (TDT).
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Figure 1 - Association analysis on 9q31A (110500-111000kb) (left panel) and 9q31B (112000-112500kb) 
(right panel).  (A) TDT analysis on 137 Dutch HSCR trios and (B) Case-control study on Chinese using 
500k.  Associated SNPs listed in Table 1 and 2 are represented as blue diamonds.  Recombination rate 
and genes in the region are also shown (green, “+” strand; red, “-“ strand).
Revision of the population-based GWAS on Chinese identifies IKBKAP as a HSCR 
candidate gene
We used the GWAS data (above described) to investigate the association observed in 
the Dutch.  After EIGENSTRAT correction for stratification (see material and methods and 
supplementary material), genotypes of 981 SNPs spanning the entire 9q31 region were tested 
for association on 173 HSCR patients (31 with RET CDS mutations) and 436 controls.
In the Chinese dataset, 6 SNPs within the 9q31A region showed association with HSCR. 
No association was found in 9q31B.  The loci displaying the strongest statistical evidence for 
association were rs10979596 and rs10979597 (in intron 25 of the IKBKAP gene) which are in 
complete LD with each other (r2=1) (Figure 1B and Table 2).  Four additional SNPs within 
IKBKAP also showed marginally significant association (p<0.03) with HSCR.  These include 
the IKBKAP I816L missense polymorphism (rs2230793, p=0.024) and 3 intronic SNPs (Table 
2).  Mutations in IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells ki-
nase complex-associated protein, involved in transcription elongation) are associated with a 
neurodevelopmental disease, the Riley-Day syndrome, also known as familial dysautonomia 
(FD).39, 40  FD is an autosomal recessive disorder that occurs almost exclusively in persons of 
Ashkenazi Jewish descent.  This neuropathy results from depletion of subsets of autonomic 
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and sensory neurons.41  FD patients are born with fewer neurons in their dorsal root and sym-
pathetic ganglia than their peers, and over time, neurons become more scarce.42  Most impor-
tantly, some patients with FD also suffer from gastrointestinal dysfunction shortly after birth 
and interestingly, the co-occurrence of both FD and HSCR has been reported.43  Interestingly, 
the region encompassing our 6 IKBKAP associated SNPs includes the region where FD-causing 
mutations lie.  Ikbkap is expressed in the rat developing gut and IKBKAP in the human colon, 
supporting a biological role for this gene in the development of enteric nervous system.42, 44 
The association of IKBKAP is stronger in Chinese HSCR patients with RET mutations
The Chinese HSCR patients were also stratified according to the RET CDS mutation 
status.  We then tested again the 981 SNPs in the 9q31 region for association by independently 
comparing RET CDS mutation carriers (31 Chinese HSCR patients; discovery group) against 
436 controls as well as non-carriers (142 HSCR patients) versus the same control set.  
Twelve SNPs were found associated with HSCR in RET mutations carriers (p<0.01).  Im-
portantly, 6 of these SNPs mapped to the IKBKAP loci in the 9q31A and had been found as-
sociated with HSCR before the stratification of the patients according to the mutation status 
(Figure 2).  This data suggested that the initial association detected was mainly driven by this 
subset of RET mutation carriers and that the original marginal association had been masked 
prior stratification because of the small number of carriers.  Among the 12 SNPs segregating 
with RET mutations, four IKBKAP SNPs survived the conservative Bonferroni correction for 
multiple testing (≈1000 SNPs) (Table 3).  The frequency of the risk SNPs alleles tended to in-
crease with the severity of the RET mutations, yet the small sample does not allow to draw 
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Figure 2 - Association analysis on RET Chinese CDS mutation carriers (left) and Chinese non-carriers 
(right).  Blue diamonds represent associated SNPs before stratification by mutation status.  Dark blue 
diamonds indicate the 4 SNPs that survived the Bonferroni correction multiple for testing (only 3 dark blue 
diamonds can be observed as there is overlapping between two SNPs).
To validate the association of the IKBKAP SNPs with HSCR patients carrying RET CDS 
mutations, we genotyped (by PCR followed by direct sequencing) the 2 perfectly linked SNPs 
(rs10979596 and rs10979597) in an independent set of 21 HSCR patients (replication group) 
bearing RET mutations and 71 controls collected from mainland China.  These SNPs were 
chosen for replication because they fall in the same amplicon and on the basis of genetic 
homogeneity between Northern and Southern Chinese.  We successfully detected the associa-
tion of rs10979596 and rs10979597 in the replication sample, with logistic regression associa-
tion value of p=9.45x10-3 and OR=3.38 (95% CI: 1.35, 8.49) (Table 4).  Logistic regression was 
also used for the combined analysis of HSCR samples bearing RET mutations (discovery, 
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a: Survived Bonferroni correction for multiple testing;  b: Frequency in HSCR patients carrying RET CDS 
mutations;  c: same frequencies for these two SNPs as r2=1;  d: corrected  trend test computed using 
EIGENSTRAT;  MAF: minor allele frequency;  Note that the MAFs increase with the severity of the RET mutation.
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p=2.71x10-6 and OR=3.15 (95% CI:1.95, 5.09) for the heterozygous genotype under an addi-
tive model.  Considering the possible population stratification, we employed the same lo-
gistic regression approach conditioning on the strata defined by sample origins (Northern 
and Southern Chinese), obtaining a significant level of association of p=5.75x10-6 with OR=3.29 
(95% CI:1.97, 5.51) (Table 4).  Results of the latter approach were very similar, indicating that 
samples collected inside and outside Hong Kong (discovery and replication phases) were 
homogeneous, with little stratification. 
DISCUSSION
This study aims at the identification of a HSCR susceptibility locus in the 9q31 region.  As 
the association of this region was initially reported in families of European descent, we first 
explored the region in a Dutch cohort.  As the evaluation of an association in two popula-
tions of different ethnic origins would definitively increase confidence in the finding, we also 
explored the 9q31 region in the Chinese.  We reasoned that this strategy would allow us to 
determine i) whether the 9q31 locus exerted an effect in patients of European descent other 
than those in whom the locus was initially identified, ii) assess whether the association of the 
9q31 locus with HSCR is population specific, and if not; iii) use population differences in LD 
to fine-map the gene of interest.









































Table 4 -  Summary of the statistics for the IKBKAP rs10979596 and rs10979597 markers 




NA:  all cases and control used in the replication stage had the same ancestral origin of northern Chinese; 
a: HSCR patients carrying RET CDS mutations
b: P-value adjusted for population substructure in GWAS (500K) analysis and for both the substructure and strata 
defining analysis stages (500K and replication) in combined analysis
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bearing no RET CDS mutations.  This finding ratifies the reported linkage to the 9q31 region 
in HSCR families with no RET CDS mutations.  The case-control replication of the SVEP1 
association in the Dutch did not reach statistical significance indicating that the initial asso-
ciation was spurious or that there is a population stratification issue in the samples used for 
replication.  This point would need further exploration in a much larger sample.  The role of 
SVEP1 is not well characterized.  Study of its possible implications in the development of the 
nervous system should follow.
Intriguingly, the analysis of the region in the Chinese population demonstrated the exis-
tence of a HSCR-associated locus (IKBKAP) that, although within 9q31, is not correlated at all 
with the SVEP1 locus identified in the Dutch.  The association of IKBKAP SNPs with HSCR in 
Chinese became much more prominent in those patients with RET CDS mutations which is at 
odds with the initial findings described by Bolk and our own findings in the Dutch.  Impor-
tantly, the IKBKAP association with HSCR bearing RET CDS mutations was replicated in the 
same Chinese population.  No IKBKAP association was detected in the Dutch (supplementary 
Table 4).  
We investigated whether the lack of cross-population replication of the associations of 
SVEP1 and IKBKAP SNPs with HSCR could be due to population LD and allele frequencies 
differences, in which case, some true associations may not be replicated, regardless of the 
sample size of the study.  Close examination of the SVEP1 and IKBKAP regions showed no 
major LD differences between CEU and CHB HapMap populations indicating that lack of 
replication across populations was not due to differences in LD structure (Supplementary 
Figures 2 and 3).  Lack of replication could also be attributed to a false positive result on the 
Chinese sample although we think this is unlikely since the initial association found in Chi-
nese was replicated in an independent sample.  
In view of these results, we would conclude that the 9q31 locus that appears associated 
with HSCR in families bearing no RET CDS mutations is indeed population specific, as the 
findings in Chinese point to a different locus with a completely different genetic behavior 
than that identified in the Dutch.  As 9q31 locus was reported to segregate exclusively with 
RET-linked families of Caucasian origin whose members had weak or hypomorphic RET CDS 
mutations, the investigation of SVEP1 rare variants in these type of patients is warranted.  
The association of IKBKAP in Chinese implies that RET mutation carriers may have an 
additional risk.  As yet, no genotype-phenotype correlation could be found which, after all, is 
in line with the genetic complexity inherent to HSCR.  Had parental DNA been available, we 
might have been able to provide an argument for the role of IKBKAP SNPs on the penetrance 
of inherited RET CDS mutations.  SNPs may modulate the penetrance or phenotype of a par-
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ticular mutation through epistasis as exemplified by the exclusive action of the FGFR2 and 
MAP3K1 SNPs in BRCA2 mutation carriers.45
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A: Minor allele; B: Major allele;  a: ‘T and ‘U’ indicate transmitted and untransmitted minor allele of each SNP
41
Fine mapping of the 9q31 Hirschsprung disease locus
Figure 1 - Plot of principal components identified by EIGENSOFT.
Figure 2 - LD structure across the 9q31A (right) and 9q31B (left) regions in CEU and CHB+JPT
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Figure 3 - LD structure of IKBKAP SNPs in CHB and CEU.  The associated SNPs in 
Chinese which fail to replicate in Dutch are shown along the x axis (highlighted in blue: p-
value passing multiple testing).  SNPs in moderate to high LD in CHB (y-axis) can also be 
tagged effectively (r2>0.8) by at least one of these nine associated SNPs (x-axis) in CEU, 
demonstrating the population-specific association.  LD information for monomorphic SNP 
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Hirschsprung disease is a congenital disorder characterized by the absence of enteric ganglia 
in a variable length of the intestinal tract. A linkage study performed on a large, multi-gener-
ational, Dutch family with five family members affected with Hirschsprung disease revealed 
significant linkage to 4q31.3-q32.3. We have sequenced the exomes of two patients from this 
family, focusing our search for mutations on this linkage region. We assumed an autosom-
al dominant model of inheritance with low penetrance, suggesting that the mutation in the 
linkage region is necessary but not sufficient to cause disease development. Exome sequenc-
ing revealed only one possible mutation in the linkage region, a single nucleotide change in 
exon 20 of the LRB gene. This variant was validated in all five affected family members. As 
this variant is located downstream of MAB21L2, a gene which plays a role in enteric neural 
crest cells (ENCCs) migration during ENS development, we hypothesized that this mutation 
might regulate MAB21L2 expression in ENS, thereby disturbing ENS development. How-
ever, we identified this variant in four individuals out of 220 screened controls and once in 
87 Hirschsprung patients. It is therefore unlikely that it is disease-associated. As this was the 
only variant we identified in the linkage region, we must have missed the causative mutation, 
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INTRODUCTION
Hirschsprung (HSCR) disease is a congenital disorder characterized by the absence of enteric 
ganglia in a variable length of the intestinal tract. Based on the length of the aganglionic re-
gion, HSCR is classified into three types: short-segment (S-HSCR), long-segment (L-HSCR) 
and total colonic aganglionis (TCA). The estimated incidence of HSCR varies in different pop-
ulations; it is lowest in Caucasians (1:5000) and highest in Asians (1.4:5000). Mostly, HSCR oc-
curs sporadically and most cases are diagnosed with S-HSCR and only in a minority of cases 
(5-15%) is more than one patient seen in a family (familial HSCR).1 
The pattern of inheritance of sporadic cases can be multifactorial, recessive or dominant 
with low penetrance, while familial cases can be either recessive or autosomal dominant, in 
both cases with incomplete penetrance2. So far, 12 genes and five loci have been implicated in 
HSCR and RET is considered to be the major gene in HSCR etiology. The 12 genes are: RET 3, 
EDNRB 4, EDN3 5, 6, GDNF 7, 8, NTN 9, SOX10 10, 11, PHOX2B 12, ECE1 13, KIAA1279/KBP 14, ZF-
HX1B 15, 16, TTF-1/TITF1 17, 18 and NRG1 19. Besides RET, most other genes are involved in what 
is called syndromic-HSCR, HSCR patients who also suffer from other congenital malforma-
tions besides HSCR. Altogether, mutations in these 12 genes explain no more that ~20% of the 
total heritability, suggesting that other disease associated genes must exist.
In a previous linkage study, Brooks and colleagues identified a linkage region on 4q31.3-
q32.3 in a multi-generational, Dutch HSCR family with five affected members.20 The pattern 
of inheritance in this family seems to be autosomal dominant with low penetrance, indicating 
that the mutation in this region is necessary but not sufficient to cause the disease. It therefore 
seemed likely that in addition to the chromosome 4 mutation, other modifier genes or variants 
contribute to the development of the disease. This 4q linkage region contains at least 57 genes. 
From a functional point of view, Brooks et al. picked the MAB21L2 gene as the most promising 
candidate, however no coding mutation was found in this gene. 
We have now sequenced all exons (the exome) of two affected family members from dif-
ferent branches of the family in an attempt to identify the disease-associated mutation in the 
linkage region. Furthermore, we looked for possibly other modifier mutations elsewhere in 




Patients and DNA Samples
DNA from the five affected individuals, from 220 normal controls and from 87 HSCR patients 
was isolated from peripheral blood leucocytes using a standard protocol. For exome sequenc-
ing, we selected two affected members from different branches of the family (V-1 and V-4, 
see Figure-1). Validation of some identified variants by Sanger sequencing was performed in 
these two individuals and on three more affected family members (IV-3, V-2 and V-3).
Figure 1 - Pedigree structure and haplotypes. Patients are represented as black symbols. The segre-
gating haplotype, 4q31-q32, is depicted. The minimum critical region at chromosome 4 spans 11.7 cM 
between D4S3049 and D4S1566 (adapted from Brooks et al. 2006). 
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Exome Sequencing and Pipeline Data Analysis
Five microgram of DNA from each individual was used for exome sequencing. For exome 
capturing and enrichment, we used the hybrid capture SureSelect Human All Exon kit (Agilent 
Technologies, Amsterdam, the Netherlands) which targets most human exons (approximately 
38 Mb). The captured fragments were sequenced on a Genome Analyzer II (Illumina, San Diego, 
USA). The alignment of the sequencing results, the SNP calling and data filtering was performed 
using a pipeline set up by the Genomics Coordination Centre (GCC), hosted by the Department 
of Genetics, UMCG, Groningen. The pipeline is based on the genome analysis toolkit (GATK) 
version 1.0.4418 developed at the Broad institute (Boston, USA). dbSNP v1.29 is incorporated 
into this pipeline for filtering of known SNPs. The SNPs that passed the threshold of all the 
criteria of the pipeline and that were unknown in dbSNP v1.29 were further filtered by check-
ing whether they were known in a later version of dbSNP (dbSNP v1.31) or mentioned in the 
1000 Genomes database. SNPs were further checked for their presence in both the sequenced 
patients and in an unrelated sample that was run at the same time on the Genome Analyzer II 
(Illumina). The list of variants of this unrelated sample we call ”in-house controls”. This last 
step was incorporated into the whole filtering process to reduce the number of false-positives 
introduced during the enrichment and sequencing processes. As the pattern of inheritance is 
autosomal dominant, we focused on searching for heterozygous mutations. 
Deletion-Insertion Polymorphism (DIP) Analysis
Deletion-insertion polymorphism (DIP) analysis was performed using a program called 
CLC bio (CLCbio, Muehltal, Germany). It was performed only for chromosome 4. Again, 
as the pattern of inheritance seems to be autosomal dominant, we focused on searching for 
heterozygous DIPs and we set the minimum variant frequency at 30%, with a window length 
of 11 bp, a maximum number of gaps and mismatches of 2, and a coverage of at least 10. 
Validation of Candidate Variants (PCR and Sequencing)
PCR reactions were performed in a final volume of 15 µl, containing 100 ng of DNA, 
1.5 µl of 10X PCR buffer (Invitrogen, Leek, the Netherlands), 15mM MgCl2, 0.15 µl of 
25mM dNTPs, 1 unit of Taq Polymerase (Invitrogen) and 1 µl of 20 pmol/µl of each prim-
er. The following primers were used for LRBA 5’CCACATAACTTAAGGTTGATTC3’ and 
5’GATATAAGGAGATGTGGCTG3’; for ARMC9 5’ TGGCCAGGTTTGTCTTGC3’ and 5’ 
GGCTTCCTAAAGGCCTCTTG3’; for CD27 5’ CTGGGATTACAGGCATGAG3’ and 5’ GC-
CTGAGACAGTTCTTACG3’. The PCR conditions were as follows: pre-heating 1 min at 95°C, 
followed by 35 cycles of 45 seconds at 95°C, 45 seconds at 60°C and 45 seconds at 72°C. The 
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final elongation step was 10 min at 72°C. PCR purification was performed by using EXOSAP 
IT according to the manufacture’s manual (GE Healthcare, Eindhoven, the Netherlands). For 
Sanger sequencing we used 5 µl of purified PCR product. 
RESULTS
Exome Sequencing 
A total of 2.9-3.0 GB of paired-end sequence data was generated per individual, with a mean 
read length of 101 bps. About 84.4% of bases were mapped to the target exons and, on aver-
age, 64.8% of the exome was covered at least 10 times. A summary of the exome sequencing 
performance is shown in Table 1.  
13,403 and 14,637 variants per individual passed the pipeline’s thresholds for SNP call-
ing. After filtering with dbSNP build 129, version 131 and the 1000 Genome database, using 
the SeattleSeq annotation, 501 and 544 novel variants were identified per individual. To iden-
tify potentially pathogenic variants, we focused only on missense, splice-site, and nonsense 
mutations also insertions and deletions (indels). An overview of our SNP calling results is 
shown in Table 2. DIP analysis on chromosome 4 did not identify any heterozygous deletion 
or insertion.
Raw data yield (bp) 2.974.801.379 3.023.364.300
Target region (bp 38.925.539 38.925.539
Base-pairs mapped to genome 2.325.231.999 2.336.642.676
Base-pairs mapped to target region 1.303.155.126 1.382.373.365
Base-pairs mapped to target and flanking regions 2.036.529.862 2.065.636.143
Mean read length (bp) 101 101
Mean depth of target region 37.34 38.71
Coverage of target region 33.47 35.51
Fraction of targets covered ≥ 2X (%) 80.14 83.29
Fraction of targets covered ≥ 10X (%) 62.85 66.70
Fraction of targets covered ≥ 20X (%) 50.39 53.70
Fraction of targets covered ≥ 30X (%) 40.29 42.82
Capture specificity (%) 43.80 45.72
Patient V-1 Patient V-4
Table 1 - Summary of the statistics of exome sequencing analysis of two HSCR patients.
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Selection of Possible Disease-Causing SNPs
As the two individuals we sequenced are related they should have mutations in com-
mon. Ten new variants proved to be present in both individuals (genome-wide) (Table 3). 
Three of them, however, were also identified in the “in-house controls” and were therefore 
not considered as possible disease-associated candidate variants. Three of the seven remain-
ing SNPs that were still possibly disease-causing were predicted as probably damaging in 
Polyphen-2 (Polymorphism Phenotyping v2). One of the three variants was in the linkage 
region, in exon 20 of LRBA (LPS Responsive beige-like Protein Kinase A anchor). A second 
possibly damaging variant was located in exon 19 of ARMC9 (chromosome 2) and the third 
was located in exon 1 of the OR1F1 gene (chromosome 16). 
Variants identified (pipeline) 13,403 14,637
Unknown SNPs (in dbSNP129) 743 859
Unknown SNP in dbSNP131 and the 1000 genome database 501 544
*coding-synonymous 115 102






*splice-sites (SS) 1 3
*utr-3 4 19
*utr-5 4 6
Missense+SS+nonsense variants 203 224
Missense+SS+nonsense variants present in both patients 10 10
Variants - probably damaging (Polyphen) 3 3
Variants - benign (Polyphen) 6 6
Variants - unknown (Polyphen) 2 2
No. of genes in overlapped variants 9 9
Private missense + SS + nonsense variants 193 214
Patient V-1 Patient V-4
Table 2 - Overview of the SNP calling and filtering steps in two HSCR patients.
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Validate of Candidate Variants
To confirm a role for these missense mutations in the disease process, we 
screened all five affected individuals for the presence of these variants The variant in 
exon 20 of the LRBA gene was confirmed in all five affected family members, while 
the variant in ARMC9 was confirmed in three of the five (V-1, V-3 and V-4). The 
variant on CDC27 was not confirmed in any of the five individuals, showing that an 
allele-balance (AB) threshold less than 0.6 is crucial to defining the real variant and 
notifying a false-positive one. For this reason we did not validate the remaining four 
candidate variants as all of them had an AB value of more than 0.6. The variant in 
exon 20 of LRBA is a missense mutation that changes an Asparginine to a Serine (N > 
S). This amino acid (N) is conserved in humans, mouse and zebrafish (Figure 2A).
A 784 YNVLFEILIEQIGTQVIHKQHPDPDSSVKIQNPQILKV 821 Homo sapiens(LRBA)
 784 YNVLFEILIEQICTQVIHKQHPDPDSTVKIQNPQILKV 821 Mus musculus(LRBA)
 142 YNVLFEILTEQICTQVIHKQHPDPDSTVKIQNPQILKV 162 Danio rerio (LRBA-like)
 142 YNVLFEILTEQICTQVIHKQHPDPDSTVKIQNPQILKV 162 Danio rerio (LRBA-like)
B 536 REEARAMGMEDILRCFIKEGNAEMIRQIEFIIKQLNSE 563 Homo sapiens (ARMC9)
 536 REEARAMGMEDILRCFIKEGNAEMIRQIEFIIKQLNSE 564 Mus musculus (ARMC9)
Figure 2 - A) Comparative alignment of part of the protein seqeunce of LRBA (using human, mouse and 
zebrafish data). The amino acid encoded by the LRBA variant (N > S) is colored in grey. B) Comparative 
alignment of part of the ARMC9 amino acid sequence of human and mouse. The amino acid encoded by 
the ARMC9 variant (R > C) is colored in red. Zebrafish has a predicted ortholog of ARMC9, however the 














































































































































































































































































































































































































































































































































































LRBA Variant in Controls and HSCR Patients
We checked for the prevalence of the LRBA variant in a control population and in a 
HSCR population. The HSCR patients that were screened do not carry a RET coding sequence 
mutation. The LRBA variant was identified heterozygously in four of the 220 healthy indi-
vidual (4/440 chromosomes: 0.9%) and heterozygously in one of the 87 HSCR patient (1/174 
chromosomes: 0.57%). 
ARMC9 Variant in Controls 
We checked for the prevalence of ARMC9 variant in a control population and we identi-
fied the variant heterozygously in six healthy individual (6/296 chromosomes: 2%). 
DISCUSSION
We identified a possible disease-associated variant in exon 20 of the LRBA gene in two cases 
from a large, multi-generational HSCR family on which we performed exome sequencing. We 
confirmed the presence of this variant in all five affected family members by Sanger sequenc-
ing. However, this variant proved to be present in the control population (0.9%, 4/440 chro-
mosomes), and as the incidence rate of this variant is lower in our HSCR population (0.5%, 
1/174 chromosomes) compared to the control population, it is unlikely that the variant is a 
strong HSCR-predisposing mutation or even a modifier gene for HSCR. A second variant was 
identified in ARMC9. The variant was identified in three of the five affected members (V-1, 
V-3 and V-4). However, the variant was also present in the control population (0.57%, 6/298 
chromosomes) which again makes it unlikely that this variant is a disease-associated. 
As the LRBA variant was the only variant we found on chromosome 4 that was present in 
both the exome-sequenced cases, we assume that we have probably missed the causative vari-
ant that all the cases in this family should have in common on chromosome 4. This was likely 
due to technical issues. One of the criteria we used in SNP calling was a minimum coverage 
of 10. The statistical data presented in Table 1 show that only 62.8% and 66.70% of the target 
sequences were covered with a minimum number of 10 reads. In fact, we found that when we 
lowered the coverage to 2, we still only had a coverage of 80.14% and 83.29%, respectively. 
In short, this means that by taking a coverage of 10, we do miss mutations in almost 40% of 
the target sequences (Table 1). Furthermore, the enrichment kit used in this experiment cov-
ers 81.33% of all human exons. So, in addition to the missed 40% of target sequences, we also 
missed about 19% of all exomic data. These figures led us to conclude that we might well have 
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missed the real disease-causing mutation.
Although we did not find any common mutation on chromosome 4, we wondered 
whether we could still select the best possible candidate gene associated with HSCR based on 
function in order to perform additional analysis. This led us to MAB21L2, which was men-
tioned earlier. MAB21L2 is expressed in the neural crest derivatives, including the progenitor 
cells of the neurons and the glial of the enteric nervous system.21 MAB21L2 is a downstream 
target of the TGF-β/SMADs signaling pathway, which is important for ENS development. 
Knock-down of the MAB21L2 ortholog in zebrafish showed that subsequent ENCCs migra-
tion along the intestine is perturbed and a reduction of cell differentiation was seen, all indi-
cating that normal MAB21L2 function is required for normal ENCCs migration during ENS 
development (I. Sheperd, personal communication). 
As mentioned earlier, MAB21L2 has already been sequenced and no coding mutation 
was found.20 We therefore decided to extend our sequencing efforts to the promoter region, 
and in fact we sequenced 16 Kb upstream of MAB21L2 in all five affected family members. 
However, again, no mutation was identified (data not shown). One could argue that our anal-
ysis more or less excluded MAB21L2 as the best candidate HSCR gene. However, this might 
not be completely true as will become clear from the following reasoning.
MAB21L2 is located within the LRBA gene, shown in Figure 3. The MAB21L2 is tran-
scribed from the anti-sense strand of LRBA gene. This unique nested gene pair (LRBA and 
MAB21L2) is conserved in mouse, chick, frog and zebrafish. 
 
  
Figure 3 - Schematic overview of the LRBA and the MAB21L2 genes and their position in the genome. 
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Moreover Tsang and colleagues identified five paralogous, non-coding elements (pNEs) 
that are scattered throughout LRBA. They are located both upstream and downstream of 
MAB21L2 and could regulate the expression of a reporter gene in a tissue-specific manner 
during mouse embryonic development, comparable to the expression patterns of MAB21L2.22 
Mutations in the LRBA locus might also have a regulatory effect on the gene that is tran-
scribed from the anti-sense strand, namely MAB21l2. As we screened only part of the LRBA/
MAB21L2 locus, we cannot exclude that there are mutations in the locus that have an influ-
ence on MAB21L2 expression. 
We therefore propose to re-sequence the affected family members, but with a higher cov-
erage and for a larger targeted sequence, including the entire LRBA genomic region (thereby 
including the multiple species conserved region that are involved in expression regulation of 
MAB21L2)
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Background & Aims: Two non-coding RET variations, the T allele of SNP rs2435357 (Enh1:C>T) 
and the A allele of SNP rs2506004 (Enh2:C>A), are strongly associated with Hirschsprung disease 
(HSCR) susceptibility. These SNPs are in strong linkage disequilibrium and located in an enhanc-
er element in intron 1 of the RET gene. For Enh1 it has been shown that the disease-associated 
T allele results in reduced expression in Luciferase experiments, via disturbed SOX10 binding, 
compared to the non-disease associated C allele. We aimed to determine whether Enh2-A is also 
a functional variant. 
Methods: We evaluated the function of Enh2-A by Luciferase assays of constructs containing 
both alleles, separately or in combinations. We performed in silico analysis to identify a possi-
ble transcription activator or repressor that binds to Enh2-C (non-disease associated variant). 
Results: Luciferase assays showed that not only the Enh1-T allele but also the Enh2-A allele 
decreased Luciferase expression. In silico analysis identified the sequences of Enh2-C and 
its surroundings sequences (-ACGTG-) as a potential binding site for the NXF/ARNT2 and 
SIM2/ARNT2 heterodimers. The binding affinity of NXF/ARNT2 to Enh2-C was confirmed by 
Electrophoresis Mobility Shift Assays and Supershift. Transfections of NXF/ARNT2 or SIM2/
ARNT2 into neuroblastoma cell lines increased and decreased RET expression, respectively. 
Conclusions: Our results show that more than one SNP on an associated haplotype can influ-
ence disease development. Our data strongly implicate the involvement of NXF, ARNT2 and 
SIM2 in RET expression regulation, thereby contributing to HSCR development. 
Abbreviation: CME, central nervous system midline enhancer; ENS, enteric nervous system; 
HSCR, Hirschsprung disease; MCS, multi-species conserved sequences; NLBs, neurosphere-
like bodies; NPE, nuclear protein extract; NCSCs, neural crest stem cells; SNP, single nucle-
otide polymorphism
Keywords: Hirschsprung disease, RET expression, Down Syndrome
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INTRODUCTION
Loss-of-function mutations in the RET gene are associated with Hirschsprung’s disease 
(HSCR), a congenital disorder characterized by the absence of ganglia in the distal part of the 
gut. Genetic dissection of HSCR has led not only to the identification of mutations in RET, but 
also to coding mutations in 10 other genes. Of these eleven genes, RET is believed to be the 
major factor in the etiology of HSCR. Coding sequence mutations in RET have been found 
in up to 50% of familial and 15 to 35% of sporadic cases of HSCR.1 However, genome-wide 
linkage analysis on multigenerational HSCR families and sibpairs studies on smaller HSCR 
families showed that in almost all of the families, RET seems to play a role2, 3. This led to the 
hypothesis that non-coding RET mutations likely play a role in these familial cases. It further 
led us to hypothesize that non-coding variants may also play a role in the sporadic cases. 
Association studies carried out on several European and Asian patient populations, 
mostly without RET mutations, indeed showed a very strong association with a specific RET 
haplotype (Figure 1)1, 4-15. In fact, regardless of the population, the same haplotype, spaning 
~27 Kb (4 Kb of the 5’ UTR and exon 1; 23 Kb of intron 1 and exon 2) is present in most HSCR 
patients. It is now believed that the mutation(s) on this haplotype are probably present in 
intron 1, within an enhancer region13, 14. In both zebra fish and mice it was shown that the re-
porter gene expression patterns driven by this enhancer element (called MCS+9.7) are similar 
to RET, both in a tissue and in a time-wise manner16, 17. There are two SNPs in this enhancer 
sequence: rs2435357 (Enh1:C>T) (also called RET+3)13 and rs2506004 (Enh2:C>A) (also called 
IVS+9494)14, of which the Enh1-T and the Enh2-A alleles both are strongly associated with 
HSCR13, 14. Emison proposed that Enh1-T was most likely the disease-associated allele based 
on conservation and functional arguments14 18. However, the Enh2-A allele, an allele in strong 
linkage disequilibrium with Enh1-T (r = 0.969), was also present in the constructs used for the 
functional interpretation of Enh1-T14. Thus we cannot totally exclude that this Enh2-A allele 




Figure 1 - An overview of the reported Hirschsprung (HSCR) disease-associated SNPs
MATERIALS AND METHODS
Construction of Vectors
The enhancer elements, containing one or both HSCR-associated SNPs, were PCR ampli-
fied using patients DNA as template, and cloned into KpnI/XhoI sites of a pGL3-Luciferase 
construct already containing the RET promoter or the SV40 promoter (Promega, Madison, 
WI, USA). Constructs containing a combination of non-disease- and disease-associated vari-
ants for both SNPs were generated in RETprom+Enh1-C/Enh2-C by site-directed mutagenesis 
(QuickChange XL Site-Directed Mutagenesis kit, Stratagene, Texas, USA). For primers see 
Supplementary Table 2.  The sequences of the inserts were checked by direct sequencing. 
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Figure 2 - Schematic overview of the RET gene and the constructs used in this study. (A) SNP rs2435357 
(Enh1:C>T) and SNP rs2506004 (Enh2:C>A) are both located in a conserved region of intron 1, called 
MCS+9.7, separated by 217 bp. (B) RET and SV40 promoter constructs coupled to Luciferase and en-
hancer sequences used in this study. 
Luciferase Assays
Transient transfections were performed using a mouse neuroblastoma cell line (Neuro-
2A) which was cultured according to the ATCC protocol. 0.5 x 106 Neuro2A cells were plated 
in 35 mm dishes for 48 hours prior to transfection. Cells were co-transfected with 100 ng of 
pRL-SV40-Renilla Luciferase (Promega, Madison, USA) as an internal control and 1 mg of the 
reporter constructs containing different enhancer elements (Figure 2B) using 4 ml of Lipo-
fectamineTM2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacture’s protocol. 
Luciferase activity was analyzed with a Dual-Luciferase-Reporter Assay (Promega) 24 hours 
after transfection. The ratios of Firefly Luciferase compared to Renilla Luciferase (normalized-
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The results presented in the graphs are fold changes of normalized-Luciferase expression of 
each construct to the control (pGL3-RET or pGL3-SV40 promoter). Activation or repression of 
Luciferase expression by NXF/ARNT2 and SIM2/ARNT2, respectively were performed by co-
transfection the NXF/ARNT2 (1mg/500ng) or SIM2/ARNT2 (1mg/500ng) with 1 mg of reporter 
construct containing different enhancer elements. In all cases the amount of the transfected 
DNA was the same, if necessary this was achieved by adding pCDNA3. The assays were 
performed in three, independent, triplicate experiments. For the dosages effect experiment, 
three different dosages of NXF/ARNT2 or SIM2/ARNT2 (100/50 ng, 500/250ng and 1 mg/ 500 
ng) were used. 
Statistical Analysis
Statistical analysis of the Luciferase assay results was performed using the one-way 
ANOVA test. The results represent the mean ± S.E.M. Statistical analysis was performed by 
GraphPad Prism 4. P-values of < 0.05 were considered significant. 
Protein Analysis 
Western blotting was performed to check the level of RET expression in the Neuro2A cell 
line, after NXF/ARNT2 or SIM2/ARNT2 transfections. Transient transfection was performed 
as described above. For the mock control, cells were only transfected with 1.5 mg pcDNA3. 
After 24 hours cells were harvested and total cell lysates were isolated using CellLyticTM (Sig-
ma Aldrich, Saint Louis, USA) according to the manufacture’s protocol. Protein concentra-
tions were determined using the BCA protein assay (Pierce Biotechnologies, Rockford, IL, 
USA) and measured on a NanoDrop® ND-1000 (Thermo Scientific, Waltham, MA, USA). 30 
mg of cell lysate was used for Western blotting. Primary antibodies anti-RET, and anti-b-Actin 
were applied and visualized with the respective IgG-HRP secondary antibodies (see supple-
mentary Table 3).
Neural Crest Stem Cells (NCSCs) Isolation and Culture
C57BL/6 mouse embryos E11.5, E12.5, E13.5, E14.5 and E15.5, were sacrificed and the gut 
(jejunum to rectum) was used for the isolation of NCSCs. The gut was mechanically dissected 
and tissues were incubated in collagenaseXI /dispaseII enzyme solution (collagenase XI [750U/
ml], Sigma Aldrich, Saint Louis, USA; dispase II [250 mg/ml], Roche, IN, USA) in PBS, incubated 
at 37°C for up to 5 minutes. Digested tissue was triturated until homogenous cell suspensions 
were created. Cell suspensions were washed and seeded onto 35 mm Petri dishes coated with 
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fibronection 2 mg/cm2 (Sigma Aldrich) in 2 ml of DMEM-F12 medium (PAA) supplemented 
by N2 supplement 1:100, B27 supplement 1:50 (Invitrogen, Carlsbad, CA, USA), Penicillin (100 
IU/ml)/ streptomycin (100 µg/ml) (PAA), 20 ng/ml FGF, 20 ng/ml EGF (Peprotech EC, London, 
UK) . Half of the medium was refreshed every two days and fresh EGF and FGF were added 
to the medium. The neural crest-derived cells were kept in culture as neurosphere-like bodies 
(NLBs) for 14 days. 
RT-PCR
Total RNA was isolated from NLBs cultures using the RNeasy mini kit (Qiagen) accord-
ing to the manufacture’s protocol. Two micrograms of RNA were transcribed into cDNA with 
the Ready-To-Go First Strand Synthesis kit (GE-Health care) according to the manufacture’s 
instruction. PCRs were performed by using 1.25 ml of cDNA for 35 cycles using the primers 
given in supplementary Table 4. 
Immunohistochemistry
Immunostaining was performed on cryosections (12 mm) of frozen NLBs. NLBs were cen-
trifuged at 180g in a microtube and then frozen in OCT embedding compound (Tissue-Tek; 
Sakura Finetek, Tokyo, Japan). Cryosections of NLBs were fixed in 4% PFA for 10 minutes at 
room temperature and rinsed three times in PBS before application of blocking solution (PBS 
containing 10% donkey serum, 0.1% Triton X-100) for 30 minutes at room temperature. Primary 
antibodies anti-RET, NXF, SIM2 and ARNT2 were applied and visualized with the respective 
fluorochrome-conjugated secondary antibodies (see supplementary Table 5). Cell nuclei were 
stained with 4’-6-diamidino-2-phenylindole [DAPI] solution (Invitrogen; 100 ng/ml) and cover-
slipped with Kaiser’s gelatine (Merck, Darmstadt, Germany). The images were captured on a 
Nikon inverted fluorescence microscope (Nikon, Dusseldorf, Germany).
EMSA and Supershift Assays
Nuclear protein extracted from Neuro2A cells transfected with NXF/ARNT2, SIM2/
ARNT2, SIM2, NXF and ARNT2 constructs were isolated using a Nuclear Protein extraction kit 
(Sigma Aldrich, Saint Louis, USA). Complementary oligonucleotides (30 bp) containing either 
Enh2-C or Enh2-A were designed (see Supplementary Table 6). Sense and antisense oligonu-
cleotide were 3’end labeled (Biotin3’end-DNA labeling kit, Pierce Biotechnologies, Rockford, 
IL, USA) according to the manufacture’s protocol. Binding experiments were performed using 
an EMSA kit (Pierce) according to the manufacture’s protocol using 20 mg of nuclear protein 
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and 1 ml of 25 fmol of biotin labeled oligonucleotides. In the competitive reactions a 1000 times 
excess of unlabeled oligonucleotides was added. In the Supershift experiments, 1 ml rabbit 
polyclonal NXF antibody (Abcam, Cambridge, UK) was mixed with 10 mg of total lysate of a 
NXF and ARNT2 positive cell line (SK-N-SH). Gelshifts were visualized using the LightShift® 
Chemiluminescent EMSA kit (Pierce).
RESULTS
Mutations in either Ehn1 or Ehn2 reduce reporter gene expression 
Constructs expressing Luciferase, driven by the RET or SV40 promoter coupled to the RET 
enhancer sequence containing SNP rs245357 (Enh1:C>T) or SNP rs2506004 (Enh2:C > A), were 
transfected into Neuro2A cells. The inserts containing Enh1, Enh2 and Enh1/Enh2 differ in 
length; 300bp, 400bp and 500 bp respectively. These differences might have an effect on bind-
ing affinity. Therefore, we compared the expression of the mutant constructs to their WT 
counterparts. Constructs with the SV40 promoter showed that both the disease-associated 
alleles (Enh1-T/Enh2-A) separately or in combination, decreased the Luciferase expression 
approximately two-fold (Figure 3A). Constructs in which the RET enhancer sequence was 
coupled to the RET promoter, however, showed that only when the two disease variants were 
both present, were able to decrease Luciferase expression (Figure 3B). In these RET promoter 
experiments, we did not test whether one or both mutant alleles were necessary for the reduc-
tion of Luciferase expression. Therefore, by using site-directed mutagenesis, we made con-
structs that contain a combination of one non-disease-associated variant and its counterpart 
disease-associated variant (Enh1-C/Enh2-A or Enh1-T/Enh2-C). We could show that a muta-
tion in either variant decreased the Luciferase expression (Fi gure 3C). 
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Figure 3 - Panel (A) shows under SV40 promoter regulation, both the Enh1-T and the Enh2-A separately 
or in combination decreased the Luciferase expression approximately 2-fold. (B) Under RET promoter 
regulation, only when both diseases associated SNPs are present they can decrease Luciferase expres-
sion. (C) Constructs with the RET promoter coupled to the enhancer sequence containing combination of 
a non-disease associated variant and its disease-associated counterpart (Enh1-T/Enh2-C and Enh1-C/
Enh2-A),, showed that both SNPs could significantly decrease Luciferase expression. The bars indicate 
the mean ± S.E.M of the fold changes of Luciferase expression for each construct. p < 0.05 was consid-
ered significant.
In silico analysis of the MCS+9.7 sequence 
MatInspector (www.genomatix.de) analysis of the MCS+9.7 sequences showed that the 
Enh2-C allele with its surrounding sequences -ACGTG- (also known as the Central Nervous 
System Midline Element (CME))  is a core binding site of the heterodimers NXF/ARNT2 and 
SIM2/ARNT2. These heterodimers have the same core binding sequence, but have opposite 






Reduced NXF/ARNT2 binding to Enh2-A compared to Enh2-C
To check whether the NXF/ARNT2 heterodimer could indeed bind to the Enh2-C se-
quence, we performed Electro Mobility Shift Assay (EMSA). Oligonucleotides containing the 
Enh2-C allele or the Enh2-A allele were mixed with the nuclear protein extract (NPE) of Neu-
ro2A cells that were transiently transfected with either the NXF or ARNT2 constructs or with 
both constructs together. Protein binding was determined to be sequence specific if the excess 
of unlabeled oligonucleotides could replace the labeled oligonucleotides (Cp-Sp) while the ex-
cess of unrelated-unlabeled oligosnucleotides could not replace it (Ns-SP). NPE of Neuro2A 
transfected with all these constructs could bind to both oligonucleotides containing Enh2-C or 
Enh2-A (Figure 4A and B: lane 1, 3 and 4). Only one band of the NPE of Neuro2A transfected 
with NXF/ARNT2 (Figure 4A lane 1, white arrow) could be completely deleted by an excess 
of unlabeled oligonucleotides and stay the same when an excess unrelated-unlabeled was 
used in the competition assay (Figure 4A lane 5 and 6). Furthermore, this specific band has 
less or no binding to the oligonucleotides containing Enh2-A (Figure 4B lane 1, white arrow). 
To confirm whether this protein complex bound to Enh2-C is NXF/ARNT2, Supershift assays 
were performed using an anti-NXF antibody and a total lysate of a SK-N-SH, a human neu-
roblastoma cell line positive for NXF/ARNT2. Total lysates of SK-N-SH had the same binding 
pattern as the NPE of Neuro2A transfected by NXF/ARNT2 (Figure 4C and D, lane 1 arrow 
white and black). When the antibody anti-NXF was applied, the upper band was shifted and 
the lower band was blocked (Figure 4C and D, lane 4) showing that these two bands contain 
the NXF protein. Notably the polyclonal ARNT2 antibody was not able to either block or su-
pershift the upper band (data was not shown). This could be because the epitope of ARNT2 
is hidden and is not recognized by the antibody. Based on these results, we conclude that the 
upper band (white arrow) is the NXF/ARNT2 heterodimer. Based on EMSA results (Figure 
4A lane 3) and Supershift results (Figure 4C lane 4, black arrow) we assume that the lower 
band most likely is NXF alone. Similar experiment was performed using NPE of Neuro2A 
cells transiently transfected with SIM2/ARNT2, SIM2 and ARNT2 (Figure 4E and F). It was 
shown that SIM2/ARNT2 and SIM2-alone gave a specific band for both Enh2-C and Enh2-A 
suggesting that only SIM2 binds to the enhancer sequence, independent of the mutation sta-
tus (Figure 4E and F, lane 1 and 3). 
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Figure 4 - Panel (A) and (B) show EMSA using labeled oligonucleotides containing Enh2-C and Enh2-A 
with nuclear protein extract (NPE) of Neuro2A cells transfected with NXF/ARNT2, NXF or ARNT2 con-
structs: an extra band (white arrow) appeared when oligonucleotides containing Enh2-C allele were used 
in combination with NPE containing both NXF and ARNT2. In a competition assay (Cp-Sp) in lane 5, the 
extra band as seen in lane 1 disappeared, while excess of unrelated, unlabeled oligonucleotide (Cp-NS), 
could not compete the specific labeled oligonucleotide (lane 6). (C) and (D) EMSA-Supershift (SS) as-
says using Enh2-C and Enh2-A labeled oligonucleotide with total cell lysates of the SK-N-SH cell line and 
anti-NXF antibody showed that the highest band was shifted upwards and the second lower band became 
weaker (was blocked) (lane 4). Based on Fig. 4C, the highest band (white arrow), which is shifted by the 
NXF antibody, is the NXF/ARNT2 complex, and the second band (black arrow), for which the binding is 
blocked in lane 4, most likely is NXF. (E) and (F) EMSA using labeled oligonucleotides containing Enh2-C 
and Enh2-A with NPE of Neuro2A transfected with SIM2/ARNT2, SIM2 or ARNT2 contruct. SIM2 has the 
same binding affinity to the enhancer sequences containing Enh2-C or Enh2-A (lane 1 and 3), the speci-
ficity of this binding is confirmed in competition specific and non-specific assays (lane 5 and 6).
RET, NXF, SIM2 and ARNT2 are expressed in NCSCs isolate from mouse embryonic gut 
Neurosphere-like bodies (NLBs), propagated in vitro from the gut of mouse embryos 
E11.5-E15.5 (Figure 5A) were checked for expression of RET, NXF, ARNT2 and SIM2 by RT-
PCR. The result showed that RET, SIM2, NXF and ARNT2 are expressed in all stages ana-
lyzed. The RET expression increase in time, while NXF and SIM2 expression reach the highest 
level on E12.5 to 14.5 and decrease on E15.5. The neural progenitor status of RET positive 






genitor marker p75 (Figure 5B). In addition, the majority of SIM2 and ARNT2-positive cells 
co-expressed RET (Figure 5C and 5D). The only available commercial NXF antibody revealed 
no satisfying results on mouse tissue and it therefore could not be used for immunostaining 
(data not shown). 
  
Figure 5 - Panel (A): By using RT-PCR method it is showed that RET, NXF, SIM2 and ARNT2 are ex-
pressed in NCSCs isolated from mouse embryonic gut: E11.5, 12.5, 13.5, 14.5 and 15.5. (B) Progenitor 
status of RET positive cells in neurosphere-like body (NLBs) cultures by co-immunostaining with the 
neural crest marker p75: i) DAPI staining, ii) RET expression, iii) p75 expression and iv) co-expression 
of RET and p75. C) SIM2 co-expression with RET in NLBs cultures: i) DAPI staining, ii) RET expression, 
iii) SIM2 expression and iv) co-expression of RET and SIM2. D) ARNT2 co-expression with RET in NLBs 
cultures: i) DAPI staining, ii) RET expression, iii) ARNT2 expression and iv) co-expression of RET and 
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NXF/ARNT2 and SIM2/ARNT2 increases and decrease RET expression respectively via the 
RET promoter and the enh2 sequences. 
Not only the RET enhancer sequence (MCS +9.7) but also the RET promoter (starting 5.1 
kb upstream of the RET start site) contains six CME (Central Nervous System Midline Ele-
ment) variants. NXF/ARNT2 and SIM2/ARNT2 might regulate RET expression via binding 
to the enhancer region containing the Enh2-C allele and the RET promoter. To prove this, we 
performed co-transfections of NXF/ARNT2 or SIM2/ARNT2 with the RET promoter (RET-
prom) constructs with or without the enhancer sequences containing Enh2-C or Enh2-A, into 
Neuro2A, a cell line not endogenously expressing NXF, SIM2 and ARNT2. Figure 6A shows 
that co-transfection of NXF/ARNT2 with the RET promoter construct increases the Luciferase 
expression 1.25-fold, while co-transfection with RETprom+Enh2-C allele, the Luciferase levels 
go up 1.75-fold. The RETprom+Enh2-A allele results in a Luciferase expression level compa-
rable to that of the RETprom construct without the enhancer sequence. This shows that NXF/
ARNT2 can regulate RET expression via both the promoter and the enhancer sequences. On 
the contrary, the co-transfection with SIM2/ARNT2 decreased the Luciferase expression level 
two-fold for the RETprom construct (without enhancer). Similar levels of Luciferase expres-
sion were obtained for the constructs containing the RET promoter coupled to the enhancer 
(for both the Enh2-C and the Ehn2-A allele). These data suggest that the binding of SIM2/
ARNT2 to either of Enh2-C or Enh2-A is ablating the enhancer effect. Therefore the expression 
levels of the RETprom with Enh2-C or Ehn2-A are equal to those of the RETprom alone, in 
the present of SIM2/ARNT2 expression.  Furthermore, by increasing the amount of constructs 
transfected, we could induce an increase of up- or down-regulation of gene expression (Fig-
ure 6C and D). This shows that expression regulated by NXF/ARNT2 and SIM2/ARNT2, via 
the RET promoter and the enhancer sequence, depends on dosage (Figure 5C).
72
Chapter 4
Figure 6 - Panel (A) shows the effect of NXF/ARNT2 to Luciferase expression of constructs containing 
the RET promoter or the RET promoter and enhancer containing Enh2-C or Enh2-A. (B) Effect of SIM2/
ARNT2 to Luciferase expression of constructs containing the RET promoter or the RET promoter and 
enhancer containing Enh2-C and Enh2-A variants. (C) and (D) a possible (not significant) dosage effect 
of NXF/ARNT2 and SIM2/ARNT2 on Luciferase expression driven by the RET promoter and enhancer 
regulation. Three dosages of NXF/ARNT2 and SIM2/ARNT2 constructs were used.  The bars indicate the 
mean ± S.E.M of fold changes of Luciferase expression for each construct after co-transfection of NXF/
ARNT2 or SIM2/ARNT2. In figures C and D the bars indicate the mean ± S.E.M of normalized-Luficerase 
expression for each construct after co-transfection with three different dosages of NXF/ARNT or SIM2/
ARNT2. p < 0.05 was considered significant.
Level of endogenous RET protein expression is up- and down-regulated after NXF/ARNT2 
& SIM2/ARNT2 transfection, respectively
To check the effect of NXF/ARNT2 and SIM2/ARNT2 on endogenous RET expression, 
we transfected three different dosages of the NXF/ARNT2 or SIM2/ARNT2 constructs into 
Neuro2A cells. The level of RET endogenous expression was checked by Westernblot. The 
transfection of the highest dosage of NXF/ARNT2 in the cell line enhanced the RET expression 
level 2.25 times, whereas the transfection of the highest dosage of SIM2/ARNT2 constructs 
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Figure 7 - Panel A shows Western blotting of total cell lysate of Neuro2A cells transfected with three dif-
ferent dosages of NXF/ARNT2 or SIM2/ARNT2: D1 (100/50 ng), D2 (500/250 ng) and D3 (1000/500 ng) 
using anti-RET and anti-b-Actin primary antibodies. (B) Densiometric analysis of the Western blots. The 
highest dosage of NXF/ARNT2 enhanced RET expression 2.25-fold compared to the RET expression in 
the mock controls. (C) Densiometric analysis of the Western blots. The highest dosage of SIM2/ARNT2 
decreases RET expression 2.6-fold compared to the RET expression in the mock controls. The bars indi-
cate the mean ± S.E.M of fold changes for RET endogenous expression after transfection of NXF/ARNT2 
or SIM2/ARNT2. p < 0.05 was considered significant.
DISCUSSION
Recent studies showed that the T allele of SNP rs2435357 (Enh1-T), a SNP present in an en-
hancer element (MCS+9.7) in intron 1 of the RET gene, contributes to HSCR development. It 
was shown in reporter assays that the construct containing the non-disease associated allele, 
Enh1-C, contrasts to that with the disease-associated allele, Enh1-T, by enhancing luciferase 
expression 6-fold14. Furthermore, in vitro assays showed that the effect Enh1-T has on RET 
expression is caused by a disruption of a SOX10 binding site within the enhancer element18. 
However, in the sequence used in all the experiments, a second SNP is also present, namely 
rs250600414. The A allele of this SNP is also strongly associated with HSCR,13 what is not sur-
prising as they are only 217 base pairs apart. We investigated whether the disease-associated 
allele, Enh2-A, also played a role in regulating RET expression. 
































gene expression regulation, we generated Luciferase-reporter constructs containing the two 
alleles of only Enh1 or Enh2 and constructs containing alleles of the two SNPs, under the 
regulation of the SV40 or the RET promoter (RETprom). Luciferase assays showed that the 
disease-associated allele of each SNP, separately or in combination, under SV40 regulation, 
could reduce Luciferase expression (Figure 3A). However, under RET promoter regulation, 
only the construct containing both non-disease associated SNPs together could yield the en-
hancer effect, while the disease-associated SNPs, together, decreased Luciferase expression 
(Figure 3B). It is likely that the constructs used to show the effect for the SNPs independently 
were lacking sequences necessary for the binding of RET-specific transcription factors. This 
experiment still left the possibility that only one of the SNPs is the functional variant. To de-
fine the function of each SNP, we generated constructs containing the non-disease associated 
allele of one SNP with the disease-associated allele of the other SNP, under RET promoter reg-
ulation. Luciferase assays of these constructs showed that Enh1-T or Enh2-A in the existence 
of its non-disease associated counterpart could significantly reduce Luciferase expression. 
The effect of the Enh1-T allele is bigger than for the Enh2-A allele, but the combination of both 
SNPs did not double the effect (Figure 3C). This experiment showed that disease-associated 
alleles of both of these SNPs can contribute to the development of HSCR. 
To elucidate the effect of Enh2-A on the functioning of the enhancer, and to identify a 
protein candidate that could bind to this SNP, we analyzed the enhancer sequences contain-
ing the non-disease and disease-associated variants by MatInspector software (www.genom-
atix.de). The Enh2-C (non-disease) allele and its surrounding sequence proved to be pres-
ent in the -ACGTG- sequence, also known as the Central Nervous System Midline Element 
(CME).20 This CME sequence element and three other CME variants (-GCGTG-, -TCGTG- and 
–CCGTG-) are binding site of NXF/ARNT2 and the SIM2/ARNT2 heterodimers.19.
NXF is a basic-Helix-Loop-helix/Per-Arnt-Sim (bHLH/PAS) protein, which is mainly 
expressed in neuronal tissues. It was shown in a previous study that NXF can form a het-
erodimer with ARNT2. Moreover, it was proven that  NXF/ARNT2 competes with the SIM2/
ARNT2 heterodimer in binding to the CME sequences.19 These two heterodimers regulate 
gene expression for the Drebrin gene as transcription activator and repressor, respectively, via 
binding to the CME sequences in the Drebrin’s promoter. We therefore hypothesized that both 
NXF/ARNT2 and SIM2/ARNT2 are also involved in regulating RET expression via the bind-
ing of these two heterodimers to the CME in the Enh2 sequence. Moreover, as we detected six 
CME variants in the promoter of RET, we cannot exclude that these sites also play a role in the 
expression regulation. By EMSAs and a Supershift assay, using a NXF antibody, we showed 
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that the NXF/ARNT2 heterodimer could indeed bind to the Enh2-C (non-disease associated) 
allele and that the heterodimer has less binding affinity to Enh2-A, the disease-associated al-
lele (Figure 4A, 4B, 4C and 4D, lane 1). EMSAs of SIM2/ARNT2 showed that also SIM2 could 
bind to Enh2 but that it had the same binding affinity to the wild type and the mutant Enh2 
sequences.
A first step to prove our hypothesis was to show that these proteins are expressed in 
the (migrating) neural crest stem cells (NCSC), the progenitors of the cells that are lacking in 
the hindgut of HSCR patients. Therefore, we checked by RT-PCR and immunohistochemical 
staining the presence of NXF, SIM2 and ARNT2 in NCSC isolated from embryonic guts (E11.5 
until E15.5). By day 15.5 the migration of the NCSCs and the formation of the enteric nervous 
system is complete in the mouse. We show that RET expression is up-regulated during this 
period, while SIM2 and NXF were expressed in all stages analyzed with the highest expres-
sion at E12.5 to E14.5. Furthermore, immunostaining of neural progenitor cells isolated from 
mouse embryonic gut day 13.5 showed that both SIM2 and ARTN2 are expressed (Figure 5C 
and D). 
To check whether NXF/ARNT2 and SIM2/ARNT2 can indeed activate and inhibit the ex-
pression of RET, via the RET promoter and/or via the enhancer region containing the Enh2-C 
allele, we co-transfected NXF/ARNT2 or SIM2/ARNT2 constructs with the RET promoter-Lu-
ciferase constructs, with or without the enhancer sequences containing the Enh2-C or Enh2-A 
alleles, into Neuro2A cell lines. The results show that NXF/ARNT2 could enhance the Lu-
ciferase expression via the RET promoter and via the enhancer sequence containing Enh2-C. 
The disease-associated allele, Enh2-A, reduces the Luciferase expression to the level of the 
RET promoter only (Figure 6A). In contrast, co-transfection of SIM2/ARNT2 resulted in a de-
crease of Luciferase expression. 
 Furthermore, the level of Luciferase expression proved to depend on the dosage of NXF/
ARNT2 and SIM2/ARNT2, as by increasing concentrations of NXF/ARNT2 or SIM2/ARNT2 a 
further up- or down-regulation of Luciferase expression was measured, respectively (Figure 
6C and D). To further strengthen these data, we also performed a comparable dosage-effect 
experiment in mouse Neuro2A cells, checking endogenous RET expression. The results con-
firmed the patterns of gene expression found in our initial Luciferase assays. The highest dos-
age of NXF/ARNT2 increased RET expression levels by 2.25-fold, while the highest dosage of 
SIM2/ARNT2 reduced RET expression levels by 2.6-fold (Figure 7). 
SIM2 is located in the critical region for Down Syndrome on chromosome 21 and it is 
expressed in the fetal brain, particularly in regions crucial for cognitive processes. Moreover, 
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it was shown that overexpression of SIM2 in rat and mouse hippocampus impairs the ability 
of learning and memory by inhibiting synaptic plasticity.21, 22 Interestingly, in Down syndrome 
patients who have three copies of the SIM2 gene, the structure of the brain regions expressing 
SIM2 are altered.23 What this overexpression of SIM2 leads to is only partly known, although it 
was shown that overexpression of this gene leads to reduced expression of Drebrin, a protein 
playing an important role in synaptic plasticity.18 Its expression is known to be decreased in the 
brains of Down syndrome patients.24 We have now shown that SIM2 overexpression results in a 
down-regulation of RET. This finding might partly explain why we see a 40-fold higher risk for 
HSCR disease in Down syndrome patients than in the general population of newborns.
In this study we have proved that not one but at least two SNPs on the HSCR-associated 
haplotype can contribute to the disease phenotype. However it is still unclear when exactly 
these SNPs act in the disease development. They might deregulate proliferation during the 
first stages of embryogenesis, or impair migration of the NCSCs, or play a role during prolif-
eration when the cells reach their final destination in the gut. We cannot exclude the possibil-
ity that the different disease-associated SNPs play a role at different stages of development, 
or are involved in different processes. Previous studies showed evidence for the involvement 
of at least two additional SNPs on the same haplotype. These SNPs are located at -5 and -1 
from the start site of the RET gene (Figure 1). It was also shown that the TTF-1 protein binds 
to this region and that TTF-1 can activate the RET promoter10, 12. Our new data and previously 
published data hold an important message for the study of complex diseases, namely that 
more than one SNP on an associated haplotype might influence disease development. So far, 
almost all studies have stopped when a SNP was found with a proven functional effect. We 
have shown that even when such a SNP has been found, there may be more SNPs involved 
in the disease development. This means that polygenic diseases are even more complex than 
originally thought. 
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Supplementary Table 3 - Antibodies used in Westernblot















R&D system, MN, USA
MP Biomedical, Irvine, CA, USA








Sense :  5’- GGTCTGGGTATGGACGTGTGGGTGGTGGCC -3’
Anti-sense : 5’-GGCCACCACCCACACGTCCATACCCAGACC-3’
Sense :  5’- GGTCTGGGTATGGAAGTGTGGGTGGTGGCC  -3’
Anti-sense : 5’- GGCCACCACCCACACTTCCATACCCAGACC -3’
Supplementary Table 6 - Oligonucleotides containing Enh-2C and Enh-2A used for EMSA







Anti-Goat IgG Alexa 488















R&D system, MN, USA
MP Biomedical, Irvine, CA, USA
Santa Cruz
Promega, Mannheim, Germany
Invitrogen, Carlsbad, CA, USA
Invitrogen, Carlsbad, CA, USA
Supplementary Table 5 - Antibodies used in Immunohistochemistry






F : 5’- CCACTGGGCCTCTATTTCTC -3’
R: 5’- TGCCCTCCTTCCGCTTAAAC -3’
F : 5’- TTGACCCTGCTGACCATCTC -3’
R: 5’- GTCTGGGAAGGTAGCACTGCTG -3’
F: 5’- TCACCTGCTCCAAGAGTACGA -3’
R: 5’- TGGCTGACATCCAGTTTGTC -3’
F: 5’-ACCAGCAGGAATGACCATAC -3’
R : 5’-CTTGGCCTTTCAGCTTAACC-3’
F : 5’-ATATCGCTGCGCTGGTCGTC -3’
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Signaling of the RET receptor is crucial for the migration, proliferation, differentiation and sur-
vival of neural crest cells (ENCCs) that form the enteric nervous system (ENS). Disturbances 
in RET signaling are associated with ENS defects, as is seen in patients with Hirschsprung 
disease.
To gain new insight into the pathways involved in or triggered by RET in ENCCs, we 
performed gene expression profiling with RNA isolated from GDNF- (the RET ligand) stimu-
lated and non-stimulated mouse ENCCs. Microarray data on ENCCs was compared with 
microarray data generated from mouse embryonic gut E14.5 and analyzed by gene set enrich-
ment analysis (GSEA) and single-gene analysis methods. Pathways that were up-regulated 
upon GDNF stimulation included those for ATP- and biosynthesis while those significantly 
down-regulated upon GDNF stimulation were several known development-dependent path-
ways, such as the Notch, Tgf-β/Bmp and Wnt signaling pathways. Moreover, we saw that the 
Toll-like receptor (Tlrs) signaling pathway, important for apoptosis and the innate immune 
response, was down-regulated upon GDNF stimulation. This is interesting as Hirschsprung 
patients often suffer from inflammation of the colon and small intestine (enterocolitis). By 
qPCR we were able to confirm down-regulation of Tlr2, Tlr4 and Tlr5 and downstream effec-
tors of the Tlrs, such as Tnfα and Il-6, pointing toward the involvement of Ret signaling in the 
immuno-modulatory capacity of ENCCs.
In conclusion, GDNF stimulation promotes proliferation of ENCCs rather than differen-
tiation. RET seems to be involved in regulating the innate immune response of ENCCs via the 
TLRs pathway which is possibly linking RET to enterocolitis.
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INTRODUCTION 
The RET proto-oncogene encodes a transmembrane glycoprotein belonging to the receptor 
tyrosine kinase (RTKs) family. During vertebrate embryogenesis, RET is expressed in motor 
and catecholaminergic neurons of the central nervous system (CNS), in the developing excre-
tory system and in all lineages of the peripheral nervous system (PNS), including neural crest 
cells (ENCCs). ENCCs originating from the vagal region of the hindbrain contribute to the 
vast majority of parasympathetic neurons and glial cells of the enteric nervous system (ENS).1 
In mouse, vagal neural crest cells migrate in a rostocaudal direction to the foregut at E9.5 and 
reach the hindgut at E15.5, while sacral crest cells migrate in the opposite direction at E13.5.1-3 
In humans, ENCCs start to invade the foregut at week 4 and reach the terminal hindgut at 
week 7 of gestation.4 This process of proliferation and migration of ENCCs into the whole 
gastrointestinal (GI) tract, followed by differentiation into ENS neurons and glial cells, is very 
complex. The timing and harmonious action of transcription factors, growth factor, their re-
ceptors and the signaling effectors is essential for each stage of development of the ENS.5, 6 The 
RET, Retinoic Acid (RA), WNT, NOTCH, BMP and FGF signaling pathways are some of the 
pathways that are known to play important roles in ENCCs development in the gut. 
Defects in proper migration, proliferation or differentiation of ENS progenitors can lead 
to the development of Hirschsprung disease (HSCR), the most common ENS-related disor-
der. It is characterized by the absence of neurons and glial cells in the myenteric and sub-
mucosal plexus of the enteric nervous system and is mostly limited to the most distal part of 
the colon. The inheritance of HSCR is complex: the disease can be transmitted as a dominant 
trait, or as a recessive trait, but in the majority of cases it is believed to be polygenic. There are 
clear differences in the sex ratio of patients, with a male predominance in short-Hirschsprung 
disease (S-HSCR) (4:1). The disease has an incomplete penetrance, variable expression and is 
associated with a large number of syndromes and congenital malformations.7 Over the last 
15 years, at least 12 genes that play an important role in the development of HSCR disease 
have been identified. The RET gene is considered to be the major disease risk factor as coding 
sequence mutations are identified in up to 50% of familial cases and in 15-35% of sporadic 
HSCR cases.8 In fact, the RET signaling pathway is believed to be one of the most important 
signaling cascades in regulating proper migration, proliferation, differentiation and survival 
of ENCCs during ENS development.1, 9 This is corroborated by several animal studies as mice 
deficient for the Ret receptor but also for the Ret co-receptor Gfrα1, or the Ret ligand Gdnf, all 
show severe defects in enteric innervation.10-13 
Little is known about the signaling cascades triggered by RET in ENCCs or the actual 
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downstream effectors of RET signaling in these cells. We therefore analyzed the RET network 
and its downstream effectors in ENCCs in detail. ENCCs were isolated from E14.5 mouse 
embryonic gut and cultured in the presence or absence of GDNF followed by expression 
profiling. We also performed gene expression profiling of mouse gut (E14.5). This study has 
identified genes and signaling pathways that are trigged by the RET signaling pathway in 
ENCCs and that can further contribute to our understanding of RET signaling pathway and 
its role in HSCR development. 
MATERIALS AND METHODS
Animals
Transgenic mice carrying Wnt1-Cre-recombinase and a LoxP/R26-YFP site were obtained 
from the Jackson Laboratory, California, USA, and maintained on a C57BL/6 background. The 
age of the embryos was set at E0.5 on the day when the vaginal plug was seen. Mouse em-
bryos carrying the transgenes produce green fluorescent ENCCs, and are easily identified by 
the green cranial face and green gut under a fluorescence microscope (Figure 1B). 
ENCCs isolation, in vitro culturing and GDNF stimulation
Pregnant female transgenic mice were sacrificed at stage E14.5. The embryos were re-
moved and transferred into cold PBS solution. Under the microscope, only the fluorescent 
embryos indicating transgene expression were selected. We then carefully dissected the gut 
(foregut to hindgut) and transferred these into cold PBS. The embryonic gut from a single 
embryo was dissected and treated with 1 ml of collagenase/dispase enzyme solution (Sigma 
Aldrich, Saint Louis, USA] as described before.14 The resulting cell suspension was diluted in 
1 ml of DMEM/F-12 medium supplemented by 1% N2 (Invitrogen, Carlsbad, CA, USA), 2% 
B27 (Invitrogen), 20ng/ml FGF (Peprotech EC, London, UK), 20 ng/ml EGF (Peprotech EC) 
and 1% Penicillin-Streptomycin (Invitrogen). The cell suspension was filtered using sterile cell 
strainers with 40 µm nylon mesh (Becton Dickinson, Oxford, UK). Single YFP-ENCCs were 
sorted via a MoFlow cell sorter (Beckman Coulter, London, UK) and directly seeded into a 
24-wells plate coated with fibronectin (2 µg/cm2, Sigma Aldrich) filled with 0.5 ml of culture 
medium. YFP-ENCCs cells from one gut were divided into two wells of 24-wells plate. One 
well was filled with normal medium and one with medium containing GDNF (50ng/ml). The 
plates were incubated at 37oC for 14 days in a humidified atmosphere with 5% CO2. Half 
of the medium was changed every two days and fresh GDNF (only for GDNF treated cells), 
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FGF and EGF were added. Small neurosphere-like bodies (NBLs) appeared after 3-5 days and 
were kept in culture for 14 days without splitting. 
RNA isolation and gene expression profiling
Cells were washed twice with 1 ml of RNAse free 1X PBS. RNA isolation was performed 
using the RNeasy Mini Kit (Qiagen, Crawley, UK) according to the manufacture’s instruction. 
The RNA yield, purity and integrity were determined using the Agilent 2100 BioAnalyzer 
with 6000 Nano Chips (Agilent Technologies, Amsterdam, the Netherlands). Custom DNA 
microarray experiments and RNA quality controls were performed by ServiceXS (Leiden, the 
Netherlands) using the GEneChip Mouse Genome 430 2.0 arrays of Affymetrix. These array 
experiments were performed on RNA isolated from nine independent ENCCs cultures, un-
treated and treated with GDNF (in total 18 samples) and eight arrays were hybridized with 
RNA isolated from the whole gut of embryonic mice, C57BL/6 wild-type E14.5.
Data analysis
Student’s t-tests, with Bonferroni multiple testing corrections (p< 0.05) were used for the 
single gene analysis. Gene Set Enrichment Analysis (GSEA) was performed using GSEA 2.0 
(Broad Institute, Cambridge, MA, USA).15, 16 In our analysis, we assembled genes sets from 
well-accepted and widely used curated pathway databases, such as the KEGG and TRANS-
FAC.17, 18 We used a nominal p-value < 0.05 and a false discovery rate (FDR) < 0.10 to define 
sets of genes that were significantly differentially expressed between two conditions (with or 
without GDNF). 
ENCCs GDNF activation and immunomodulatory capacity
ENCCs (3–4x104cells/well) were seeded into 24-well plates. After one night of culturing, 
GDNF 50 ng/ml of medium (Peprotech EC) was added and incubated for 48 hours, untreated 
cells served as control. Supernatants were collected and secreted protein levels of Tnfα and 
Il-6 were measured by mouse Tnfα and Il-6 ELISAs LEGEND MAXTM (Biolegend, San Diego, 
USA). ELISAs were performed on three independent experiments in triplicate (n = 9).The cells 
from which we used the supernatant for the ELISAs were also used to isolate RNA for a qRT-
PCR experiment (see below). For this, cells were washed with 1X PBS and RNA was isolated 
using the GeneJetTM RNA purification kit (Fermentas, St.Leon-Rot, Germany) and cDNA was 




RNA levels of Tlr2, Tlr4, Tlr5, Tnfα, Il-6, Il1-β, p50 (Nf-κb component) and Ifnγ were quan-
tified by real-time PCR using the 7900HT Fast Real-Time PCR System (Applied Biosystems, 
Nieuwerkerk a/d IJssel, the Netherlands). Primers were designed to cross exon-exon bound-
aries for either the forward or the reverse primer. The length of the amplicons designed were 
around 51-209 bp and the annealing temperature was always 60oC. The primers we used 
are listed in Supplementary Table 1. qRT-PCRs were performed on three independent ex-
periments in triplicate (n=9) with iTaq™SYBR®Green Supermix ROX (Bio-Rad, Veenendaal, 
the Netherlands). For data normalization we used the expression data of the house-keeping 
gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Data were analyzed using the 
method described by Livak.19
Immunohistochemistry
Immunostaining was performed on cryosections (12 µm) of mouse embryonic gut E14.5. 
Cryosections of mouse embryonic gut were either fixed in 4% PFA (Sox10), ice-cold acetone 
(Ret) or 70% ethanol/glycine (Gfap) for 10 minutes at respective temperatures. When acetone 
was used for fixation, sections were dried for a further 4 hours. All slides were rinsed three 
times in PBS before applying a blocking solution (PBS containing 10% donkey serum, 0.1% 
Triton X-100) for 30 minutes at room temperature. For Sox10 staining, sections were addition-
ally pretreated by boiling in citrate buffer (10mM, pH 6.0; Sigma) for 10 minutes. Primary an-
tibodies, anti-mouse Ret, Sox10, Gfap, Tlr2, Tlr4 and Tlr5 were applied and visualized with the 
respective fluorochrome-conjugated secondary antibodies (see Supplementary Table 2). Cell 
nuclei were stained with 4’-6-diamidino-2-phenylindole [DAPI] solution (Invitrogen; 100 ng/
ml) and cover-slipped with Kaiser’s gelatine (Merck, Darmstadt, Germany). The images were 
captured on a Nikon inverted fluorescence microscope (Nikon, Dusseldorf, Germany).
Statistical analysis of qRT-PCR
Statistical analysis of the qRT-PCR results was performed using the Student’s t-test. The 
results represent the means ± standard deviation (SD). Statistical analysis was performed by 
GraphPad Prism 4. P values <0.05 and <0.005 (one-tailed distribution) were considered sig-
nificant. 
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RESULTS
ENCCs isolation 
The applied cell culture protocol resulted in almost pure ENCCs cultures as confirmed by 
fluorescence microscopy (see Figure 1C). After treatment with GDNF, we noticed that neuro-
sphere-like bodies (NLBs) were larger in size (diameter: 100 µm) than the untreated control 
culture (diameter: 30-50 µm) (Figure 1C). 
  
Figure 1 – A) Schematic overview of the Wnt1-Cre-recombinase and Loxp-YFP cassettes. B) Wnt1-Cre/
Loxp-YFP embryonic mouse E14.5 showing YFP-positive cells in the neural crest-derived craniofacial 
structures, and in the gut. C) ENCCs after 14 days of culture, with and without GDNF treatment (5X, 10X 
and 32X magnification).
Expression array analysis 
Single Gene Analysis (Student’s t-test, Bonferroni p<0.05)
Microarray data of gene expression profiling obtained from mouse embryonic gut, ENCCs 
untreated and treated with GDNF were used for single gene analysis using the Student’s t-test 
with Bonferroni multiple correction testing p<0.05. A schematic overview of the experiments 
and of the single gene analysis is given in Figure 2. The data collected from single gene analysis 
can be divided into five groups. The first group consists of genes that are significantly differ-
entially expressed in ENCCs treated with GDNF versus those untreated. From the 428 genes 
in this list (see Supplementary Table 3), the top 25 are presented in Table 1.  Genes that up-
regulated (398 genes) were those important for the GTP metabolic process, for GTPase activ-
ity, cell-cell signaling, synaptic vesicle transport, neuron projection and genes important for 




































Figure 2 – Schematic overview of the experiments performed and the outcome of the single gene 
 analysis
The second group consists of genes that are expressed significantly different in ENCCs com-
pared to the gut. We identified 1608 genes belong to this group, among these were two known 
HSCR genes Phox2b and Ece1 that were up-regulated and down-regulated in ENCCs compared to 
gut, respectively (see Table 2). There were 559 genes that up-regulated in ENCCs compared to gut, 
the top 25 genes are presented in Table 3. Among these genes are Sox2 and Gfrα2.
The third group consists of genes that are up-regulated in ENCCs compared to the gut 
and further up-regulated in ENCCs upon GDNF treatment. There are 39 genes belonging to 
this group (see Supplementary Table 4). Among these genes are Scg10 (Stmn2) that has re-
cently been proposed as a candidate gene for HSCR 20, 21 and Snca (α-synuclein) a gene known 
to be involved in Parkinson’s disease.22 
The fourth group consist of genes that are up-regulated in ENCCs compared to the gut, 
but down-regulated in ENCCs upon GDNF treatment. Only 10 such genes belong to this group 
(see Supplementary Table 5), including Rora (Retinoic acid receptor-related orphan receptor 
alpha), a transcription factor important for cell survival and differentiation of Purkinje cells.23
 












2900 genes * : 1121 down- ; 1779 up-regulated 
Single Gene Analysis 
Student’s t-test, Bonferroni  p < 0.05 
              1608 genes # 
1049 down- ; 559 up-regulated in ENCCs (-) 
            428 genes 
30 down- ; 398 up-regulated in ENCCs (+) 
49 genes overlap 
39 genes: Gut< ENCCs(-) <ENCCs (+) 
10 genes: Gut < ENCCs(-) > ENCCs (+) 
# HSCR genes: Phox2b   , Ece1 
*HSCR genes: Phox2b  , Edn3  , Gfra1  , Nrg1  , RET  , Nrtn 
: Up-regulated : Down-regulated 
 R genes: Phox2b   , Ece1
*HSCR genes: Phox2b  , Edn3  , Gfra1  , Nrg1  , RET  , Nrtn
    : Up-regulated   : Down-regulated
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The fifth group consists of the genes that were expressed significantly different in ENCCs 
treated with GDNF compared to the gut. There were 2900 genes belong to this group. Among 
these were the known HSCR genes: Ret, Phox2b, Gfrα1, Nrtn and Nrg1 were all up-regulated 
in ENCCs whereas Edn3 was down-regulated in ENCCs (see Table 2). 
No. Gene Symbol Gene Name Human Chromosome
Table 1 - Single Gene Analysis: Top 25 genes that were expressed significantly higher in 



















































TMF1-regulated nuclear protein 1 
sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 2
transmembrane protein 59-like 
amyloid beta (A4) precursor-like protein 1
metallo-beta-lactamase domain containing 2
VGF nerve growth factor inducible
delta/notch-like EGF repeat containing 
clavesin 2
- 
ribonuclease L (2’,5’-oligoisoadenylate 
synthetase-dependent)
solute carrier family 25 (mitochondrial carrier: 
glutamate), member 22 
-
ring finger protein 157
regulated endocrine-specific protein 18
beta-1,3-N-acetylgalactosaminyltransferase 1 
(globoside blood group) 
zinc finger, DHHC-type containing 22
cytochrome P450, family 4, subfamily X, 
polypeptide 1
StAR-related lipid transfer (START) domain 
containing 7
WNK lysine deficient protein kinase 3




sterile alpha motif domain containing 10
cell cycle exit and neuronal differentiation 1
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No. Gene Symbol Gene Name Human Chromosome
Table 3 - Single Gene Analysis: Top 25 genes that were expressed significantly higher in 












































































protein tyrosine phosphatase, 
non-receptor type 21
transformed mouse 3T3 cell double 
minute 2
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We identified differential expression of a number of transcription factors that are known 
to play an important role in embryonic and ENS development, such as transcription factors 
belonging to the Sox (SRY-related HMG-box), Fox (Forkhead) and Hox (homeobox) transcrip-
tion factors family. We also identified differential expression of Dlx1 and Dlx2 which are re-
quired for coordinating and programing neurite maturation and migration24 and Etv1 that is 
known to play an important role in differentiation of dopaminergic neurons in C.elegans and 
mouse.25 The summary of transcription factor expression differences is presented in Table 4. 
Sox2 - - Up- 3.30E-07 Up- 0.00280
Sox4 - - Up- 0.0134 - -
Sox6 - - Up- 0.00247 - -
Sox17 - - Down- 0.02739 - -
Sox18 - - Down- 0.02430 Down- 0.00163
Sox21 - - - - Down- 0.00085
Phox2b - - Up- 0.03796 Up- 0.00375
Foxk2 Up- 0.00514 - - - -
Foxf1a - - - - Down- 0.04777
Foxp2 - - - - Down- 0.04632
Foxd3 - - Up- 0.00092 - -
Dlx1 - - - - Up- 5.87E-05
Dlx2 - - Up- 0.01264 - -
Hoxb4 - - - - Up- 0.00205
Hoxb5 - - - - Up- 6.21E-05
Hoxa9 - - - - Down- 0.013288
Hoxc8 - - - - Down- 0.007206
Etv1 - - - - Up- 4.13E-07
Etv5 - - - - Up- 3.35E-05
Ets2 - - - - Down- 0.041972
Cdx1 - - Down- 0.009328 Down- 0.003229
Cdx2 - - Down- 0.003811 Down- 0.003811









Pathways Analysis using the Gene Set Enrichment Analysis (GSEA) method 
The pathway analysis we performed showed that some pathways previously implicated 
in ENS as well as in embryonic development, such as Tgfβ/Bmp, Notch and Wnt were down-
regulated in ENCCs on GDNF stimulation (Table 5). The Notch signaling pathway for instance 
is known to be involved in various aspects of neurogenesis, although it is also involved in cell 
proliferation.26, 27 Within the Notch pathway we saw down-regulation of Notch1, Notch2, Jag1, 
and the Notch co-activators Maml1 and Maml2. With respect to the Wnt signaling pathway, 
it is known that Wnt signaling in ENCCs is important for cell lineage decision-making rather 
than maintaining cells in their progenitor state.28 Wnt (2, 5B, 9A and 10B), and Wnt receptor 
Fzd (2 and 6) are some of the genes in the Wnt signaling pathway that were down-regulated 
by GDNF. The Tgf-β/Bmp signaling pathway plays a role in many cellular processes includ-
ing cell proliferation, apoptosis, differentiation and migration. Tgf-β, Tgfβr1, Smads, Bmps, 
Bmpr1, Rock1 are some of the Tgf-β/Bmp signaling pathway genes that are down-regulated by 
GDNF. Rock signaling is involved in regulating neural precursor cell (NPC) migration. Knock 
down of Rock1 and Rock2 in mouse promotes NPC migration to the olfactory bulb.29 With 
respect to Bmps, Bmp2 and Bmp44, these proteins are known to be involved in neuronal dif-
ferentiation of post-migratory enteric neural crest.30, 31 Bmp2 is also known as a stimulator of 
Mash1 expression, which is an important protein for neurogenesis.32 Rock1, together with the 
Semaphorins and the Plexin protein family (a Semaphorin co-receptor) are all part of the axon 
guidance signaling pathway. We found that this axon signaling pathway is down-regulated 
during GDNF stimulation, suggesting that neuronal differentiation of ENCCs is suppressed 
upon RET activation. 
Adherens junctions, tight junctions (cell-cell adhesion) and focal adhesion (cell-matrix 
adhesion) play an important role in cell migration. In this study, genes that belong to these 
signaling pathways were down-regulated on GDNF treatment. Down-regulation could lead 
to loss of, or less tight, cell-cell and cell-matrix contact, a crucial process for cell migration and 
proliferation. Tjp1 (tight junction 1) and Snai2 (Slug) are genes that were down-regulated and 
these are members of the tight and adherens junction signaling pathways, respectively. Slug is 
known to play a role in ENCCs migration and homozygous deletion leads to the development 
of Waardenburg syndrome type 2D, an auditory-pigmentary syndrome.33
We also observed that cell cycle signaling pathways are down-regulated on GDNF stimu-
lation. Histone deacetylases (Hdac1 and Hdac2), Mdm2, Cdkn1a (p21), Cdkn2b (p15), Rb1 are all 
on the list of cell cycle signaling genes that are down-regulated on GDNF treatment. HDACs 
have a role in cell growth arrest, differentiation and cell death, while Mdm2 inhibits the G0/
G1-S phase transition of human diploid cells, and over-expression of MDM2 would induce 
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growth arrest in normal cells. Mdm2, p21, p15 and Rb1 are negative regulators of the cell 
cycle. Down-regulation of the expression of these genes will most likely reduce their growth-
inhibitory function and induce cell proliferation as a consequence. Although GDNF treatment 
results in a down-regulation of many genes involved in the cell cycle and cell growth, there 
are also some down-regulated genes that play a role in cell division, such as Ccnd (cyclin D) 
and Cdks (cyclin-dependent kinase). The harmonization of negative and positive regulators of 
the cell cycle process eventually results in cell division or cell cycle arrest. In this context it is 
interesting to note that the ENCCs cultures with and without GDNF (Figure 1C) show a clear 
difference, namely that GDNF-treated ENCCs have bigger Neurosphere-Like Bodies (NLBs) 
than those not treated with GDNF, pointing towards the higher proliferative state of these 
treated cells 
On the other hand, signaling pathways that play pivotal roles in apoptosis, such as the 
p53 and Toll-like receptors (Tlrs) pathways are down-regulated on GDNF treatment. The 
down-regulation of genes involved in cell cycle arrest and apoptosis upon Ret activation 
could point toward a model in which ENCCs proliferate and survive better during ENS de-
velopment. 
Finally the JAK-STAT signaling pathway is known to be activated by RET.34 Our mi-
croarray results, to our surprise, showed that this pathway is down-regulated on GDNF treat-
ment. However, most of the genes that are down-regulated in this signaling pathway are ones 
important for cytokines and their receptors’ expression. Among these are Il-15, Il-12b, Il-6r, 
Il-28R, Ifnαρ1, and Ifnγr1. Together with the Tlrs signaling pathways, it seems that GDNF 
activation reduces the immunomodulatory capacity of ENCCs.
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Pathway P-Value FDR #Genes
Table 5 - Pathways analysis (ENCCs_GDNFneg Vs ENCCs_GDNFpos)





















































































































































































































RET mediated gene expression in ENS precussor
GDNF stimulation significantly reduces Tlr2, Tlr4, Tlr5, Tnfα and Il-6 mRNA levels in ENCCs 
Pathway analysis showed that the Tlr signaling pathway is down-regulated in ENCCs on 
GDNF stimulation (see Table 5). In particular, among the genes listed in the Tlr pathway, Tlr2 
and Tlr5 were notably down-regulated after GDNF treatment. To confirm these data we per-
formed qRT-PCR on Tlr2 and Tlr5 in ENCCs treated and untreated with GDNF. As it is known 
from previous studies that Tlr4 is also expressed in the myenteric plexus35, 36, we included Tlr4 
in this experiment as a positive control. As activation of Tlr signaling is known to activate 
Nf-κb (p65-p50 complex) and initiate the innate immune response by inducing expression of 
pro-inflammatory cytokines, we also measured the mRNA level of several pro-inflammatory 
cytokines such as Tnfα, Ifnγ, Il-6 and Il-1β. 
d significantly reduced in ENCCs on GDNF stimulation compared to the untreated cells. 
The results are presented in Figure 3A-B. Tnfα expression levels in the ENCCs were not de-
tectable by ELISA. Il-6, which was detectable by ELISA, showed no significant difference in 
the level of expression between the control and the GDNF-treated cells. 
Figure 3 - GDNF significantly reduces the mRNA level of: A) TLR2, TLR4 and TLR5 in ENCCs, B) TNFα 
and Il-6 in ENCCs. The bars indicate the means ± SD of the fold changes of the mRNA level for each 
gene between control and GDNF treated cells. *p < 0.05 and **p < 0.005 were considered significant 
(one-tailed distribution).
Tlr2, 4 and 5 are expressed in enteric glial, neurons and ENS progenitor cells of the 
embryonic myenteric plexus
Tlr2, Tlr4 and Tlr5 are expressed in the myenteric plexus of mouse embryonic colon 
E14.5. In particular, the Tlrs could be demonstrated in the glial cells, as shown by co-staining 
with Gfap, and in neurons as shown by co-staining with Ret. Moreover they were already 
detected in the ENS progenitors as shown by co-staining with Sox10 (Figure 4A-C). In all the 
stainings, Tlrs did not overlap completely with Ret, Gfap or Sox10. It seems that parts of the 
smooth muscle layer were also positively-stained for Tlrs, especially for Tlr5. This is in line 
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C
Figure 4 - Tlr2, Tlr4 and Tlr5 are expressed in the myenteric plexus of embryonic mouse gut E14.5. A) 
Co-staining of Tlrs with Ret, B) Co-staining of Tlrs with the glial marker (Gfap), and C) Co-staining of Tlrs 
with ENS progenitor marker Sox10. The merged images of each Tlr with Ret, Gfap and Sox10 staining are 
shown in the third column of each panel. The magnifications of co-stained Tlrs are shown in the respective 
insets. Tlr4 and Tlr5 are also expressed on colon epithelial cells as shown by arrowheads in Figure C.
DISCUSSION 
Several genes have been implicated in HSCR development, including RET, GDNF, EDNRB, 
EDN3, SOX10, NTN, ECE1, ZFXH1B, KBP, TTF1 and NRG1. The majority of these genes can 
be divided into three groups: the ones involved in the RET pathways (RET, GDNF, NTN), the 
ones involved in EDNRB pathways (EDNRB, EDN3, ECE-1), and transcription factors that can 
affect both RET and/or EDNRB pathways (SOX10, ZFXH1B, PHOX2B). Increasing evidence 
has shown that the proteins encoded by these genes are interconnected. A genome-wide as-
sociation study, using 43 trios from a genetically isolated Mennonite population, reported 
statistically significant joint transmission of RET and EDNRB alleles.37 Furthermore, mice ho-
mozygous for the recessive hypomorphic allele of Ednrb (EdnrbS or Piebald) and heterozy-
gous for a Ret null mutation (Ret+/–) showed high frequencies of aganglionosis. These findings 
are suggestive of epistasis between EDNRB and RET and this idea was further supported by 
Ret/Ednrb mouse crosses.38 Similar studies showed that, whereas Ret51/51 and Edn3ls/ls (lethal 
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spotting) mice display colonic aganglionosis, combinations of these mutant alleles lead to 
almost complete intestinal aganglionosis.39 
Furthermore, the transcription factor SOX10 is involved in the regulation of both RET 
and EDNRB expression.40-42 PHOX2B is also a transcription factor that is expressed in several 
classes of differentiating neurons of both the peripheral and central nervous systems. Mice 
with a homozygous disruption of Phox2b show lack of enteric ganglia and no Ret expression 
which suggests that Phox2b might play a regulatory role in Ret expression.43 All these data 
indicate a central role for RET in the development of both HSCR and ENS. It was these find-
ings that encouraged us to undertake this study. By determining the RET-associated gene 
networks in ENS progenitors we hoped to gain insight not only into ENS development but 
also a better understanding of how HSCR might develop, eventually leading to HSCR candi-
date genes.
To gain such insight we performed gene expression profiling studies on RNA isolated 
from mouse ENCCs treated and untreated with GDNF, the ligand for the RET receptor, and 
compared these data to each other and to the expression profile from the whole mouse em-
bryonic gut (all E14.5). The data were used to perform pathway analysis using GSEA and for 
a single gene analysis by a Student’s t-test. 
Single Gene Analysis
With our single gene analysis we identified a large number of genes that were differ-
entially expressed in ENCCs upon GDNF treatment. Moreover, the gene expression profiles 
from the mouse gut helped us to identified ENCC-specific genes. The number of genes we 
identified, as differentially expressed in these experiments was very high, even after multiple 
testing correction. The reason we did identify so many significantly differentially expressed 
genes is mainly due to the large number of replicates we analysed. 
The data generated gives new insights in which genes are important for ENS, develop-
ment, hence important for HSCR development. By comparing genes profile of ENCCs to that 
of mouse embryonic gut, we identified two genes that directly can be linked to RET namely, 
Phox2b which acts as a transcription factor for Ret, 43, 44and Gfrα2 that is a known co-receptor 
of Ret.45 Moreover, we also identified Sox2 which in a recent study proved to be an excellent 
ENS progenitor cell marker.46 Genes belonging to this group, i.e genes expressed in ENCCs 
but not in the gut, might therefore be considered candidate ENS progenitor markers. Among 
the down-regulated genes, the known HSCR gene, Ece1, was identified. Furthermore, by com-
paring genes profile of ENCCs treated with GDNF to that of the mouse embryonic gut, we 
identified six of 12 known-HSCR genes (see Table 2). 
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We, also identified genes that were up-regulated in ENCCs compared to those in the 
gut and further up-regulated or down-regulated upon GDNF treatment (see Supplementary 
Table 4 and 5). It suggests that these genes are ENCCs specific and are downstream effectors 
of Ret. Snca (α-synuclein) was among the genes that were up-regulated (higher in NCC when 
compared to the gut and further up-regulated upon GDNF treatment). This suggests that de-
fects in RET signaling will most likely reduce the expression of α-synuclein. Interestingly, in 
Parkinson’s patients, the presence of Lewy bodies (aggregation of α-synuclein) in their gut is 
associated with chronic constipation. These findings suggest that α-synuclein might play an 
important role in ENS functioning.47, 48 
Several comparable expression profiling studies, all aiming at a better understanding of 
ENS and HSCR development and to find new candidate HSCR genes, have been performed. 
Different study designs have been used: Heanue and colleagues compared gene expression 
of mouse embryonic gut from wild type (WT) mice with those of Ret knock-out mice (Ret-/-)49; 
Vohra and colleagues performed a study with a design comparable to Heanue et al. How-
ever, they analysed mouse intestines of two different developmental stages (E14 and P0)50; 
Iwashita and colleagues compared gene expression profiles of neural crest stem cells (NC-
SCs) with the profiles made of total mouse embryos while Ngan and colleagues compared 
gene expression profiles of ENCCs isolated from mice WT with those from ENCCs isolated 
from Ret mutant mice (E11.5). These ENCCs were treated and untreated with GDNF at two 
different time-points (8 and 16 hours) before RNA isolation.51, 52 Each study has its own ad-
vantages and disadvantages. The use of knock-out mice (Heanue) clearly has an advantage 
as also the influence of other endonegous RET ligands can be measured. However using gut 
instead of ENCCs might be considered a drawback as the ENS progenitor cells are less than 
5% of the total cell population in the mouse embryonic gut. The use of NCSCs without cul-
turing as described by Iwashita has an advantage over cultured ENCCs (Ngan et al. and our 
study) as it omits the potential of in vitro influences on gene expression. However to study the 
RET-GDNF genes network in ENCCs (or NCSCs) without GDNF treatment might not cover 
completely the dynamic changes of RET-dependent genes expression. Furthermore, the use 
of expression profiles from gut (our study) compared to those from total embryos (Iwashita) 
for instance might have some advantages as differences in expression of genes in non-ENCCs 
of the gut might be identified as well. The study by Ngan et al. was very similar to our study, 
although they did not compare the ENCCs profiles with the expression profile of the gut or 
total embryo. Because of this it is difficult to identify ENCCs specific genes. In our study we 
could detect six of the 12 known-HSCR genes by comparing the gene expression profiles of 
ENCCs (+GDNF) to the expression profiles of the gut, whereas ENCCs treated versus un-
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treated did not detect any of these 12 known-HSCR genes. This shows that this comparison 
is very informative. The strength of our study is the use almost pure ENCCs isolated from 
mice carrying Wnt1-Cre-recombinase and a LoxP/R26-YFP, and the fact that we used large 
numbers of replicates. The last resulted in, even after Bonferroni multiple testing corrections 
(p< 0.05), large numbers of significantly down or up regulated genes. 
When comparing our results with those generated by the other studies we saw that 70% 
of genes (33/47) that were thoroughly examined by Heannue et al. (expression in the ENS 
by in situ hybridization) were present in our data set. Among these are Tgfβ2, Mab21l1, Sncg, 
Etv1, L1cam and Fgf13. From the 38 genes thoroughly examined by Vohra et al (expression in 
the ENS by in situ hybridization) 52% of genes (20/38) proved to be present in our gene set. 
Among these genes are Elavl4, Ncam2, Hoxb5, Ndrg4, Stmn3 and Dlx2. The comparison with 
the study of Iwashita et al. we saw 27% of genes (29/107 annotated genes) were present in our 
data. Among these are Ret, Gfrα1, Gfrα2, Emb and Syngr1. The comparison with the study of 
Ngan et al., we saw 58.6% of genes (17/29) were present in our data. Among these are Map-
k8ip2, Tesc, Kcnd2 and Vip.
These comparisons show considerable overlap between the studies. We did not find ma-
jor differences between these 4 studies and our study. The differences found, different gene 
sets, most likely are the result of the different study designs used.
Pathway analysis 
GSE analysis based on the data of the KEGG database showed that upon GDNF stimu-
lation, several sets of genes were significantly up- or down-regulated in the ENCCs (results 
shown in Table 5, see also supplementary Figure 1A). The Pathways that were up-regulated 
were those which are important for energy supply (citrate cycle and oxidative phosphoryla-
tion), for steroid and valin-leucin-isoleucin biosynthesis and lipid metabolism (peroxisome 
and peroxisome proliferators-activated receptors/ PPARs). Signaling pathways that are con-
sidered important for ENS development such as the Notch, Tgfβ/Bmp and Wnt signaling 
were all significantly down-regulated upon GDNF stimulation. Sets of genes important for 
cell-cell and cell-matrix contacts (e.g. adherens junctions, tight junction and focal adhesion 
formation), cell cycle arrest, apoptosis (p53, Toll-like receptor signaling) and innate immune 
system signaling (Toll-like receptor signaling) were also down-regulated. We summarize the 
possible biological function of the signaling pathways mentioned above in the supplementary 
Figure 1B. 
Pathway analysis based on the TRANSFAC database showed similar results to those col-
lected from the KEGG database. Genes under the regulation of transcription factors that are 
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important for determining cell differentiation, such as Sox5 and Foxo1, are down-regulated 
by GDNF, while genes under the regulation of Egr3, a transcription factor that is important 
for cell growth and cell migration, are up-regulated on GDNF treatment. The same goes for 
Rest, a transcription repressor which is highly expressed in the neuronal progenitor cells and 
which is known as a negative master regulator of neurogenesis.53, 54
TLRs signaling pathway
 TLRs recognize viral and bacterial infections and induce an innate immune response 
by activating pro-inflammatory cytokines such as TNFα. Furthermore, several studies have 
shown that TLRs can also induce apoptosis through the activation of Caspases (as reviewed 
by B. Salaun).55 
Recently it was shown that TLR4 is expressed in neurons of the myenteric plexus of 
the human illieum.36 Tlr3 and Tlr7 are expressed in the ENS and in the dorsal root ganglia 
(DRG).35 Our microarray data and our immunostainings show that Tlr2, Tlr4 and Tlr5 are ex-
pressed in ENCCs and in the ENS (the progenitors, neurons and glial cells, see Figure 4A-C). 
The expression of Tlrs in the ENS precursor cells could indicate that these cells play a role in 
the immunomodulatory mechanism against viral and bacterial infection. This might seem il-
logical as in the normal situation the ENS is not directly in contact with the luminal contents. 
However, bacteria and viruses can cross the epithelial barrier and reach the deeper layers 
of cells, such as the ENS, and thereby induce an immune response in these cells.56, 57 More-
over, we show that all three Tlrs were down-regulated upon GDNF stimulation, implying that 
these particular Tlrs genes are down-stream effectors of Ret signaling. Based on these data, we 
hypothesize that RET-GDNF activation will reduce the expression of TLRs and, consequently, 
will also reduce the expression of cytokines. Therefore, defects in RET signaling, as often seen 
in HSCR patients, will result in higher expression levels of TLRs, which subsequently lead to 
an overexpression of cytokines. This condition might well contribute to activating the innate 
immune response system, which might manifest itself as HSCR-associated enterocolitis. This 
idea is corroborated by an animal study which demonstrated that mRNA levels of Tlr2 and 
TlrR4 are increased in the intestinal epithelial cells (IEC) of enterocolitis rat.58 Furthermore, it 
has also been shown that TLR4 expression is elevated in the intestinal mucosa of humans and 
that TLR4 plays a critical role in the development of necrotizing entercolitis .59  
In summary, there seems to be a general trend in our data that genes encoding proteins 
that stimulate cell differentiation or that are negative regulators of cell proliferation, and genes 
that inhibit cell-cell adhesion and apoptosis were generally down-regulated in neural crest 
cells upon treatment with GDNF. On the other hand, genes that encode proteins that have the 
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opposite effect, such as genes for an early growth response, those involved in the inhibition 
of cell differentiation, and those that are important for energy supply and biosynthesis, were 
up-regulated. Furthermore, in the ENCCs we saw a connection between Ret signaling and the 
innate immune response, as stimulation of Ret resulted in down-regulation of several Tlrs and 
their pro-inflammatory cytokines. These data provide new insight into the gene networks ac-
tivated upon RET stimulation by GDNF in ENCCs. They also will serve as a catalog of genes 
possibly involved in HSCR. This might will prove extremely helpful once we start sequencing 
exomes or even genomes of HSCR patients and revealing enormous numbers of DNA vari-
ants, most of which will not in fact play a role in HSCR. 
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Gene Primers Product length
Supplementary Table 1 - Primers used for qPCR amplification and product length
F:  5’ CTCAGAGGATGCTACGAGCTC 3’
R:  5’ GAATAGAGGTGAAAGACCTGGAGC 3’
F:  5’ GAATCCCTGCATAGAGGTAGTTCC 3’ 
R:  5’ TGATCCATGCATTGGTAGGTAATATTA 3’
F:  5’ TCAGCAGGATCATGGCATGTC 3’ 
R:  5’ TGAAGATCACACCTATGAGCAAGTCA 3’
F:  5’ GACGTGGAACTGGCAGAAGA 3’
R:  5’ GCCACAAGCAGGAATGAGAA 3’
F:  5’ CCTCTCTGCAAGAGACTTCCATCCA 3’
R:  5’ GGCCGTGGTTGTCACCAGCA 3’
F:  5’ GGCAGGCAGTATCACTCATT 3’
R:  5’ AAGGTGCTCATGTCCTCATC 3’
F:  5’ CATGGTGGTTGGCTTTGCA 3’
R:  5’ ACACGCCTCTGTCATCCGTG 3’
F:  5’ ACTGGCAAAAGGATGGTGAC 3’
R:  5’ GCTGATGGCCTGATTGTCTT 3’
F:  5’ CATCAAGAAGGTGGTGAAGC 3’
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Rank Affymetrix Name Gene Symbol T Bonferronni
Supplementary Table 3 - Single Gene Analysis: Genes were expressed significantly 
different in ENCCs treated with GDNF compare to untreated ENCCs (Bonferroni : p < 0.05)
1 1453008_at Trnp1 -49.711785 1.34E-06
2 1435026_at Spock2 -43.762722 3.70E-06
3 1452825_at Tmem59l -42.657373 4.54E-06
4 1435857_s_at Aplp1 -40.88871 6.35E-06
5 1437261_at Mblac2 -35.864703 1.80E-05
6 1436094_at Vgf -33.761245 2.92E-05
7 1456379_x_at Dner -33.271202 3.28E-05
8 1437292_at Rlbp1l2 -31.037683 5.69E-05
9 1428333_at 2900062L11Rik -29.839986 7.78E-05
10 1426604_at Rnasel -29.703856 8.07E-05
11 1452653_at Slc25a22 -29.609467 8.27E-05
12 1437528_x_at A730017C20Rik -29.389713 8.78E-05
13 1434427_a_at Rnf157 -27.830259 0.000135269
14 1417988_at Resp18 -26.224421 0.000216607
15 1418736_at B3galnt1 -26.088397 0.000225711
16 1459723_at Zdhhc22 -25.644417 0.000258556
17 1441662_at Cyp4x1 -25.349314 0.000283353
18 1449628_s_at Stard7 -25.219314 0.000295116
19 1443924_at Wnk3 -25.062297 0.000310062
20 1451679_at 6530401D17Rik -24.824377 0.000334356
21 1427893_a_at Pmvk -24.621329 0.00035679
22 1435756_at Samd10 -24.571621 0.000362536
23 1421349_x_at Cend1 -24.564025 0.000363423
24 1426662_at Cmas -24.553795 0.000364622
25 1417428_at Gng3 -24.541655 0.000366051
26 1455260_at Lcorl -24.130619 0.000418331
27 1423280_at Stmn2 -24.044308 0.000430345
28 1418671_at Capn5 -23.886055 0.000453394
29 1418400_at Larp6 -23.766463 0.000471734
30 1460262_a_at 1700037H04Rik -23.762846 0.000472301
31 1455888_at Lingo2 -23.645762 0.000491093
32 1427482_a_at Car8 -23.417563 0.000530181
33 1455792_x_at Ndn -23.39489 0.000534252
34 1422711_a_at Pnck -23.389166 0.000535285
35 1450863_a_at Dclk1 -23.246707 0.000561739
36 1434754_at Garnl4 -23.232605 0.000564437
37 1454687_at Lrfn5 -23.111085 0.000588295
38 1436134_at Scn2b -23.073987 0.000595802
39 1440132_s_at Prkar1b -22.863039 0.000640594
40 1424624_at 2900011O08Rik -22.81546 0.000651211
41 1460239_at Tspan13 -22.703032 0.000677096
42 1438370_x_at Dos -22.614644 0.000698258




44 1433876_at Lrrc24 -22.526199 0.00072018
45 1423352_at Crispld1 -22.47565 0.000733055
46 1436087_at LOC100047231 -22.311623 0.000776651
47 1422605_at Ppp1r1a -22.177671 0.000814419
48 1460292_a_at Smarca1 -22.159762 0.000819623
49 1424443_at Tm6sf1 -22.156432 0.000820595
50 1448312_at Pcsk2 -21.990273 0.000870767
51 1455652_at Kif3a -21.95774 0.000880989
52 1433443_a_at Hmgcs1 -21.884633 0.000904454
53 1416965_at Pcsk1n -21.881448 0.000905492
54 1455080_at Ppp1r16b -21.802173 0.000931768
55 1450773_at Kcnd2 -21.669177 0.000977796
56 1436450_at D11Bwg0517e -21.570151 0.001013727
57 1452240_at Brunol4 -21.456076 0.001056969
58 1416935_at Trpv2 -21.285768 0.001125436
59 1447725_at C030034E14Rik -21.204243 0.001159963
60 1447738_s_at Ankrd13d -21.110093 0.001201326
61 1434961_at Asb1 -21.097184 0.001207125
62 1450659_at Rgs7 -21.007074 0.001248493
63 1424482_at Arhgef7 -20.930141 0.001285075
64 1437079_at Slc18a2 -20.809908 0.001344682
65 1436179_a_at Dnajc5 -20.385681 0.001581199
66 1451092_a_at Rangap1 -20.242769 0.001671131
67 1434657_at Gls -20.023423 0.001820554
68 1420499_at Gch1 -19.889409 0.001919206
69 1423282_at Pitpna -19.852766 0.001947215
70 1459881_at Fbll1 -19.848639 0.001950398
71 1428370_at 1500011B03Rik -19.796438 0.001991169
72 1418829_a_at Eno2 -19.701832 0.002067524
73 1454972_at Atcay -19.57182 0.002177875
74 1441197_at 9530059O14Rik -19.554945 0.002192676
75 1442180_at Dleu7 -19.524284 0.00221986
76 1448832_a_at Cplx1 -19.437734 0.002298659
77 1457755_at Gng8 -19.31441 0.002416422
78 1424017_a_at Hint1 -19.163534 0.002569807
79 1427229_at Hmgcr -19.154594 0.002579232
80 1432464_a_at 2310057J16Rik -19.053404 0.002688674
81 1441905_x_at Snrpn /// Snurf -19.049584 0.002692906
82 1418209_a_at Pfn2 -18.993873 0.00275549
83 1426615_s_at Ndrg4 -18.990207 0.002759665
84 1451008_at St8sia3 -18.922381 0.002838206
85 1423317_at 3110001D03Rik -18.83419 0.002944109
86 1428765_at Meg3 -18.818445 0.002963479
87 1451322_at Cmbl -18.758269 0.003038838
88 1457092_at Fam19a1 -18.679781 0.003140383
89 1448595_a_at Bex1 -18.617769 0.003223309
90 1460223_a_at Epb4.9 -18.575406 0.003281371
91 1421152_a_at Gnao1 -18.494733 0.003395217
92 1421493_a_at Rgs20 -18.48937 0.003402941
93 1433791_at Rab9b -18.465285 0.003437872
94 1455014_at Hint3 -18.252221 0.003765047
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95 1453078_at 2610002M06Rik -18.167393 0.003904918
96 1456392_at Negr1 -18.164024 0.003910593
97 1429022_at Adcyap1r1 -18.118995 0.003987329
98 1441944_s_at Gpr135 -18.100384 0.004019536
99 1448660_at Arhgdig -18.070941 0.004071088
100 1436552_at Jakmip2 -18.063323 0.004084547
101 1418062_at Eef1a2 -18.011533 0.004177382
102 1435641_at Mgat4a -17.985843 0.004224308
103 1451499_at Cadps2 -17.976442 0.004241627
104 1424308_at Slc24a3 -17.974323 0.004245543
105 1428089_at Slitrk1 -17.954827 0.004281753
106 1451394_at Dpp6 -17.943084 0.004303732
107 1436605_at Tkt -17.929896 0.004328565
108 1437234_x_at Prmt2 -17.917984 0.004351133
109 1437618_x_at Gpr85 -17.803552 0.004574799
110 1431403_a_at Mtap7d2 -17.72493 0.004735946
111 1434155_a_at 2310061I04Rik -17.693038 0.00480312
112 1415671_at Atp6v0d1 -17.665455 0.004862083
113 1450888_at Napb -17.632404 0.004933805
114 1420554_a_at Rac3 -17.560163 0.005094746
115 1431086_s_at Pcmt1 -17.539057 0.005142872
116 1428354_at Foxk2 -17.538998 0.005143007
117 1435630_s_at Acat2 -17.510206 0.005209486
118 1455313_at Ablim2 -17.498944 0.00523575
119 1434346_at Rufy2 -17.491789 0.005252513
120 1450693_at Rgs17 -17.436449 0.005384226
121 1417997_at Ngb -17.427255 0.005406465
122 1423724_at Zwint -17.418391 0.005428004
123 1438672_at Parvb -17.404948 0.005460853
124 1435014_at Rab39b -17.374322 0.005536528
125 1438619_x_at Zdhhc14 -17.338304 0.005627033
126 1422941_at Wnt16 -17.293055 0.005743098
127 1416392_a_at Atp6v0c -17.225169 0.005922297
128 1440270_at Fgf12 -17.217381 0.005943254
129 1442884_at Hgf -17.201465 0.00598634
130 1425893_a_at Fhit -17.112659 0.006233277
131 1449983_a_at Nqo2 -17.103442 0.006259555
132 1449377_at Nicn1 -17.072009 0.006350107
133 1436237_at Ttc9 -17.059961 0.006385204
134 1451503_at Nol3 -17.025724 0.006486134
135 1455258_at Kcnc2 -16.969797 0.006654878
136 1428550_at Ydjc -16.941611 0.006741787
137 1433987_at Hpcal4 -16.937396 0.006754889
138 1456108_x_at Rnf112 -16.917326 0.006817684
139 1449491_at Card10 -16.881509 0.006931384
140 1452332_at Ccdc85a -16.846635 0.007044136
141 1443327_at D130043K22Rik -16.840347 0.007064684
142 1434170_at Decaf12l1 -16.833805 0.007086133
143 1438054_x_at Ppp2r2c -16.825827 0.007112391
144 1426249_at Adrbk1 -16.819502 0.007133283
145 1438667_at 5730410E15Rik -16.816992 0.007141596
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146 1452711_at Atl1 -16.798857 0.007201962
147 1417609_at Ube2a -16.792496 0.007223273
148 1418178_at LOC100047943 -16.758641 0.00733789
149 1455796_x_at Olfm1 -16.736336 0.007414517
150 1455509_at Nacad -16.717595 0.007479597
151 1460570_at Pgbd5 -16.691408 0.007571608
152 1426956_a_at Trp53bp1 -16.678548 0.007617257
153 1422852_at Cib2 -16.675134 0.007629427
154 1452800_a_at Apoo -16.673311 0.007635937
155 1442786_s_at Rufy3 -16.627761 0.007800581
156 1422072_a_at Gstm6 -16.609159 0.007868961
157 1422977_at Gp1bb -16.586468 0.007953284
158 1435113_x_at Stmn3 -16.580414 0.007975952
159 1420880_a_at Ywhab -16.576786 0.007989571
160 1415993_at Sqle -16.490009 0.008323233
161 1451895_a_at Dhcr24 -16.453165 0.008469606
162 1435605_at Actr3b -16.433418 0.008549245
163 1416098_at Syngr3 -16.413526 0.008630315
164 1426712_at Slc6a15 -16.379991 0.008768951
165 1428996_at Pdp2 -16.323407 0.00900857
166 1435917_at Ociad2 -16.31635 0.009038965
167 1428578_s_at Ppfia4 -16.305943 0.009084001
168 1433787_at Nell1 -16.276958 0.009210769
169 1459890_s_at 1110008P14Rik -16.227167 0.009433186
170 1455321_at Ddhd1 -16.208564 0.009517823
171 1420545_a_at Chn1 -16.197733 0.009567496
172 1437018_at Pnma2 -16.190394 0.009601318
173 1459980_x_at Rab3a -16.187444 0.009614952
174 1417672_at Slc4a10 -16.177399 0.009661535
175 1450675_at Smap2 -16.166271 0.009713438
176 1452915_at Prkar2a -16.141985 0.009827805
177 1435200_at Ncrna00086 -16.131233 0.009878915
178 1454787_at Zdhhc9 -16.095105 0.010052862
179 1426255_at Nefl -16.074527 0.010153473
180 1423418_at Fdps -16.052983 0.010260016
181 1418085_at Prkcz -16.000829 0.010523169
182 1448991_a_at Ina /// LOC100047943 -15.915841 0.010968373
183 1419580_at Dlg4 -15.895684 0.011077038
184 1425760_a_at Pitpnm1 -15.797923 0.011621484
185 1417788_at Sncg -15.797841 0.011621952
186 1435083_at Ctxn1 -15.788938 0.011673013
187 1437211_x_at Elovl5 -15.773696 0.011761007
188 1437147_at Gabrg2 -15.765563 0.011808265
189 1426345_at Prepl -15.718717 0.012084646
190 1460740_at LOC100046457 -15.699916 0.012197603
191 1451747_a_at Atg12 -15.694463 0.012230591
192 1417471_s_at D1Ertd622e -15.692671 0.012241453
193 1417799_at Atp6v1g2 -15.682707 0.012302034
194 1428664_at Vip -15.662437 0.012426332
195 1431076_at Add2 -15.647016 0.012521837
196 1448663_s_at Mvd -15.623501 0.012669052
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197 1427045_at Synpo -15.611553 0.012744603
198 1433714_at Sult4a1 -15.595042 0.012849827
199 1434027_at Rcan3 -15.578334 0.012957308
200 1455269_a_at Coro1a -15.536606 0.013230161
201 1433566_at Rasl10b -15.530133 0.01327306
202 1418361_at Gas8 -15.521722 0.013329038
203 1450961_a_at Tceal6 -15.513995 0.013380698
204 1441317_x_at Jakmip1 -15.508048 0.013420608
205 1453127_at Ppm1j -15.499416 0.013478782
206 1433947_at Rab37 -15.485122 0.013575728
207 1457587_at Kcnq5 -15.465515 0.013709985
208 1454782_at Bai3 -15.45587 0.013776571
209 1418474_at Fam158a -15.449029 0.013824022
210 1423328_at Gdap1 -15.443272 0.013864094
211 1434969_at Brunol5 -15.397101 0.014190232
212 1422431_at Magee1 -15.392193 0.014225406
213 1430642_at 2900001G08Rik -15.387067 0.01426224
214 1417840_at 1500031L02Rik -15.375277 0.014347378
215 1434951_at Armc8 -15.360494 0.014454934
216 1436148_at Tnr -15.34392 0.014576593
217 1426236_a_at Glul -15.343505 0.01457965
218 1437185_s_at Tmsb10 -15.327694 0.01469681
219 1424182_at Acat1 -15.307308 0.01484943
220 1420013_s_at Lss -15.287392 0.015000248
221 1416023_at Fabp3 -15.281706 0.015043629
222 1420955_at Vsnl1 -15.278605 0.015067338
223 1417524_at LOC100044812 -15.272629 0.015113157
224 1427356_at Fam89a -15.226715 0.015470435
225 1448211_at Atp6v0e2 -15.22373 0.01549399
226 1424069_at Napg -15.222628 0.015502694
227 1460576_at Exoc6 -15.20585 0.01563592
228 1417676_a_at Ptpro -15.205287 0.015640412
229 1450466_at Cdk5r2 -15.190918 0.015755567
230 1450853_at Tle4 -15.179773 0.015845535
231 1419551_s_at Stk39 -15.158714 0.016017118
232 1434455_at Fbxo44 -15.110964 0.016413938
233 1442023_at A530030E21Rik -15.076419 0.016707893
234 1437855_at Mtap4 -15.067419 0.016785435
235 1454959_s_at Gnai1 -15.065485 0.016802159
236 1424529_s_at Cgref1 -15.056176 0.016882887
237 1458413_at Fbxw8 -15.055287 0.016890616
238 1433737_at LOC677213 /// Uhmk1 -15.042434 0.017002847
239 1436795_at 9630058J23Rik -15.026237 0.017145479
240 1449259_at Rab3d -15.011606 0.017275464
241 1431255_at Calr3 -14.991252 0.017458146
242 1439770_at 6430598A04Rik -14.978284 0.017575656
243 1437912_at Iqsec3 -14.968554 0.017664417
244 1417002_at 0610012G03Rik -14.955263 0.017786472
245 1422692_at Sub1 -14.924587 0.018071797
246 1449298_a_at Pde1a -14.916057 0.018152048
247 1427280_at Scn2a1 -14.8936 0.018365234
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248 1418453_a_at Atp1b1 -14.886328 0.018434873
249 1425248_a_at Tyro3 -14.85919 0.018697362
250 1423906_at Hsbp1 -14.845171 0.018834599
251 1426094_at Rhbdl1 -14.823518 0.019048801
252 1439031_at Jph4 -14.760349 0.019689448
253 1453003_at Sorl1 -14.756716 0.01972702
254 1420872_at Gucy1b3 -14.745665 0.019841815
255 1451257_at Acsl6 -14.731314 0.019991989
256 1424455_at Gprasp1 -14.730476 0.020000802
257 1417022_at Slc7a3 -14.707008 0.020249271
258 1451935_a_at Spint2 -14.699556 0.020328891
259 1431826_a_at Brsk2 -14.690931 0.02042148
260 1452779_at 3110006E14Rik -14.679031 0.020550015
261 1434270_at Cbx6-Nptxr /// Nptxr -14.66256 0.020729408
262 1427004_at Fbxo2 -14.658023 0.020779128
263 1449229_a_at Cdkl2 -14.642309 0.020952374
264 1428638_at Efhc2 -14.636313 0.021018912
265 1440531_at Rbm11 -14.624637 0.021149153
266 1449494_at Rab3c -14.586689 0.021578746
267 1435028_at Wdr7 -14.580738 0.021646998
268 1428387_at Acsl3 -14.57717 0.021688032
269 1456210_at 5430407P10Rik -14.573942 0.021725238
270 1434641_x_at Sez6l2 -14.556641 0.02192584
271 1424386_at Reep2 -14.514886 0.022418612
272 1424145_at Prr3 -14.511926 0.022454011
273 1423569_at Gatm -14.501683 0.022577001
274 1417683_at Diablo -14.494192 0.022667423
275 1456708_at 2610028E06Rik -14.490687 0.022709871
276 1451040_at Dtd1 -14.481389 0.022822909
277 1424764_at Sez6l -14.472233 0.022934832
278 1434640_at Nrsn2 -14.468432 0.022981479
279 1426272_at Lmbr1 -14.447456 0.023240822
280 1460397_at Armc6 -14.435543 0.023389564
281 1418046_at Nap1l2 -14.434213 0.023406234
282 1420824_at Sema4d -14.428484 0.023478205
283 1433607_at Cbln4 -14.392068 0.023941506
284 1455829_at Usp14 -14.382448 0.024065607
285 1436099_at AI836003 -14.377229 0.024133227
286 1424124_at Mospd2 -14.372671 0.024192468
287 1423642_at Tubb2c -14.364696 0.024296502
288 1455481_at Ids -14.341279 0.024604888
289 1450647_at Hps3 -14.302782 0.025121437
290 1426167_a_at Camk4 -14.280286 0.025428918
291 1417374_at Tuba4a -14.245118 0.025918074
292 1439971_at 6330439K17Rik -14.23563 0.026051842
293 1436403_at Fam171a2 -14.231944 0.026104025
294 1419062_at Epb4.1l3 -14.186862 0.026751752
295 1455369_at Apba1 -14.181556 0.026829163
296 1423055_at Nsg1 -14.173006 0.026954431
297 1436624_at Dnm3 -14.150986 0.027280081
298 1435123_at Efr3b -14.145269 0.027365344
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299 1455636_at Lsamp -14.144254 0.027380527
300 1428405_at Hcfc1r1 -14.139908 0.02744558
301 1428209_at Bex4 -14.121669 0.027720511
302 1424935_at Gdap1l1 -14.107253 0.027940012
303 1418263_at Ddx25 -14.105193 0.027971533
304 1448530_at Gmpr  -14.103178 0.028002399
305 1451783_a_at Kifap3 -14.09768 0.02808683
306 1437744_at Slitrk4 -14.092544 0.02816596
307 1423285_at Coch -14.090176 0.028202538
308 1418493_a_at Snca -14.075296 0.028433546
309 1448193_at 5730403B10Rik -14.031732 0.02912215
310 1417626_at Pde4dip -14.027722 0.029186469
311 1435389_at Reps2 -14.006277 0.029533148
312 1416102_at Ywhaz -13.949724 0.030469732
313 1455021_at Gabbr1 -13.938683 0.030656444
314 1426517_at Gnaz -13.932864 0.03075536
315 1436674_at Rundc3a -13.929905 0.030805795
316 1457045_at Galnt13 -13.929549 0.030811866
317 1450053_at Kif2a -13.90716 0.031196596
318 1419493_a_at Tpd52 -13.900943 0.031304376
319 1417559_at Sfxn1 -13.900464 0.031312704
320 1449286_at Ntng1 -13.870132 0.031844757
321 1416936_at Aatk -13.864694 0.031941213
322 1422533_at Cyp51 -13.857524 0.032068874
323 1422592_at Ctnnd2  -13.847363 0.032250802
324 1437075_at Frmd3 -13.791405 0.033273573
325 1422583_at Rab3b -13.786418 0.033366474
326 1449423_at Mast1 -13.786152 0.033371438
327 1437472_at Unc13a -13.761468 0.033835643
328 1452451_at mCG_21548 -13.755737 0.033944448
329 1424988_at Mylip -13.751982 0.034015968
330 1434676_at Mtmr9 -13.747122 0.034108754
331 1418164_at Stx2 -13.72877 0.034461743
332 1416253_at Cdkn2d /// Gm4694 -13.72401 0.034553967
333 1417154_at Slc25a14 -13.721546 0.034601811
334 1428434_at Zcchc12 -13.719647 0.034638726
335 1420505_a_at Stxbp1 -13.716675 0.034696601
336 1426068_at Slc7a4 -13.699416 0.035034879
337 1438164_x_at Flot2 -13.691769 0.035185919
338 1429723_at 6330409N04Rik -13.648523 0.036054028
339 1429013_at Mtap7d2 -13.630973 0.036413156
340 1424691_at 5930434B04Rik -13.62781 0.036478301
341 1444085_at Pdss2 -13.626078 0.036514028
342 1428525_at 4930488B01Rik -13.624238 0.036552022
343 1434398_at Nkrf -13.615835 0.03672614
344 1454800_at Morn2 -13.60874 0.036873865
345 1448995_at Pf4 -13.580105 0.037476873
346 1451490_at Lyplal1 -13.566281 0.037771939
347 1455087_at D7Ertd715e -13.565406 0.037790709
348 1451122_at Idi1 -13.562816 0.037846303
349 1416256_a_at Tubb5 -13.537593 0.038392615
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350 1421396_at Pcsk1 -13.529433 0.038571235
351 1438176_x_at Snap47 -13.508043 0.039043896
352 1431046_at Ppfia3 -13.50241 0.039169451
353 1429266_at Tmhs -13.502068 0.039177096
354 1418746_at Pnkd -13.490861 0.039428275
355 1430034_at Cct4 -13.469681 0.039907937
356 1434083_a_at Elmod1 -13.440734 0.040574116
357 1416022_at Fabp5 -13.436336 0.040676421
358 1424072_at 2010107G23Rik -13.435663 0.040692096
359 1418444_a_at Gde1 -13.422497 0.041000217
360 1452445_at Slc41a2 -13.411501 0.04125955
361 1449381_a_at Pacsin1 -13.410627 0.041280234
362 1427347_s_at Tubb2a -13.378011 0.042060757
363 1420048_at C78859 -13.361665 0.042458149
364 1438396_at Ocrl -13.352984 0.042670904
365 1440928_at D630037F22Rik -13.352895 0.042673085
366 1418588_at Nrsn1 -13.342067 0.042940144
367 1458622_at Ntrk2 -13.332992 0.043165406
368 1435968_at Ptprn2 -13.330754 0.043221154
369 1448812_at Hpcal1 -13.325271 0.043358091
370 1456633_at Trpm3 -13.313853 0.043644829
371 1452473_at Prr15 -13.309305 0.043759635
372 1456523_at C77713 -13.293546 0.044160059
373 1434535_at Krt222 -13.285202 0.044373736
374 1415845_at Syt4 -13.27695 0.044586181
375 1435783_at Fam169a -13.272256 0.044707546
376 1455882_x_at Vwc2 -13.272005 0.044714039
377 1420679_a_at Aig1 -13.254862 0.045160473
378 1438305_at Rims1 -13.221414 0.046045986
379 1419546_at Atp6v1c1 -13.218557 0.046122538
380 1430780_a_at Pmm1 -13.215341 0.046208845
381 1434315_at Nipal3 -13.21243 0.046287131
382 1428049_a_at Nudt16l1 -13.211124 0.046322306
383 1426448_at Pja1 -13.197898 0.046680205
384 1439459_x_at Acly -13.17696 0.047253141
385 1448600_s_at Vav3 -13.173794 0.047340438
386 1426887_at Nudt11 -13.157439 0.04779438
387 1424029_at Tspyl4 -13.157206 0.047800892
388 1435852_at Spred3 -13.140179 0.048278733
389 1455144_s_at AU040829 -13.129505 0.048581007
390 1434105_at Epm2aip1 -13.105586 0.049266118
391 1423221_at Tubb4 -13.099685 0.049436807
392 1453065_at Aldh5a1 -13.090774 0.049695791
393 1453120_at Tmx4 -13.086395 0.049823632
394 1451033_a_at Trpc4 -13.076864 0.050103114
395 1452323_at Spryd3 -13.076565 0.05011191
396 1436448_a_at Ptgs1 -13.066511 0.050408738
397 1433596_at Dnajc6 -13.065176 0.050448271
398 1455148_at Tmem130 -13.064905 0.050456309
399 1451229_at Hdac11 -13.058079 0.050659175
117
RET mediated gene expression in ENS precussor
Down-Regulated    
1 1426048_s_at Tcfap2a 18.8011969 0.002984862
2 1426812_a_at Fam129b 18.6740158 0.00314799
3 1450994_at Rock1 17.4197496 0.005424697
4 1442063_at Adamtsl1 16.7292229 0.007439144
5 1436840_x_at Rpl35 16.4723071 0.008393202
6 1456135_s_at Pxn 16.4592421 0.008445266
7 1423771_at Prkcdbp 16.0717801 0.010166986
8 1430978_at Rps25 16.029682 0.010376663
9 1423425_at Plbd2 15.4008967 0.014163098
10 1449007_at Btg3 /// Gm7334 15.3044709 0.014870813
11 1428113_at Tmtc4 15.2629261 0.015187883
12 1424704_at Runx2 15.0035771 0.017347267
13 1460036_at Ap1s2 14.9437791 0.017892688
14 1449484_at Stc2 14.723464 0.020074682
15 1439439_x_at Eef1d 14.7222485 0.02008752
16 1423536_at Strn3 14.7105706 0.020211329
17 1448785_at Runx1t1 14.6854947 0.020480086
18 1436325_at Rora 14.5638037 0.021842541
19 1435972_at Cast 14.5157617 0.022408155
20 1418135_at Aff1 14.3268176 0.02479752
21 1448347_a_at Caprin1 14.3194122 0.024896819
22 1449099_at Lrba 14.2400722 0.025989119
23 1421043_s_at Arhgef2 14.1050282 0.027974052
24 1460644_at Bckdk 13.9108203 0.031133331
25 1423753_at Bambi 13.8244339 0.032665566
26 1460211_a_at Kdelr1 13.7376391 0.034290641
27 1435777_at Itpripl2 13.6238068 0.036560938
28 1416133_at Efr3a 13.619167 0.036656982
29 1418564_s_at Serbp1 13.1277282 0.048631537
T (-) : Up-regulated in ENCCs with GDNF
T (+): Down-regulated in ENCCs without GDNF
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Gene SymbolNo Gene Name Human Chromosome
Supplementary Table 4 - Single Gene Analysis: Genes with higher expression in ENCCs 
than in the gut and further up-regulated in ENCCs (+ GDNF) (Bonferroni : p < 0.05)
amyloid beta (A4) precursor-like protein 1




BR serine/threonine kinase 2
Seizure related 6 homolog (mouse)-like 2
Host cell factor C1 regulator 1 (XPO1 dependent)
Synuclein, alpha
gamma-aminobutyric acid (GABA) B receptor, 1
UDP-N-acetyl-alpha-D-galactosamine:polypeptide
cell cycle exit and neuronal differentiation 1
stathmin-like 2
proprotein convertase subtilisin/kexin type 1 inhibitor
Bruno-like protein 4
N-ethylmaleimide-sensitive factor attachment 
protein, beta
potassium voltage-gated channel, KQT-like 
subfamily, member 5
ganglioside-induced differentiation-associated protein 1
ankyrin repeat and SOCS box-containing 1
Rho guanine nucleotide exchange factor (GEF) 7
DnaJ (Hsp40) homolog, subfamily C, member 5
NDRG family member 4
neuronal growth regulator 1
RUN and FYVE domain containing 2
Regulator of G-protein signaling 17
RAB39B, member RAS oncogene family
Potassium voltage gated channel, Shaw-related 
subfamily, member 2
protein phosphatase 2, regulatory subunit B 
(PR 52), gamma isoform
atlastin GTPase 1
solute carrier family 6 (neurotransmitter 
transporter), member 15
FERM domain containing 3
myotubularin related protein 9
syntaxin binding protein 1
proprotein convertase subtilisin/kexin type 1
brain glucose-1,6-bisphosphatase
RIKEN cDNA 6330439K17 gene/ chromosome 20 
open reading frame 12
ATPase, H+ transporting, lysosomal V0 subunit E2
cyclin-dependent kinase-like 2
solute carrier family 41, member 2
thioredoxin-related transmembrane protein 4
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GeneNo Gene Name Human Chromosome
Supplementary Table 5 - Genes with higher expression in ENCCs than in the gut and 
down-regulated in ENCCs (+ GDNF) (Bonferroni : p < 0.05)
1 Aff1 AF4/FMR2 family, member 1 4q21.3
2 Cast Calpastatin 5q15
3 Tmtc4 Transmembrane and tetratricopeptide repeat containing 4 13q32.3
4 Btg3 B-cell translocation gene 3 21q21.1
5 Prkcdbp protein kinase C, delta binding protein 11p15.4
6 Adamtsl1 ADAMTS-like 1 9p22.2
7 Fam129b family with sequence similarity 129, member B 9q34.11
8 Tcfap2a transcription factor AP-2 alpha 6p24.3
9 Rora RAR-related orphan receptor A 15q22.2




Supplementary Figure 1 - A) An example of GSEA enrichment profile of the down-regulated (Tfb-β sig-
naling pathway) and the up-regulated (Oxidative Phosphorylation signaling pathway) in ENCCs treated 
with GDNF. B) Summary of GSEA enriched signaling pathways as extracted from the KEGG database 
(when comparing ENCCs treated with GDNF to untreated cells). The possible biological function in 
ENCCs during ENS development is given.
Up-regulated 
by GDNF in 
ENCCs
Parkinson’s disease       
Citrate Cycle       
      
Peroxisome       
Steroid Biosynthesis       
Valin-Leucin-Isoleucin       
PPAR       
Butanoate metabolism       
Propanoate metabolism       
Down-regulated 
by GDNF in 
ENCCs
N-Glycan Biosynthesis       
Notch       
Wnt       
TGFβ/BMP       
Axon guidance       
Adherens junction       
Tight junction       
Focal adhesion       
Cell cycle       
p53       
TLRs       
Pathaways in Cancer       
Splicesome       
Ribosome       
















































HSCR is a congenital disease characterized by the absence of ganglia in the myenteric and 
submucosal plexus of the gastrointestinal (GI) tract.1 So far, 12 genes and five loci have been 
found associated with disease development. Of these genes RET has proved to be the major 
risk factor for HSCR, as 50% of the familial cases and 15-35% of the sporadic cases have RET 
coding sequence (CDS) mutations.2 Mutations in the other 11 genes (EDNRB3, EDN34, 5, GDNF6, 
7, NTN8, SOX109, PHOX2B10, ECE111, KIAA1279/KBP12, ZFHX1B13, 14, NRG115 and TTF116) occur 
in no more than 20% of the remaining cases, most of which are syndromic-HSCR cases. The 
aims of the studies described in this thesis were first: to identify new HSCR-genes in associ-
ated loci that have been reported in previous studies, in particular in 9q31 and 4q31.1-q32.2.17, 
18 Second, we investigated whether the non-coding RET SNP rs2506004 (C>A), which we had 
previously identified as a candidate disease-associated mutation, was indeed pathogenic.19 
For this, we performed functional assays and we revealed the possible molecular mechanism 
by which the mutation pinpointed by this SNP contributes to disease development. As RET 
seems to be the central factor for HSCR- and enteric nervous system (ENS) development, we 
studied the RET networks in detail by performing gene expression profiling studies of mouse 
embryonic enteric neural crest cells (ENCCs), the progenitor cells of the ENS, untreated or 
treated with GDNF, the ligand of RET.
1. Identification of disease-causing genes in HSCR-associated loci
Mutations in the coding regions of the 12 genes that have been identified so far only explain 
about 15-35% of the sporadic HSCR cases and slightly more than 50% of the familial HSCR 
cases. Furthermore, reduced penetrance of the coding sequence (CDS) mutations of the 12 
genes and the phenotypic variability suggests the involvement of other modifier genes or 
factors in the disease development. Bolk and colleagues identified a RET-dependent modifier 
locus on 9q31 in families without RET CDS mutations but who are linked to the RET locus 
(with the exception of one family). In Chapter 2 we tried to fine map this locus and to identify 
the disease-causing gene by genotyping 301 tag-SNPs spanning 7 Mb of the 9q31 region. As 
the 9q31 locus was identified in patients of European descent, we performed this experiment 
on 137 HSCR Dutch trios. We grouped the probands based on their RET CSD mutations status 
(121 probands without the RET CDS mutation and 16 probands with it). We identified the 
SNPs rs10816998 and rs7038415, located within SVEP1, as strongly associated with HSCR 
in the patients who do not carry a RET CDS mutation. This result is in line with the find-
ing of Bolk and colleagues.17 However, we could not replicate this result in the independent 
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case-control study (again using Dutch patients and controls). This might be due to popula-
tion stratification issues, but it might also mean that this locus, in the end, does not contain 
a common disease variant for the Dutch HSCR patients. If such a common mutation does 
exist, the sample size we used was simply not large enough to detect significant association. 
We also replicated our study in 173 Chinese patients and 436 controls and we identified as-
sociated SNPs in different locations than those initially found in the Dutch population. These 
SNPs are located in the intronic and exonic regions of IKBKAP. This result was replicated in 
a second independent patient cohort, also from China. In contrast to the previous finding by 
Bolk, this association was stronger in patients with RET CDS mutations. We checked whether 
there were major linkage disequilibrium (LD) differences between the CEU and CHB Hap-
Map populations in this locus. This was not the case, so we concluded that the differences we 
found were not due to differences in LD structure but due to the different ethnic origins of 
the patient cohorts. In view of these results, we concluded that in the Chinese population, the 
9q31 locus, which was found associated with HSCR in families bearing RET CDS mutations, 
might at least contain a common disease-associated variant in the Chinese patient population. 
As this Chinese locus was not identified in the Dutch patient population, suggesting popula-
tion specificity. The unknown variant in the Chinese patient population is likely present in 
the IKBKAP gene. 
Brooks and colleagues identified a linkage region on 4q31.1-q32.2 in a multi-generational 
Dutch family affected by HSCR disease.18 This region contains 57 genes. Using an exome se-
quencing approach on two out of five affected family members (Chapter 3), we tried to iden-
tify the disease-causing gene in this locus. We found only one possible disease-causing variant 
in the linkage region, in exon 20 of the LRBA gene. This variant was present in all five affected 
family members. However, we looked for the presence of this variant in a control population 
and unfortunately found it was present in heterozygously 4 of the 220 controls (0.9%, 4 out 
of 440 chromosomes). This makes it hard to conclude that it is the disease-associated muta-
tion. As our screen was genome-wide, we were also able to look for disease modifiers not 
present on chromosome 4. A possible modifier present in three out of the five affected family 
members was found on chromosome 2, in exon 19 of ARMC9. Again however, we found this 
variant in 2% of the control population (6 out of 289 chromosomes). These results showed that 
these variants are unlikely to be HSCR-predisposing mutations.
Why did we not find any clear mutation on chromosome 4 although linkage was iden-
tified? Did we miss the mutation? It seems we did. The enrichment method we used only 
covered around 81.33% of all human exons, meaning that we lost 18.67% data to begin with. 
Furthermore, only 62.8% and 66.70% of the data for the two patients had a minimum coverage 
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of 10, the criteria we set for SNP calling. In total, we were unable to look at coding mutations 
in more than 40% of the exome. This we think is probably the best explanation for not finding 
the real causative-variant in the linkage region. 
This finding also directly points to the difficulties we, as researchers, will meet when per-
forming exome sequencing. Of course, we might find a mutation (and would be happy), but 
if unsuccessful, the question remains of what should we do next? Wait for better enrichment 
kits or develop locus-specific exome enrichment kits? This seems like a good idea and might 
solve most of the problems. However, we should not totally exclude the possibility that the 
mutation is present in an intronic or regulatory sequence. For the LRBA gene, we speculate in 
Chapter 3 that there may indeed be non-coding mutations that influence not the LRBA gene 
but the MAB21L2 gene, which is present within the LRBA locus (for an extended discussion 
on this, see Chapter 3). If so, the enrichment kits might just not cover the mutation. We could 
of course go back to specific genes in the linkage area and focus on those, and think of making 
enrichment kits for these candidates (both coding and non-coding). But, as shown in Chap-
ter 3, we did go back to the best candidate gene, MAB21L2, and sequence the entire genome 
region, including the regulatory sequences, but we still did not find any candidate disease-
causing mutation. So focusing on a candidate gene is not always the answer to the problem. 
In the case of MAB21L2, we might extend the sequence region to the entire LRBA gene (see 
above) but even this might not prove successful. These difficulties are also nicely illustrated 
by a previous study we performed on a family with Goldberg-Shprintzen syndrome.12 None 
of the candidate genes in the linkage area proved to be mutated, and in fact it was the last gene 
on a list of 35 that finally proved to be mutated. In this specific family, the unbiased approach 
of exome sequencing might have been helpful.
Another problem that became clear in this study is that our search for modifiers will be 
extremely difficult. Screening exomes results in hundreds of variants, while screening large 
numbers of patients and controls will be necessary to prove any possible involvement. Fur-
thermore, the variants we found were not present in the larger databases such as dbSNP and 
1000 Genomes, but by screening population-specific controls, we confirmed their presence 
in our population. This last finding shows that we really need to build population-specific 
databases. 
Clearly, exome sequencing is a great tool that will help us in an unbiased way to find 
mutations, but equally clearly, this approach will not always be successful and the results 
obtained should be examined with great care.
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2. Functional studies on HSCR-associated variant SNP rs2506004 (C>A)
As mentioned above, mutations in coding sequences of the known HSCR genes only explain 
some of the HSCR cases, hence it is predicted that there are more genes involved in the dis-
ease development. However, besides other genes, non-coding mutations in the known genes 
might also contribute to disease development. Indeed, in the past six years, substantial evi-
dence was presented that RET non-coding sequence mutations play an important role in dis-
ease development, especially in sporadic S-HSCR cases. At least three RET non-coding vari-
ants have been identified and proven to be functional variants, as the mutant allele of these 
variants decreased reporter gene expression in luciferase assays. Two out of the three variants 
are located in the RET promoter region (rs10900296, G>A; rs10900297, A>C) and one is located 
in the multi-species conserved region (MCS+9.7) in intron 1 (rs2435357, C>T) of RET. We iden-
tified another associated-variant (SNP rs2506004, C>A) which is located 217 bp downstream 
of SNP rs2435357, also in MCS+9.7.19 We considered this variant a good candidate since it is 
highly associated with HSCR disease and conserved not only in mammals but also in avian 
species (chicken). Interestingly, when Emison and colleagues performed luciferase assays for 
the region containing SNP rs2435357 (named Enh1 from now onward), they also included 
SNP rs2506004 (named Enh2 from now onward). In their in vitro studies they showed that 
the T- (disease-associated) allele of Enh1 reduced the luciferase expression and disturbed the 
binding site of SOX10, the transcription factor of RET. However, it has not yet been proven 
that Enh2, which was present in the construct used in these studies, did not contribute to the 
disease development. We therefore decided to perform functional assays for Enh2 (Chapter 
4). Luciferase assays showed that both of the disease-associated alleles (Enh1-T and Enh2-A) 
reduced the luciferase expression independently under regulation of the RET-promoter. 
Using in silico analysis we identified Enh2-C, the non-disease allele, and its surrounding 
sequence to be present in the -ACGTG- sequence, also known as the Central Nervous System 
Midline Element (CME), is a binding site of Nxf/Arnt2 and the Sim2/Arnt2 heterodimers. 
By electrophoresis mobility shift assay (EMSA) we showed that Nnxf/Arnt2 has less binding 
affinity to CME containing the Enh2-T (disease associated) allele compared to CME contain-
ing the Enh2-C (non-disease) allele, while Sim2/Arnt2 has the same binding affinity to both 
disease and non-disease associated alleles. Interestingly, we identified six CME regions in the 
RET promoter. This led us to hypothesize that NXF/ARNT2 and SIM2/ARNT2 regulated RET 
expression not only by binding to Enh2 but also by binding to the RET promoter. We proved 
this hypothesis by co-transfection of constructs containing Nxf/Arnt2 or Sim2/Arnt2 with the 
RET promoter coupled to luciferase into a mouse neuroblastoma cell line (Neuro2A). The re-
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sults showed that Nxf/Arnt2 and Sim2/Arnt2 increase and decrease the luciferase expression, 
respectively. Furthermore, the transfection of Nxf/Arnt2 or Sim2/Arnt2 into mouse neuroblas-
toma cells line (Neuro2A) showed increased and decreased endogenous RET expression. This 
strengthens the idea that NXF/ARNT2 and SIM2/ARNT2 are transcription regulators for RET 
expression. It is interesting to mention that SIM2 is located in the critical region of Down’s 
syndrome (DS) in chromosome 21. It has been hypothesized that overexpression of SIM2 in 
DS patients reduces the expression of Drebrin (DBN1), a protein that is important for synaptic 
plasticity. In this study we showed that overexpression of Sim2 leads to down-regulation of 
Ret expression. This could explain why DS patients have a 40-fold higher risk of having HSCR 
disease. In conclusion, in this study we showed that Enh1 and Enh2 are both functional vari-
ants and the disease-associated alleles of both variants decrease luciferase expression. We also 
showed that Nxf/Arnt2 and Sim2/Arnt2 are expressed in the enteric nervous system (ENS) 
progenitor cells and these heterodimers are a transcription activator and repressor, respec-
tively, for RET expression. 
Besides the fact that we could confirm the probable involvement of the SNP we had 
previously identified, we had to conclude that multiple SNPs present on the same disease-as-
sociated haplotype may play a role in the disease, likely at different stages of development, or 
are involved in different processes. As mentioned above, previous studies showed evidence 
for the involvement of at least two additional SNPs on the same haplotype. These SNPs are lo-
cated at -5 and -1 from the start site of the RET gene (Figure 1 in Chapter 4). It was also shown 
that the TTF-1 protein binds to this region and that TTF-1 can activate the RET promoter16, 20, 
21. Therefore, previously published data and our new data hold an important message for the 
study of complex diseases, namely that more than one SNP on an associated haplotype might 
influence disease development. So far, almost all studies have stopped if they found a SNP 
with a proven functional effect. We have shown that even when one such SNP has been found, 
there may still be more involved in the disease development. This means that polygenic dis-
eases are even more complex than originally thought. 
As we have identified new transcription regulators for Ret, there is the question of 
whether variants/mutations in those transcription regulators might also contribute to disease 
development. So far, association to 11q13 (where NXF is located) or 15q25.1 (where ARNT2 
is located) has not been reported. Rare coding mutations have not yet been looked for, but 
whether they exist in these transcription factors and cause or contribute to HSCR can, how-
ever, be doubted. These transcription factors are involved in many developmental processes 
and if any mutation were present, it is most likely it would result in a complex clinical phe-
notype. It is more likely that the sequences in HSCR genes to which these transcription fac-
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tors bind (the CME regions) might contain SNPs that disturb proper binding, as shown for 
SNP rs2506004 in MCS+9.7. We have already performed one study to test this hypothesis. We 
checked the six CME regions within the RET promoter for mutations in 107 HSCR patients 
(patients who do not carry RET CDS) but did not find any mutation (unpublished data). 
3. RET mediated gene expression in ENS precursors
The 12 HSCR genes that have been identified so far can be roughly classified into three groups: 
those involved in the RET pathways (RET, GDNF, NTN), those involved in EDNRB pathways 
(EDNRB, EDN3, ECE-1), and transcription factors that can affect both RET and/or EDNRB 
pathways (SOX10, ZFXH1B, PHOX2B). These three protein groups/pathways, however, are 
not totally independent. For instance, a genome-wide association study using 43 trios from a 
genetically isolated Mennonite population reported statistically significant joint transmission 
of RET and EDNRB alleles.22, 23 Furthermore, mice homozygous for the recessive hypomorphic 
allele of Ednrb (EdnrbS or Piebald) and heterozygous for a Ret null mutation (Ret+/–) showed 
high frequencies of aganglionosis. These findings suggest epistasis between EDNRB and RET, 
and this idea was further supported by Ret/Ednrb mouse crosses.24 Similar studies showed 
that, whereas Ret51/51 and Edn3ls/ls (lethal spotting) mice display colonic aganglionosis, combi-
nations of these mutant alleles lead to almost complete intestinal aganglionosis.25 Moreover, 
the transcription factor SOX10 is involved in regulating both RET and EDNRB expression.26-28 
PHOX2B is also a transcription factor that is expressed in several classes of differentiating 
neurons of both the peripheral and central nervous systems. Mice with a homozygous dis-
ruption of Phox2b show no enteric ganglia and no Ret expression, which suggests that Phox2b 
might play a regulatory role in Ret expression.29 
These data together indicate that all the known HSCR genes seem to be connected, phys-
ically or indirectly, and they point to a central role for RET in the development of both HSCR 
and the enteric nervous system (ENS) development. Therefore, understanding the protein 
networks in which the HSCR associated proteins are involved, in particular the RET associ-
ated pathways, might help us not only in understanding ENS development, but also in iden-
tifying the missing HSCR genes.
However, these pathways are still largely unknown, in particular the signaling pathways 
regulated by RET in ENCCs. To gain more insight into the RET protein network, we per-
formed gene expression profiling studies on RNA isolated from mouse ENCCs, untreated or 
treated with GDNF, the ligand for the RET receptor (Chapter 5). We compared these data to 
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each other and also to the expression profile from the whole mouse embryonic gut (all E14.5). 
The data were used to perform pathway analysis using GSEA and for single gene analysis. 
With single gene analysis we identified genes that were differentially expressed in ENCCs 
with GDNF compared to those in untreated ENCCs. Moreover, by having gene expression 
profiling from the mouse gut, we also identified genes that were differentially expressed in 
ENCCs compared to those in the gut. This group of genes could be considered as the ENS 
marker candidate resource, as Sox2 that was recently identified as a maker of ENS progeni-
tor cells by Heanue et al. was listed in this group.30 Two HSCR-associated genes, Phox2b and 
Ece1, were up- and down-regulated respectively in ENCCs compared to those in the gut. By 
comparing the gene expression profiling of ENCCs treated with GDNF to those in the gut, we 
were able to identify more HSCR-associated genes, including Ret itself, Phox2b, Edn3, Nrg1, 
Gfrα1 and Nrtn. This led to the question whether these genes, including RET, are down-effec-
tors of the RET signaling pathway and hence RET signaling would have a positive feedback 
loop system. As it was known from a previous study that PHOX2B is a transcription activator 
for RET expression, the up-regulation of PHOX2B upon GDNF stimulation, as shown in this 
study, would be a possible mechanism of the RET positive feedback loop system. We also 
identified Snca (α-Synuclein), a gene known to be involved in Parkinson’s disease, as being 
up-regulated in ENCCs and further up-regulated upon GDNF stimulation. Our data suggest 
that defects in RET signaling would most likely reduce the expression of α-synuclein. Inter-
estingly, in Parkinson’s patients, the presence of Lewy bodies (aggregation of α-synuclein) 
in their gut is associated with chronic constipation. These findings suggest that α-synuclein 
might play an important role in ENS functioning. Recently, it has been proposed that detect-
ing Lewy bodies in the gut could be a method for the early detection of Parkinson’s disease. 
Despite many interesting new findings in single gene analysis, it is still rather difficult 
to gain a bigger picture and conclude what actually happens when we stimulate RET with 
GDNF in ENCCs. RET is believed to be important for ENCCs proliferation, differentiation, 
migration and survival during ENS development, but it has not yet been reported in detail 
which signaling pathways triggered by RET play these roles. To get more insight into the RET 
signaling pathway in ENCCs, we therefore decided to analyze our data by pathway analysis, 
using the gene set enrichment analysis (GSEA) method.31 The results showed that some path-
ways previously implicated in ENS, as well as in embryonic development, such as Tgfβ/Bmp, 
Notch and Wnt were down-regulated in ENCCs upon GDNF stimulation. These pathways 
are known to be important for cell differentiation and neurogenesis. It has been reported 
earlier that GDNF stimulation inhibits cell apoptosis of ENCCs.32 In this study, we showed 
that the signaling pathways important for inducing cell apoptosis, e.g. p53 and TOLL-like 
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receptors (TLRs), were down-regulated, and the set of genes that induce cell cycle arrest in 
the cell cycle pathway (p53, mdm2, p21) were also down-regulated. Our study showed that to 
induce cell proliferation, instead of activating cell division genes, the RET signaling pathway 
represses the negative regulators of cell cycle genes. GDNF is known to be a chemo-attractant 
for ENCCs and to stimulate their migration and we showed that GDNF down-regulated ad-
herens and tight junction pathways in ENCCs. As a consequence the cell-cell contact might 
loosen and thereby stimulate cell migration. This process is a possible mechanism for how 
GDNF encourages ENCCs to migrate during ENS development. Altogether, there is a general 
trend in our data that genes encoding proteins that stimulate cell differentiation, negative 
regulators of cell proliferation, and those important for cell-cell adhesion and apoptosis are 
down-regulated in ENCCs upon treatment with GDNF. On the other hand, genes that encode 
proteins that have the opposite effect, such as genes for early growth response, those involved 
in inhibiting cell differentiation, and those important for energy supply and biosynthesis, are 
up-regulated.
It is known that the TLRs signaling pathway can induce cell apoptosis and and innate 
immune response by stimulating pro-inflammatory cytokine expression. Down-regulation of 
TLRs expression upon GDNF stimulation in ENCCs might repress the expression of pro-in-
flammatory cytokines. Furthermore, to our surprise, the JAK-STAT pathway that is known to 
be activated by RET-GDNF was down-regulated in our data set.33 We went through the genes 
listed in the leading subset of genes from GSEA analysis of the JAK-STAT signaling pathway 
and found many of them are genes encoding cytokines and cytokine receptors. Based on 
data of these two pathways, it seems that RET is involved in regulating the innate immune 
response and GDNF activation down-regulates this response in ENCCs. We confirmed Tlrs 
expression in mouse gut (E14.5) by immunostaining and showed that Tlr2, Tlr4 and Tlr5 are 
indeed expressed in neuron, glial and ENS progenitor cells in the myenteric plexus. We also 
confirmed by qRT-PCR that GDNF down-regulates the expression of Tlr2, Tlr4 and Tlr5 and 
some pro-inflammatory cytokines, such as Tnfα and Il-6. These data showed that ENCCs have 
an immunomodulatory capacity and that the RET signaling pathway is involved in regulating 
the innate immune response. Defects in RET signaling, as often seen in HSCR patients, will 
induce TLRs expression and subsequently pro-inflammatory cytokine expression, and acti-
vate the innate immune response. Overexpression of pro-inflammatory cytokines in the gut 
might lead to HSCR-associated enterocolitis. However, the level of Tnfα expression in ENCCs 
was very low so that we could not detect protein levels by ELISA. On the other hand, for the 
Il-6, even though we were able to detect its protein level by ELISA, we were not able to detect 
the changes in protein level in ENCCs, untreated or treated with GDNF. We think that even 
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though ENCCs may play a role in the immune response, their response is not as fast as that of 
immune cells and that it therefore takes much longer for them to produce pro-inflammatory 
cytokines. The immune response is a very complex process, where the cross-talk between 
cytokines produced by different cells is needed to modulate the response. The in vitro study 
that we performed might not be a perfect model for studying such a complex process. A bet-
ter and more straightforward method to prove the involvement of RET-GDNF signaling in 
the immune response would be an in vivo study using transgenic mouse bearing RET(+/-) and 
RET(-/-), and wild-type mouse, to sensitize them with bacteria and virus infections in their gut 
and compare their sensitivity in developing enterocolitis. We could also perform quantitative 
immunostaining for TLRs and RET in myenteric plexus and check for its association with 
enterocolitis development in these mice. This study could be combined with in vitro studies 
on ENCCs isolated from the transgenic and wild-type mice mentioned above. We could then 
check the expression levels of the pro-inflammatory cytokines upon stimulation with various 
pathogens recognized by TLRs (e.g. LPS, LPA, Flagellin). 
4. Overall conclusion
In this thesis we describe both genetic and functional studies performed to identify and char-
acterize HSCR-associated mutations and genes. Our work clearly shows the many difficulties 
encountered when working on a complex disease. 
Identification of a gene in a susceptibility locus proved difficult. Both our attempts on 
chromosomes 4 and 9 were largely unsuccessful (Chapters 2 and 3). Larger patient cohorts 
for the association and exome sequence studies and better enrichment kits for the exome se-
quencing are necessary to be more successful. 
Moreover, we should not forget that non-coding sequence variants can also play an im-
portant role in complex diseases (Chapters 4). This should certainly be taken into consider-
ation if exome sequencing proves unsuccessful (Chapter 3). Importantly, we showed that 
multiple SNPs on a haplotype can be involved in disease development.
Finally, we gained insight into the signaling properties of RET in ENCCs (Chapter 5). 
Not only does this study offer new insight into ENS-related processes and a long list of can-
didate HSCR genes, it also made us hypothesize that RET could be a factor in the occurrence 
of enterocolitis in HSCR patients. 
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In Chapter 1, we review the genetics, the developmental background, the clinical characteris-
tics, and the diagnosis and treatment of Hirschsprung disease (HSCR). HSCR is a congenital 
disease characterized by the absence of ganglia in the myenteric and submucosal plexus of 
the gastrointestinal (GI) tract. The incidence of HSCR is 1 in 5000 live births and most HSCR 
patients present as sporadic cases, although in about 5-15% of the cases the disease is familial. 
In about 70% of the cases, HSCR occurs as an isolated trait, while the rest are associated with 
other diseases or syndromes. So far at least 12 genes and five loci (9q31, 4q31-q32, 3p21, 19q21 
and 16q23) have been found associated with HSCR development. RET is a major genetic risk 
factor for HSCR as RET coding sequence (CDS) mutations are identified in 50% of the familial 
cases and in 15-35% of the sporadic cases. Mutations in 11 other genes (EDNRB, EDN3, GDNF, 
NTN, SOX10, PHOX2B, ECE1, KIAA1279/KBP, ZFHX1B, NRG1 and TTF1) occur in around 
20% of the cases, most of which prove to be syndromic. This leads to our hypothesis that there 
are probably several other disease-causing genes. 
Bolk and colleagues identified linkage to 9q31 in five large HSCR families, all of which 
also showed linkage to RET (10q11.2), but none of them had a clear RET coding mutation and 
in one family that was not linked to RET and obviously did not have a RET coding mutation. 
In Chapter 2 of this thesis, we describe the fine mapping of this locus, to identify the disease-
contributing gene. We genotyped 301 tag-SNPs spanning 7 Mb on 9q31 region in 137 HSCR 
Dutch trios, of whom 121 probands did not carry a RET CDS mutation while 16 probands 
did. We identified two HSCR-associated SNPs in the gene SVEP1 (rs10816998 and rs7038415) 
in patients not having a RET CDS mutation confirming Bolk’s data. However, this result was 
not replicated in 107 independent HSCR Dutch patients without a RET CDS mutation. In 
a Chinese HSCR population, HSCR was found associated with SNPs in IKBKAP but not in 
SVEP1. This association was stronger in patients with RET CDS mutations than those without 
RET CDS mutations. The data was confirmed in an independent Chinese HSCR cohort. We 
concluded that association with chromosome 9 is population-specific and that in Chinese 
HSCR patients the gene likely involved is IKBKAP. The data, as found in the Chinese patients, 
further implies that Chinese RET mutation carriers may have an additional risk through this 
associated IKBKAP variant.
In a previous linkage study performed by Brooks and colleagues on a Dutch multi-gen-
erational HSCR family, linkage was identified for a region on 4q31-q32. In Chapter 3 we tried 
to identify the disease-causing mutation in this linkage region. All of this was done by exome 
sequencing. We identified only one variant in the linkage region, in exon 20 of the LRBA gene. 
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The LRBA gene harbors MAB21L2 and MAB21L2 plays a role in ENCCs migration during 
ENS development. It was therefore postulated that this variant might influence not LRBA but 
MAB21L2. However, although this variant was present in all five affected family members, it 
was also identified in 0.9% of healthy controls (4/440). It is thus unlikely that this variant is the 
disease-causing variant. But as this was the only variant we identified in the linkage region, 
we assume that we must have missed the causative mutation, possibly because the enrich-
ment method and criteria we used was only able to analyze 65% of the target region properly. 
We will therefore repeat this experiment with a better enrichment method which covers all 
the exons in the genome.
Previous studies showed that, regardless of the RET CDS mutation status, almost all fa-
milial cases of HSCR are linked to the RET locus. Furthermore, association studies performed 
by several groups in Caucasian and Asian populations revealed a strongly associated RET 
haplotype. This haplotype covers 27 kb, starting 4 kb upstream of RET through intron 1 to 
the beginning of exon 2. Some of the variants present on this haplotype have been reported 
or suggested as HSCR-causative variants. However, for some associated variants, in particu-
lar SNP rs2506004 (C>A), which is present in an enhancer region for RET, the pathogenic 
nature has not yet been examined. In Chapter 4, we describe functional studies performed 
on this SNP (rs2506004, C>A). By in silico analysis we found that the C-allele (wild type) is 
located in a Central Midline Element (CME) sequence element, which is a binding site for 
Nxf/Arnt2 and Sim2/Arnt2, transcription activators and repressors, respectively. Luciferase 
assays showed that the enhancer element containing the A- (disease-associated) allele, when 
coupled to the RET promoter, reduced Luciferase expression compared to that measured for 
the same construct having the C- (non-disease associated) allele, or to the construct having 
the RET promoter only. We checked the binding affinity of Nxf/Arnt2 and Sim2/Arnt2 het-
erodimers to the oligos containing the C-allele or A-allele by EMSA and a supershift assay. 
We confirmed that Nxf/Arnt2 binds to the C-allele much more strongly than to the A-allele, 
while Sim2/Arnt2 has an equal binding capacity to the A- and C-alleles. The effects of Nxf/
Arnt2 and Sim2/Arnt2 on the expression of Ret were further confirmed by co-transfection of 
constructs containing Nxf/Arnt2 or Sim2/Arnt2 into a mouse neuroblastoma (Neuro2A) cells 
line. We checked the endogenous Ret expression on protein level by Western blot and could 
show that Nxf/Arnt2 and Sim2/Arnt2 increased and decreased the endogenous expression of 
Ret, respectively. SIM2 is located in the Down syndrome’s (DS) critical region in chromosome 
21, and interestingly, 77% of DS patients have gastrointestinal (GI) abnormality, in which 
2-15% of the cases have HSCR disease. As we proved that Sim2 is a transcription repressor of 
Ret, this might partly explain the high incidence of HSCR disease in DS patients.
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All the published data indicate that the known HSCR genes identified so far seem to be 
connected, physically or indirectly. Moreover, they point to a central role for RET in the 
development of both HSCR and the enteric nervous system (ENS). Therefore, understand-
ing the protein networks in which the HSCR-associated proteins are involved, in particular 
the RET-associated pathways, might help us to not only in understanding better ENS de-
velopment, but also to identify candidate HSCR genes. However, these pathways are still 
largely unknown, in particular the signaling pathways that are regulated by RET in neural 
crest cells (ENCCs). To gain more insight into the RET protein network, we performed gene 
expression profiling studies on RNA isolated from mouse ENCCs, untreated or treated 
with GDNF, the ligand for the RET receptor (Chapter 5). We compared these data to each 
other and also to expression profiles from the whole mouse embryonic gut (all E14.5). The 
data were used to perform pathway analysis using gene set enrichment analysis (GSEA) 
and for a single gene analysis. The results of the pathway analysis showed a general trend 
in ENCCs treated with GDNF, towards down-regulation of genes encoding proteins that 
stimulate cell differentiation, negative regulators of cell proliferation, and proteins impor-
tant for cell-cell adhesion and apoptosis. On the other hand, genes that encoded proteins 
that have the opposite effect, such as genes for early growth response, those involved in 
the inhibition of cell differentiation, and genes that are important for energy supply and 
biosynthesis, were up-regulated. 
The Tlrs signaling pathway which plays a role in cell apoptosis and the innate immune 
response was also down-regulated by GDNF stimulation. By immunostaining we confirmed 
that Tlr2, Tlr4 and Tlr5 were expressed in the neuron, glial and ENS progenitor cells in the my-
enteric plexus of mouse gut E14.5. We also confirmed by qPCR that down-regulation of Tlrs 
in ENCCs by GDNF stimulation reduced the mRNA level of the pro-inflammatory cytokines 
Tnfα and Il-6 significantly. This result showed, for the first time, the connection between RET 
signaling and the innate immune response of ENCCs in the gut. This suggests that the inacti-
vation of RET (e.g. as in RET CDS mutations in HSCR patients) could lead to the activation of 
the innate immune response (i.e hypersensitivity of immune response), which might manifest 
itself as HSCR-associated enterocolitis. 
Together, our studies led to the identification of a candidate HSCR gene in the 9q31 
locus, specifically for Chinese HSCR patients. We revealed a possible mechanism for SNP 
rs2506004 in regulating the expression of RET and hence revealed how the disease-associated 
allele contributes to disease development. Furthermore, we studied the RET signaling path-
way in ENCCs in more detail. Our studies have led to more insight into HSCR- and ENS 





In hoofdstuk 1 bespreken we de genetica, de embryologische ontwikkeling, de klinische ken-
merken en de diagnose en behandeling van de ziekte van Hirschsprung (HSCR).  HSCR is een 
aangeboren ziekte die wordt gekenmerkt door de afwezigheid van ganglia in de myenteric 
en submucosale plexi van het maag-darmkanaal. De incidentie van HSCR is 1 op de 5000 
levend geborenen. De meeste HSCR patiënten zijn sporadisch (zijn de enige in de familie) 
maar familiaire HSCR komt wel degelijk voor. We zien dit in ongeveer 5-15% van alle geval-
len. In 70% van alle gevallen hebben de patiënten alleen HSCR, terwijl de overige 30% van de 
patiënten naast HSCR ook een andere ziekte of een syndroom heeft. Tot nu toe zijn 12 genen 
en vier chromosomale gebieden (dit noemen we loci) gevonden die geassocieerd zijn met 
de ontwikkeling van HSCR. RET is de belangrijkste erfelijke risicofactor voor HSCR, omdat 
in 50% van de familiaire gevallen een RET mutatie wordt gevonden. Dit getal is lager in de 
niet-familiaire gevallen (15-35%). Mutaties in de 11 andere genen (EDNRB, EDN3, GDNF, 
NTN, SOX10, PHOX2B, ECE1, KIAA1279/KBP, ZFHX1B, NRG1 en TTF1) verklaren ongeveer 
20% van de rest van de gevallen. De meeste patiënten met mutaties in de 11 andere genen 
blijken een syndroom te hebben waar HSCR een onderdeel van is. Omdat een groot deel van 
de patiënten geen mutatie heeft in de 12 genen is onze hypothese dat er waarschijnlijk nog 
verscheidene andere ziekte veroorzakende genen moeten zijn. 
Bolk en collega’s identificeerden een koppeling van de ziekte aan een stukje van chromo-
soom 9 (9q31). Ze vonden dit in vijf grote HSCR families. Vier van deze families bleken echter 
ook te koppelen met het RET gen (10q11.2), maar in geen van deze families was een duidelijke 
RET mutatie gevonden. De vijfde familie, die niet gekoppeld kon worden aan het RET gen, 
had logischerwijs ook geen RET mutatie. In hoofdstuk 2 van dit proefschrift beschrijven we 
de zoektocht naar de genmutatie in dit gebied op chromosoom 9. We genotypeerden 301 tag-
SNPs (Single Nucleotide Polymorphism (SNP)) verspreid over het gekoppelde gebied in 137 
Nederlandse HCSR patiënten en hun ouders (121 hadden geen RET  mutatie, 16 hadden dat 
wel). We identificeerden 2 HSCR geassocieerde SNPs in een gen genaamd SVEP1 (rs10816998 
en rs7038415). We vonden de associatie in patiënten die geen RET mutatie hebben. Dit beves-
tigde de data van Bolk. Echter, dit resultaat herhaalde zich niet in 107 onafhankelijke Neder-
landse HSCR patiënten zonder een RET mutatie. In een Chinese HSCR populatie, bleek ook 
een associatie aanwezig te zijn maar met een ander gen, genaamd IKBKAP. Deze associatie 
was sterker in de groep patiënten met een RET mutatie dan in de groep zonder RET mu-
tatie. De Chinese data kon wel worden bevestigd in een onafhankelijke groep Chinese HSCR 
patiënten. We concludeerden daarom dat de associatie met chromosoom 9 populatie specifiek 
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is en dat in de Chinese HSCR patiënten waarschijnlijk het gen IKBKAP betrokken is bij de 
ontwikkeling van de ziekte. 
In een studie, beschreven door Alice Brooks en haar collega’s werd in een grote Neder-
landse HSCR familie koppeling gevonden tussen de ziekte en een regio op chromosoom 4 
(4q31-q32). In hoofdstuk 3 hebben we een poging gedaan het gen en de genmutatie te vinden 
die de ziekte in deze familie veroorzaakt. Om dit te doen hebben we alle genen in het ge-
noom geanalyseerd (‘Exoom sequencing’). We vonden één variant in het gekoppelde gebied, 
in exon 20 van het LRBA gen. In het LRBA gen ligt ook een ander gen, te weten MAB21L2. Van 
dit gen is bekend dat het een rol speelt in de migratie van NCCs en dus betrokken is bij de 
ontwikkeling van het zenuwstelsel van de darm. Mogelijk zou een variant in LRBA een inv-
loed kunnen hebben op MAB21L2 en dus indirect HSCR kunnen veroorzaken. Toen we echter 
controles gingen analyseren op aanwezigheid van de variant bleek deze ook in de normale 
populatie voor te komen (4/440), wat het zeer onwaarschijnlijk maakt dat de variant de ziekte 
kan veroorzaken. Waarschijnlijk hebben we dus de mutatie gemist wat mogelijk komt door-
dat we niet alle genen in het koppelingsgebied helemaal hebben kunnen bekijken. We hebben 
kunnen berekenen dat we slechts 65% van alle genen hebben bekeken, dus mogelijk zit er een 
mutatie in het missende deel. Daarom gaan we dit experiment herhalen.
Eerdere studies lieten zien dat, ongeacht het hebben van een mutatie in het RET gen, 
bijna alle familiaire gevallen aan RET zijn gekoppeld. Dit blijkt echter niet alleen het geval 
te zijn voor de familiaire gevallen, het is ook zo voor de sporadische patiënten. Associatie 
studies, uitgevoerd op patiënten groepen uit Europa en Azië, lieten sterke associatie zien met 
één specifiek RET haplotype.  Dit haplotype spreidt zich uit over een gebied van 27.000 bp, 
startende 4000 bp upstream van de RET startsite tot en met het einde van exon 2. Een aantal 
aanwezige varianten in dit gebied is gemeld of gesuggereerd als HSCR-veroorzakende vari-
anten.  Echter, niet voor alle geassocieerde varianten, in het bijzonder SNP rs2506004 (C>A) is 
de pathogenicitiet ook daadwerkelijk onderzocht. In hoofdstuk 4 beschrijven we functionele 
studies die voor deze SNP (rs2506004, C>A) zijn uitgevoerd. Met behulp van in silico analyse 
hebben we gevonden dat het C-allel (wild type) gelokaliseerd is in een Central Midline Ele-
ment (CME) sequentie element, dat een bindingsplaats is voor de eiwitcomplexen Nxf/Arnt2 
en Sim2/Arnt2,  respectievelijk transcriptie activatoren en repressors. Luciferase assays lieten 
zien dat de sequentie met het ziekte geassocieerde allel, wanneer zij gekoppeld is aan de 
RET promotor, verminderde expresse liet zien als we die vergeleken met het niet ziekte geas-
socieerde allel. We controleerden de bindingsaffiniteit van de Nxf/Arnt2 en Sim2/Arnt2 het-
erodimeren aan DNA oligos met het C-allel of het A-allel met behulp van EMSA (elektrofore-
tische mobiliteit shift assay) en een supershift assay. We bevestigen dat Nxf/Arnt2 veel sterker 
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bindt aan het C-allel dan aan het A-allel, terwijl Sim2/Arnt2 een gelijke bindingscapaciteit 
heeft voor de A- en C-allelen. De effecten van Nxf/Arnt2 en Sim2/Arnt2 op de expressie van 
RET werden verder bevestigd door co-transfecties met constructen die Nxf/Arnt2 of Sim2/
Arnt2 tot expressie brachten in een muize neuroblastoma (Neuro2A) cellijn. We controleerden 
de endogene RET expressie op eiwit niveau met behulp van Western blotting en konden laten 
zien dat Nxf/Arnt2 en Sim2/Arnt2, respectievelijk de endogene expressie van RET verhogen 
en lieten afnemen. We hebben hiermee aangetoond dat de SNP daadwerkelijk bij de ziekte is 
betrokken. Sim2 bevindt zich in het kritische gebied voor Down syndroom op chromosoom 
21.  77% van de patiënten met het syndroom van Down hebben maagdarm (GI) afwijkingen, 
waarvan 2-15% van de gevallen HSCR hebben. Omdat Sim2 een transcriptie repressor voor 
RET is, zou overexpressie van SIM2 veroorzaakt door een extra kopie van het gen, de hoge 
incidentie van HSCR in Down syndroom patiënten mogelijk kunnen verklaren. 
Alle gepubliceerde data geven aan dat de tot nu toe geïdentificeerde HSCR genen direct 
of indirect met elkaar verbonden zijn.  Bovendien wijst alle data op een centrale rol voor 
RET in de ontwikkeling van zowel HSCR als het zenuwstelsel van de darm. Het ontrafelen 
van het RET geassocieerde eiwitnetwerk zou ons daarom niet alleen inzicht geven in hoe het 
zenuwstelsel in de darm zich ontwikkelt, maar ook zou het helpen in het identificeren van 
kandidaat HSCR genen. Deze kennis, en dan met name de eiwitnetwerken rond RET in de 
voorloper celen van het darm zenuwstelsel  enteric neurale-lijst-cellen (ENCCs), ontbreekt 
helaas nog. Om hier inzicht in te krijgen hebben we genexpressie studies uitgevoerd op NCCS 
geïsoleerde uit de darm van de muis. In deze cellen hebben we RET geactiveerd of juist niet 
door ze te behandelen met GDNF, de activator (ligand ) voor de RET receptor (hoofdstuk 
5). De genexpressie data van de ENCCs hebben we met elkaar vergeleken (wel of niet ge-
stimuleerd met GDNF) en vergeleken met het expressieprofiel van de gehele (embryonale) 
muizendarm. De data hebben we geanalyseerd met behulp van een programma dat kijkt naar 
signaalroutes en gennetwerken die verrijkt zijn in de dataset waarin de onderzoeker geïnter-
esseerd is (‘gene set enrichment analysis, GSEA’) en we hebben de data geanalyseerd per gen 
(zogenaamde ‘single gene analysis’). Uit de resultaten die gegenereerd waren met behulp van 
het GSEA programma bleek dat, over het algemeen, een activatie van RET resulteert in een 
lagere expressie van genen die coderen voor eiwitten die betrokken zijn bij celdifferentiatie, 
eiwitten die celdeling negatief beïnvloeden en eiwitten die belangrijk zijn voor cel-cel interac-
ties en apoptose. De expressie gaat echter juist omhoog voor genen die coderen voor eiwitten 
die celdifferentiatie tegengaan en eiwitten die een rol spelen in de energie bevoorrading en 
biosynthese. 
Een eiwitnetwerk dat ook als geheel een lagere expressie liet zien was de Toll like recep-
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tor (Tlr) signaalroute, een route betrokken bij apoptose en bij de aangeboren (aspecifieke) im-
muunrespons. We hebben met behulp van immuno-kleuringen kunnen bevestigen dat Tlr2, 
Tlr4 en TLr5 inderdaad tot expressie komen in de neuronen, de glia en de zenuwcel voorlo-
percellen (ENCCs) in de darmwand van de muis. We konden ook laten zien dat GDNF stimu-
latie van RET leidt tot een lagere expressie van de eiwitten die door Tlrs worden geactiveerd, 
Tnfalpha, and IL-6. We laten hiermee voor het eerst zien dat RET activiteit een effect heeft 
op de de aangeboren immuunrespons van de ENCCs die zich in de darm bevinden. HSCR 
patiënten hebben vaak RET mutaties die resulteren in een verlaging van de activiteit van RET 
en dit zal daarom zorgen voor een hogere immuunrespons. HSCR patiënten hebben vaak last 
van chronische ontstekingen aan de darm (HSCR-associated enterocolitis). Onze bevindingen 
zouden dit mogelijk kunnen verklaren.
Concluderend kunnen we zeggen dat onze studies hebben geresulteerd in de identifi-
catie van een HSCR gen in het 9q31 gebied, specifiek voor Chinese HSCR patiënten. Verder 
hebben we kunnen aantonen dat SNP rs2506004 betrokken is bij het ontstaan van HSCR en 
hebben we het mechanisme achter de mutatie opgehelderd. Ook hebben we ons inzicht ver-
groot met betrekking tot het RET eiwit netwerk in de ENCC. Onze resultaten geven meer 
duidelijkheid over het ontstaan van het zenuwstelsel van de darm, over de genen betrokken 




Bab 1 mengulas genetika, biologi perkembangan, karakteristik klinis, diagnosis dan pengo-
batan penyakit Hirschsprung (HSCR). HSCR adalah penyakit bawaan yang ditandai oleh 
ketidakadaanya ganglia dalam pleksus submukosa dan myenteric di saluran pencernaan. In-
siden penyakit HSCR adalah 1 dalam setiap 5000 kelahiran, yang mana mayoritas merupakan 
kasus sporadis dan sekitar 5-15% merupakan kasus turunan. Sekitar 70% kasus merupakan 
kasus HSCR terisolasi sedangkan sisanya merupakan kasus sindromik, yaitu HSCR yang di-
sertai sindrom lainnya. Sampai saat ini, 12 gen dan lima lokus (9q31, 4q31-P32, 3p21, 19q21 
dan 16q23) telah teridentifikasi berasosiasi dengan perkembangan penyakit HSCR. Gen RET 
adalah faktor genetis utama penyakit HSCR dan mutasi pada gen RET (CDS) teramati pada 
sekitar 50% kasus turunan dan pada 15-35% kasus sporadis. Mutasi pada 11 gen lainnya (ED-
NRB, EDN3, GDNF, NTN, SOX10, PHOX2B, ECE1, KIAA1279/KBP, ZFHX1B, NRG1 dan TTF1) 
hanya terjadi pada sekitar 20% kasus, yang sebagian besar ditemukan pada kasus sindromik. 
Hal Ini mengarah pada hipotesis bahwa terdapat gen-gen lain yang berkontribusi kepada 
perkembangan penyakit HSCR. 
Bolk dan kolega mengidentifikasi lokus 9q31 berasosiasi dengan HSCR pada enam kelu-
arga. Lima diantaranya menunjukkan asosiasi dengan lokus 10q11.2, tempat gen RET berada. 
Bab 2 memaparkan pemetaan lokus 9q31 dalam mengidentifikasi gen yang berkontribusi 
terhadap perkembangan penyakit HSCR. Kami memeriksa genotip 301 tag-SNP (single nu-
cleotide polymorphism) yang mencakup 7 Mb (juta pasang basa) pada lokus 9q31 dari sampel 
DNA 137 penderita penyakit HSCR beretnis Belanda beserta DNA orang tuanya (data trios). 
Sebanyak 121 diantara penderita tersebut tidak memiliki mutasi pada gen RET, sementara 
16 lainya memiliki mutasi pada gen RET. Kami mengidentifikasi dua SNP pada gen SVEP1 
(rs10816998 dan rs7038415) berasosiasi dengan HSCR pada pasien yang tidak memiliki mu-
tasi gen RET. Akan tetapi, hasil ini tidak dapat dikonfirmasi ulang pada cohort pasien lain 
dari etnis yang sama (107 pasien etnis Belanda yang tidak memiliki mutasi RET). Percobaan 
serupa diakukan pula dengan sampel DNA yang diperoleh dari penderita penyakit HSCR 
beretnis Cina. Pada penelitian yang menggunakan pendekatan case-control study ini, teriden-
tifikasi beberapa SNP yang terletak pada gen IKBKAP berasosiasi dengan HSCR. Asosiasi ini 
lebih kuat pada pasien dengan mutasi RET dibandingkan pasien tanpa mutasi RET. Data ini 
dapat dikonfirmasi ulang pada cohort HSCR pasien etnis Cina dan dapat disimpulkan bahwa 
asosiasi kromosom 9 dengan HSCR adalah populasi spesifik dan pada pasien HSCR etnis 
Cina terdapat kemungkinan keterlibatan gen IKBKAP. Data yang diperoleh menunjukkan 
bahwa pembawa mutasi RET pada etnis Cina dapat memiliki tambahan resiko menderita 
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penyakit HSCR jika memiliki varian gen IKBKAP.
Melalui metoda Linkage analysis, Brooks dan kolega mengidentifikasi locus 4q31-32 bera-
sosiasi dengan HSCR pada keluarga multi-generasi etnis Belanda. Bab 3 memaparkan pene-
litian guna mengidentifikasi gen pada lokus 4q31-32 yang bertanggung jawab atas perkem-
bangan penyakit HSCR pada keluarga multi-generasi tersebut. Variasi pada exon 20 gen 
LRBA dapat diidentifikasi dengan menggunakan teknik exome sequencing. Pada untai DNA 
anti-sense gen LRBA terdapat gen MAB21L2 yang berperanan penting pada proses migrasi 
ENCCs saat perkembangan ENS. Penelitian telah menunjukkan bahwa beberapa daerah gen 
LRBA adalah pengatur ekspresi gen MAB21L2. Hal ini menimbulkan spekulasi bahwa var-
ian yang ditemukan pada exon 20 gen LRBA adalah bagian dari daerah pengatur ekspresi 
MAB21L2. Varian gen LRBA ini terbukti dimiliki oleh seluruh penderita HSCR pada keluarga 
tersebut di atas. Namun demikian, varian ini juga ditemukan pada 4 dari 440 kromosom kon-
trol yang diperiksa (0.9% dari populasi). Oleh karena kemungkinan varian tersebut adalah 
varian yang bertanggung jawab terhadap perkembangan penyakit HSCR adalah kecil. Akan 
tetapi, karena varian pada exon 20 gen LRBA adalah satu-satunya varian yang teridentifikasi 
pada lokus 4q31-32, maka besar kemungkinan varian penyebab HSCR yang sesungguhnya 
belum teridentifikasi. Hal ini bisa disebabkan karena metoda pengayaan (enrichment method) 
dan analisis exome sequencing yang digunakan hanya mampu menganalisis sekitar 65% exon 
genom manusia. Oleh karena itu, penelitian selanjutnya akan menggunakan exome sequencing 
dengan metoda pengayaan yang mencakup seluruh exon genome manusia.  
Penelitian sebelumnya menunjukkan bahwa, terlepas dari status mutasi gen RET, ham-
pir seluruh kasus HSCR turunan berasosiasi dengan lokus RET. Association study yang telah 
dilakukan oleh beberapa kelompok peneliti atas populasi Kaukasia dan Asia mengidenti-
fikasi adanya general RET haplotype yang berasosiasi dengan penyakit HSCR. Haplotype ini 
mencakup 27 kb (ribu pasang basa), mulai dari 4 kb di bagian hulu gen RET, intron 1 dan 
sampai ke bagian awal ekson 2. Beberapa varian yang diidentifikasi pada haplotype ini te-
lah dilaporkan dan diusulkan sebagai varian yang terlibat dalam perkembangan penyakit 
HSCR. Namun pengujian fungsi beberapa varian seperti halnya SNP rs2506004 (C> A) yang 
terletak di intron 1 gen RET belum pernah dilakukan. Bab 4 memaparkan hasil uji fungsi 
SNP rs2506004 (C> A). Melalui analisis in silico teridentifikasi bahwa C-alel (wild type) SNP 
rs2506004 terletak pada elemen Central Nervous System Midline Enhancer (CME). CME meru-
pakan urutan DNA tempat menempelnya Nxf/Arnt2 dan Sim2/Arnt2 yang masing-masing 
merupakan aktivator dan repressor transkripsi. Luciferase assay menunjukkan penurunan 
ekspresi gen Luciferase jika elemen enhancer yang memiliki A-alel (alel yang berasosiasi den-
gan HSCR) digabungkan dengan promoter RET; dibandingkan dengan elemen enhancer yang 
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memiliki C-alel  atau dibandingkan dengan promoter RET saja (kontrol). Afinitas Nxf/Arnt2 
dan Sim2/Arnt2 heterodimer terhadap oligonucleiotide pembawa C-alel atau A-alel kami uji 
dengan menggunakan metoda EMSA (Electrophoretic Mobility Shift Assay) dan supershift as-
says. Hasil pengujian menunjukkan Nxf/Amt2 memiliki afinitas yang lebih tinggi terhadap 
oligonukleotida pembawa C-alel, sementara Sim2/Amt2 memiliki afinitas yang tidak ber-
beda terhadap A-alel maupun C-alel. Efek Nxf/Arnt2 dan Sim2/Arnt2 terhadap ekspresi gen 
RET dibuktikan lebih lanjut dengan pemeriksaan level ekspresi protein RET endogenous pada 
sel Neuro2A saat ditransfeksi dengan plasmid pengkode Nxf/Arnt2 atau Sim2/Arnt2 melalui 
metoda Western blot. Hasilnya menunjukan bahwa Nxf/Arnt2 dan Sim2/Arnt2 masing-mas-
ing meningkatkan dan menurunkan ekspresi RET protein pada sel Neuro2A. Salah satu hal 
yang menarik adalah, gen SIM2 terletak pada “critical region of Down Syndrome (DS)” pada 
kromosom 21, yang mana 77% pasien DS mengalami gangguan saluran pencernaan dan 
2-15% kasus tersebut adalah HSCR. Penelitian ini telah menunjukkan bahwa SIM2 adalah 
repressor transkripsi RET. Hal ini dapat menjelaskan tingginya insiden penyakit HSCR pada 
pasien DS.
Sejauh ini, data menunjukan gen-gen penyebab penyakit HSCR saling terkait, baik se-
cara langsung maupun tidak, dengan gen RET. Data-data tersebut mengarah pada peran sen-
tral gen RET pada perkembangan sistem syaraf enteric (ENS) dan penyakit HSCR. Oleh kar-
ena itu, dengan mempelajari jaringan protein RET pada enteric neural crest cells (ENCCs) yang 
merupakan progenitor sel neuron dan glial pada ENS dapat membantu memahami proses 
perkembangan ENS dan mengidentifikasi kandidat gen yang terlibat pada perkembangan 
penyakit HSCR. Untuk mempelajari jaringan protein RET pada ENCCs kami mengisolasi 
RNA ENCCs mencit yang distimulasi dan tidak distimulasi dengan GDNF. Dengan meng-
gunakan microarray, RNA tersebut digunakan untuk memperoleh data profil ekspresi gen 
(Bab 5). Hasil microarray juga dibandingkan dengan profil ekpresi gen dari usus mencit. Ha-
sil analisis dengan menggunakan analisis gen tunggal dan analisis jaringan protein (GSEA) 
menunjukkan bahwa pada sel yang diberi perlakuan GDNF terdapat kecenderungan sebagai 
berikut, adanya represi ekspresi gen-gen yang menstimulasi diferensiasi sel, negative regulator 
sel proliferasi dan gen yang penting untuk kontak antar sel serta apoptosis. Di sisi lain, tarda-
pat peningkatan ekspresi gen-gen untuk respon awal pertumbuhan, yaitu yang terlibat dalam 
penghambatan diferensiasi sel, dan gen yang penting dalam pengaturan pasokan energi dan 
biosintesis.
Selain represi di atas, stimulasi GDNF pun merepresi alur sinyal Toll-like receptors (TLRs) 
yang berperan dalam apoptosis dan renspon imun bawaan. Kami menunjukkan bahwa Tlr2, 
Tlr4 dan Tlr5 diekspresikan pada neuron, glial dan progenitor sistem syaraf enteric saluran 
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pencernaan mencit dengan mengunakan tenik immunostaining. qRT-PCR mengkonfirmasi 
bahwa GDNF dapat menurunkan secara signifikan ekspresi gen TLRs dan juga beberapa cy-
tokines pencetus reaksi inflamasi seperti IL-6 dan TNFα. Untuk pertamakalinya data yang 
diperoleh menunjukan bahwa gen RET terlibat dalam pengaturan respon imun bawaan. Hal 
ini mengarahkan pada hipotesa bahwa inaktivasi gen RET (seperti halnya mutasi RET CDS 
pada penderita HSCR) akan mengakibatkan aktivasi reaksi imunitas bawaan (hypersensitivi-
tas) yang bisa mengarah pada perkembangan penyakit enterocolitis.
Hasil penelitian yang telah kami lakukan mengarah pada identifikasi kandidat gen 
HSCR pada lokus 9q31 penderita HSCR etnis Cina. Kami juga berhasil mengungkapkan me-
kanisme keterlibatan SNP rs2506004 (C>A) pada pengaturan ekspresi gen RET sehingga da-
pat menjelaskan bagaimana A-alel pada SNP tersebut berkontribusi terhadap perkembangan 
penyakit HSCR. Selain itu, kami mempelajari jaringan protein RET pada ENCCs dengan lebih 
terperinci. Secara umum hasil penelitian kami memberikan informasi mengenai gen-gen dan 





ARMC9  Armadillo repeat containing 9
ARNT2  Aryl-hydrocarbon receptor translocator 2
ARTN  Artemin
BMPs  Bone morphogenetic proteins
bp  Base pair
BRCA2  Breast cancer 2, early onset
CCHS  Congenital central hypoventilation
CDS  Coding sequences
CME  Central midline element
CNS  Central nervous system
Cp-Ns  Competitive non-specific
Cp-Sp  Competitive specific
CTNNAL1 Catenin (adherin-associated protein), alpha-like 1
DAPI  4’,6-diamidino-2-phenylindole
dbSNP  Database single nucleotide polymorphism
DIP  Deletion-insertion polymorphism
DMEM  Dulbecco’s Modified Eagle Medium
DNA  Deoxyribonucleic acid
DS  Down’s syndrome
E14.5  Embryonic day 14.5
ECE1  Endothelin converting enzyme
EDN3  Endothelin 3
EDNRB  Endothelin receptor type B
EGF  Epidermal growth factor
ELISA  Enzyme-linked immunosorbent assay
EMEM  Eagle’s minimal essential medium
EMSA  Electrophoretic mobility shift assay
ENCCs  Enteric neural crest cells
Enh  Enhancer
ENS  Enteric nervous system
FD  Familial dysautonomia
FDR  False discovery rate
FGF  Fibroblast growth factor
FGFR2  Fibroblast growth factor receptor 2
FOX  Forkhead box
GALNACT-2 Chondroitin sulfate N-acetylgalactosaminyltransferase 2
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
GATK  Genome analysis toolkit
GDNF  Glial cell derived neurotrophic factor
GFAP  Glial fibrillary acidic protein
GFRa1  Glycosyl-phosphatidylinositol-anchored co-receptor of GDNF-1
GI  Gastrointestinal
GOSH  Goldberg-Shprintzen
GSEA  Gene set enrichment analysis
GTP  Guanosine-5’- triphosphate
GWAS  Genome association study
HAEC  Hirschsprung-associated enterocolitis
HOX  Homebox
HSCR  Hirschsprung
IEC  Intestinal epithelial cells
IFNg  Interferon gamma
IKBKAP  Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-
associated protein
IL-6  Interleukin 6
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JAK  Janus tyrosine kinase
KBP  Kinesin binding protein
KBP  Kilo base
KEGG  Kyoto encyclopedia of genes and genomes
LD  Linkage disequilibrium
L-HSCR  Long-segment Hirschsprung
LOD  Logarithm of the odds
LPS  Lipopolysaccharide
LRBA  LPS-responsive vesicle trafficking, beach and achor containing
MAB21L2  Mab-21(C.elegans)-like 2 
MAF  Minor allele frequency
MAP3K1  Mitogen-activated protein kinase kinase kinase 1
Mb  Mega base pairs
MCS  Multiple-species conserved sequences
MUSK  Muscle, skeleta, receptor tyrosine kinase
NCAM  Neural cell adhesion molecule
NCSCs  Neural crest stem cells
NEC  Necrotizing enterocolitis
NLBs  Neurosphere-like bodies
NPE  Nuclear protein extract
NRG1  Neuregulin 1
NTN  Neurturin
NXF (NPAS4) Neuronal PAS domain protein 4
OR  Odd ratio
P53  Tumor protein 53
PBS  Phosphate buffer saline
PCR  Polymerase chain reaction
PFA  Paraformaldehyde
PHOX2B  Paired-like homeobox 2B
pNEs  Paralogous, non-coding elements
PPARs  Peroxisome proliferators-activated receptors
PSPN  Persephine
qRT-PCR  Quantitative reverse transcription-polymerase chain reaction
RASGEF1A RasGEF domain family, member 1A
RET  Rearrange during transfection
RETprom  RET promoter
RNA  Ribonucleic acid
RTK  Tyrosine kinase receptor
SD  Standdard deviation
S-HSCR  Short-segment Hirschsprung
SIM2  Single-minded homolog 2
SNP  Single nucleotide polymorphism
SOX10  SRY (sex determining region Y)-box 10
STAT  Signal transducer and activator of transcription
SV40  Simian vacuolating virus 40
SVEP1  Sushi, von Willebrand factor A, EGF and pentraxin domain
TCA  Total colonic aganglionosis
TDT  Transmission disequilibrium test
TGFb  Transforming growth factor, beta 1
TIA  Total intestinal aganglionosis
TLRs  TOLL-like receptors
TRANSFAC Transcription factor binding predictions
TTF1  Thyroid transcription factor 1
WNT  Wingless-type MMTV integration site family, member 1
WS4  Shah-Waardenburg syndrome type 4
YFP  Yellow fluorescent protein
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 Dear Wanda, it’s nice to know you and it’s always been good to talk to you. Thank you 
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Pieter and Cleo, thank you for the CLC-Bio tutorial, you’ve been a great help. Thanks also to 
Martijn and Freerk for helping with the pipeline data over the last few months.
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consortium, it was always great to meet you all and share our latest scientific results.
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Hans Verbeek, Thomas, Duco and Rajendra. It’s been nice to meet you all, share experiences, 
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now far away, you’ve always been willing to help me during my PhD period. Thanks a lot 
Greg! Dear Maria, we started nearly everything together, and although we come from two dif-
ferent cultures, I am glad we get along so well together and can share our worries, dreams and 
going through the good and bad times of PhD life. Thank you for everything and I wish you 
all the best in the future. Dear Christine, life is not the same without you here, I’m less talk-
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continent you’re on, you always have time to chat with me and show concern, not only for 
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laughing, sharing a lot of stories and, most of all, you were the person who persistently talked 
to me in Dutch. :-D It helped improve my Dutch, too bad that we are no longer office mates 
because my Dutch is disappearing. Thank you also for being one of my paranimfen. I wish you 
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I would like to thank to Joke Verheij for helping and provide me with all the information 
I needed related to HSCR patients. I thank Bart Eggen for always being willing to spend time 
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